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Supplementary Figures 
 
Supplementary Figure 1  Association test statistics for FEV1 and FEV1/FVC. 
A) Quantile-Quantile (QQ) plots show –log10(P) of observed genome-wide association results against expected 
association results for FEV1 and FEV1/FVC. λGC before genomic control was 1.12 for FEV1 and 1.09 for 
FEV1/FVC. The QQ plot for all SNPs is shown in black. The QQ plot for remaining SNPs after exclusion of SNPs 
from loci previously reported by the SpiroMeta and CHARGE consortia1,2 is shown in red; SNPs within 500kb 
of the lead reported SNP were excluded. The previously reported loci were TNS1, FAM13A, GSTCD/NPNT, 
HHIP, HTR4, ADAM19, AGER, GPR126, PTCH1, and TSHD4. 
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B)  Regional association plots of 16 novel lung function-associated loci. Statistical significance of each SNP on 
the –log10(P) scale as a function of chromosome position (NCBI Build 36) in the meta-analysis of Stage 1 data 
alone. The sentinel SNP at each locus is shown in blue with the correlations (r2) of surrounding SNPs to the 
sentinel indicated by colour (red: r2>0.8, orange: r2>0.5, yellow: r2>0.2, grey: r2<0.2, white: r2 unknown).  The 
fine scale recombination rate is shown in blue.  
FEV1 only 
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FEV1/FVC only 
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Both FEV1 and FEV1/FVC 
 
 
 
 
 
  
FEV1 FEV1/FVC 
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C) Forest plots for the 16 loci associated with lung function for Stage 1 and Stage 2 separately. Each of the SNPs 
included in the figure showed genome-wide significant association (P<5×10−8) with either FEV1 or FEV1/FVC in the 
data from Stages 1 and 2. For each SNP there is a plot for the meta-analysis of the Stage 1 data and another for the 
meta-analysis of the Stage 2 data. The contributing effect (transformed beta) from each study is shown by a square, 
with confidence intervals indicated by horizontal lines. The contributing weight of each study to the meta-analysis is 
indicated by the size of the square. The combined meta-analysis estimate is shown at the bottom of each graph. 
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Supplementary Tables 
 
 Supplementary Table 1 Sample population characteristics and genotyping platform details for each study. 
 
A) Sample population characteristics for each study. Characteristics are shown for studies analyzed in Stage 1 
(GWAS meta-analysis), Stage 2 (follow-up). Stage 1 studies: AGES, Age, Gene/Environment Susceptibility; 
ARIC, Atherosclerosis Risk in Communities; B58C-T1DGC, British 1958 Birth Cohort–Type 1 Diabetes Genetics 
Consortium; B58C-WTCCC, British 1958 Birth Cohort–Wellcome Trust Case Control Consortium; BHS1, 
Busselton Health Study 1; CHS, Cardiovascular Health Study; the CROATIA- Korcula study; the CROATIA-Vis 
study; ECRHS, the European Community Respiratory Health Survey; EPIC obese cases, European Prospective 
Investigation into Cancer and Nutrition, Obese Cases; EPIC population based, European Prospective 
Investigation into Cancer and Nutrition Cohort; FHS, Framingham Heart Study; FTC, Finnish Twin Cohort 
incorporating FinnTwin16 and FITSA; H2000, Finnish Health 2000 survey; Health ABC, Health, Aging, and 
Body Composition; KORA F4, Cooperative Health Research in the Region of Augsburg; KORA S3, Cooperative 
Health Research in the Region of Augsburg; NFBC1966, Northern Finland Birth Cohort of 1966; ORCADES, 
Orkney Complex Disease Study; RS-I and RS-II, Rotterdam Study; SHIP, Study of Health in Pomerania; the 
TwinsUK-I study. Stage 2 studies: ADONIX, Adult-Onset Asthma and Nitric Oxide; BHS2, Busselton Health 
Study 2; BRHS, British Regional Heart Study; BWHHS, British Women’s Heart and Health Study; CARDIA, 
Coronary Artery Risk Development in Young Adults; the CROATIA-Split study; the Gedling study; GS:SFHS, 
Generation Scotland: Scottish Family Health Study; LBC1936, Lothian Birth Cohort 1936; the LifeLines study; 
MESA-Lung, Multi-Ethnic Study of Atherosclerosis; HCS, Hertfordshire Cohort Study; the Nottingham 
Smokers study; NSHD, Medical Research Council National Survey of Health and Development (also known as 
the British 1946 Birth Cohort); RS-III, Rotterdam Study; SAPALDIA, Swiss study on Air Pollution and Lung 
Disease in adults; the TwinsUK-II study. * Total number of individuals with both genotype and phenotype 
data and which were included in the analyses described in this paper.
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Study N 
Total 
N 
male 
N 
female 
Age range (y) 
at FEV1/FVC 
measurement 
Mean age, y 
(s.d.) 
Mean FEV1, 
L (s.d.) 
Mean FVC, 
L (s.d.) 
Mean 
FEV1/FVC 
(s.d.) 
N 
never-
smoker
s  
N 
ever-
smoker
s 
Genomic inflation 
factor (λ) FEV1 
Genomic inflation 
factor 
(λ) FEV1/FVC 
Stage 1: GWAS           Ever-
smoker
s 
Never-
smokers 
Ever-
smoker
s 
Never-
smokers 
AGES 1689 686 1003 66-95 76.19 (5.63) 2.13(0.69) 2.86(0.85) 0.74(0.11) 803 886 1.009 1.012 1.003 1.003 
ARIC 9078 4279 4799 44-66 54.27 (5.70) 2.94 (0.78) 3.99 (0.98) 0.74 (0.08) 3620 5458 1.034 1.007 1.019 1.019 
B58C T1DGC 2343 1131 1212 44–45 44.5 (0) 3.31 (0.78) 4.19 (0.96) 0.79 (0.08) 692 1651 1.009 0.999 1.023 1.009 
B58C WTCCC 1372 691 681 44–45 44.5 (0) 2.93 (0.75) 4.18 (0.96) 0.79 (0.08) 394 978 0.999 0.996 1.007 0.99 
BHS1 1168 455 713 17-91 52.98 (17.07) 2.81 (0.97) 3.68 (0.11) 0.76 (0.09) 653 515 1.02 1.034 1.02 1.015 
CHS 3140 1226 1914 65-95 72.3 (5.4) 2.12 (0.66) 3.00 (0.87) 0.71 (0.11) 1543 1597 1.035 1.021 1.02 1.033 
CROATIA-Korcula 825 300 525 18–90 55.5 (13.5) 2.84 (0.81) 3.37 (0.93) 0.84 (0.09) 397 428 1.039 1.014 0.999 1.041 
CROATIA-Vis 769 323 446 18–88 56.3 (15.3) 3.39 (1.22) 4.38 (1.43) 0.77 (0.09) 328 441 1.019 1.002 1.066 1.027 
ECRHS 1594 784 810 19-48 33.90 (7.17) 3.78(0.82) 4.59 (1.03) 0.83 (0.07) 699 895 1.018 1.014 1.005 1.024 
EPIC obese cases 1104 476 628 39–76 59.1 (8.8) 2.35 (0.69) 2.84 (0.87) 0.82 (0.17) 489 615 1.005 1.02 1.02 1.014 
EPIC population based 2336 1100 1236 39–77 59.2 (9.0) 2.50 (0.72) 3.04 (0.90) 0.85 (0.16) 1061 1275 1.013 1.008 1.002 1.018 
FHS 7911 3650 4261 19-92 52.2 (14.6) 3.03 (0.94) 4.02 (1.14) 0.75 (0.08) 3556 4355 1.02 1.032 1.007 1.026 
FTC 134 13 121 23–76 57.4 (19.3) 2.69 (0.94) 2.93 (0.61) 0.79 (0.09) 104 30 1.054 1.011 1.005 1.003 
Health ABC 1472 786 686 70-79 73.7 (2.8) 2.31 (0.66) 3.11 (0.81) 0.74 (0.08) 641 831 0.997 1.001 0.998 1.012 
Health 2000 821 394 427 30-75 50.47(10.91) 3.29 (0.90) 4.16 (1.07) 0.79 (0.07) 249 572 1.001 1.023 1.007 1 
KORA F4 904 426 478 42-61 53.82(4.39) 3.25 (0.79) 4.20 (0.97) 0.77 (0.06) 344 560 1.051 1.013 1.032 1.017 
KORA S3 555 261 294 29–73 47.6 (9.0) 3.43 (0.78) 4.18 (0.99) 0.83 (0.07) 266 289 1.014 1.019 1.012 1.029 
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NFBC1966 4556 2182 2374 31–31 31.0 (0) 3.96 (0.79) 4.73 (0.99) 0.84 (0.06) 1648 2908 1.022 1.011 1.023 1.004 
ORCADES 692 322 370 19–93 54.9 (15.3) 2.88 (0.84) 3.58 (0.98) 0.80 (0.09) 404 288 1.014 1.046 1.015 1.051 
RS-I 1224 556 668 65-97 74.5 (5.6) 2.31 (0.73) 3.16 (0.92) 0.73 (0.08) 361 863 1.029 1.023 1.026 1.017 
RS-II 852 381 471 58-88 67.2 (6.3) 2.71 (0.78) 3.61 (1.08) 0.76 (0.09) 287 565 1.027 1.006 1.009 1.016 
SHIP 1777 870 907 25–85 52.3 (13.7) 3.28 (0.89) 3.87 (1.03) 0.87 (0.06) 773 1004 1 0.996 1.016 0.991 
TwinsUK-I 1885 0 1,885 18–79 48.4 (12.2) 2.73 (0.56) 3.40 (0.61) 0.80 (0.08) 943 942 0.998 1.012 1.009 1.005 
Stage 1 sample size 48201              
               
Stage 2: follow-up              
ADONIX 1410 660 750 25-75 49.08 (13.54) 3.34 (0.86)  4.24(1.02) 0.79 (0.07) 792 618     
BHS2   3038 1368 1670 18-97 50.0 (16.7) 3.05 (0.951)  3.97 (1.15) 0.78 (0.08) 1633 1405     
BRHS     3862 3862 0 58-80 68.72 (5.48) 2.58 (0.69) 3.38 (0.84) 0.77 (0.17) 1121 2741     
BWHHS  3635 0 3635 59-80 68.83 (5.49) 1.98 (0.52) 2.82 (0.76) 0.71 (0.09) 2055 1580     
CARDIA  1626 768 858 17-32 25.6 (3.33) 3.68 (0.81) 4.70 (1.00) 0.82 (0.06) 932 694     
CROATIA-SPLIT 491 209 282 18-85 49.07 (14.60) 3.19 (0.91)  3.80 (1.06) 0.84 (0.08) 239 252     
Gedling                1266 633 633 27-80 56.14 (12.29) 2.85 (0.85) 3.68 (1.01) 0.77 (0.07) 634 632     
GS:SFHS                10399 4304 6095 18-93 46.37 (14.61) 3.11 (0.87) 4.05 (1.02) 0.77 (0.09) 5674 4725     
HCS 2848 1509 1339 59-73 66.14 (2.84) 2.44 (0.68)  3.42 (0.92) 0.72 (0.09) 1318 1530     
LBC1936  991 501 490 67-71 69.55 (0.84) 2.38 (0.67)   3.04 
(0.87) 
0.79 (0.10) 437 554     
LifeLines  3078 1232 1846 21-88 54.94 (9.75) 3.15 (0.81)  4.21 (1,01) 0.75 (0.08) 1075 2003     
MESA-Lung 1469 737 732 48-90 66.1 (9.7) 2.57 (0.76)  3.44 (0.99) 0.73 (0.09) 636 833     
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Nottingham Smokers      521 236 285 36-89 59.60 (10.48) 1.10 (0.95) 3.02 (1.05) 0.64 (0.16) 0 521     
NSHD    2511 1258 1253 53 53 2.79 (0.70)  3.50 
(0.90)  
0.80 (0.09) 1045 1466     
RS-III 1247 549 698 46-89 56.59 (5.58) 3.15 (0.85) 4.06 (1.14) 0.78 (0.09) 425 822     
SAPALDIA            5646 2753 2893 18-62 42.0 (11.4) 3.58 (0.84)  4.53 (1.04) 0.79 (0.07) 2653 2993     
TwinsUK-II 2373 0 2373 17-85 53.5(14.3) 2.62(0.61)  3.27(0.65) 0.80 (0.08) 1230 1143     
Stage 2 sample size 46411              
               
Total sample size 94612              
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B) Stage1 study, genotyping, imputation and genotype-phenotype data. Genotyping platforms, filters applied 
to SNPs and individuals (if any) before imputation, imputation software and genotype-phenotype association 
software are given. Studies: Age, Gene/Environment Susceptibility (AGES),  Atherosclerosis Risk in 
Communities (ARIC), British 1958 Birth Cohort–Type 1 Diabetes Genetics Consortium (B58C T1DGC), British 
1958 70Birth Cohort–Wellcome Trust Case Control Consortium (B58C WTCCC), Busselton Health Study 
1(BHS1), Cardiovascular Health Study (CHS), CROATIA- Korcula, CROATIA-Vis, European Community 
Respiratory Health Survey (ECRHS), European Prospective Investigation into Cancer and Nutrition-obese 
Cases (EPIC obese cases), European Prospective Investigation into Cancer and Nutrition-cohort (EPIC 
population based), Framingham Heart Study (FHS), Finnish Twin Cohort incorporating FinnTwin16 and FITSA 
(FTC), Finnish Health 2000 survey (Health 2000), Health, Aging, and Body Composition (Health ABC), 
Cooperative Health Research in the Region of Augsburg (KORA F4), Cooperative Health Research in the 
Region of Augsburg (KORA S3), Northern Finland Birth Cohort of 1966 (NFBC1966), Orkney Complex Disease 
Study (ORCADES), Rotterdam Studies (RS-I and RS-II), Study of Health in Pomerania (SHIP) and TwinsUK-I. 
Abbreviations: GWAS= Genome-Wide Association Study, imp’n=imputation, HWE= Hardy Weinberg 
Equilibrium, MAF= minor allele frequency. 
MACH  and IMPUTE are two software implementations that share similar underlying population genetic 
models3, and BIMBAM has been shown to perform similarly to MACH and IMPUTE in contrast with other 
imputation methods4,5. 
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Study name  GWAS platform  
Calling 
algorithm  
Individual call rate filter 
applied (before imp’n)  
SNP call rate 
filter applied 
before imp’n  
SNP 
HWE 
filter 
applied 
(before 
imp’n)  
SNP MAF filter 
applied (before 
imp’n)  Other filter  
No of 
SNPs 
after 
filtering 
(before 
imp’n)  
Imp’n 
software 
and version  
NCBI; HapMap CEU 
version for imp’n  
Genotype-phenotype 
association software and 
version  
AGES 
Illumina 
Hu370CNV BeadStudio 0.97 0.90 1e10-6 0.01 
remove AT/GC 
SNPs 208340 
MACH 
1.0.16 36;21a ProbABEL 0.1 
ARIC Affymetrix 6.0 Birdseed 0.95 0.95 1e10-6 0.01 
no chromosomal 
location 669,450 
MACH 
1.0.16 36;22 ProbABEL 0.1-3 
B58C T1DGC  Illumina 550K  ILLUMINUS  0.98 No  No  No  No  520010 
MACH 
1.0.13  35;21  ProbABEL 0.0-5b  
B58C WTCCC  Affymetrix 500K  CHIAMO  0.98 No  No  No  No  490033 
IMPUTE 
0.2.0  35;21  SNPTEST 1.1.3  
BHS1 Illumina 610-Quad BeadStudio 0.97 
0.99 for SNPS 
with MAF<1%, 
0.95 for all other 
SNPs 
5.7e10-
7 0.01 No 549294 
MACH 
1.0.16 36 Mach2Qtl 1.0.8 
CHS Illumina 370 CNV BeadStudio 0.95 0.97 1e10-5 
heterozygote 
frequency >0 
reproducibility 
errors<2 306,655 
BimBam 
0.99 36 R 
CROATIA-
Korcula  
Illumina 
HumanHap 
370cnv  Beadstudio  
0.98 (for SNP of call rate 
>=0.98,MAF>=0.02,HWE>=E-
10)  0.98 1e10-6 0.01 No  307728 
MACH 
1.0.15  36;22  
GenABEL 1.4.2 , 
ProbABEL  
CROATIA-Vis  
Illumina 
HumanHap 300 v1  Beadstudio  
0.97 (for SNP of call rate 
>=0.98,MAF>=0.02,HWE>=E-
10)  0.98 1e10-6 0.01 No  305068 
MACH 
1.0.15  36;22  GenABEL 1.4.2, ProbABEL  
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ECRHS 
(population 
based sample 
from first 
survey) 
Illumina Quad 
610k GenCall None None None None None 
582892 MACH 1.0 
36;22 
ProbABEL 0.0-9 
EPIC obese 
cases  Affymetrix 500K  BRLMM  0.94 0.90 1e10-6 0.01 No  397438 
IMPUTE 
0.3.1  35;21  SNPTEST 1.1.5  
EPIC 
population-
based  Affymetrix 500K  BRLMM  0.94 0.90 1e10-6 0.01 No  397438 
IMPUTE 
0.3.1  35;21  SNPTEST 1.1.5  
FHS 
Affy 500K + 50K 
Gene focused 
Bayesian 
robust linear 
modeling 
using 
Mahalanobis 
distance 
(BRLMM)  0.97 0.97 1e10-6 0.01 
MISHAP p<10-9, 
mendelian 
errors>100 378163 
MACH 
1.0.15 36;22 GWAF 
FTC  Illumina 317K  BeadStudio  0.95 0.90 1e10-5 0.01 No  315987 
MACH 
1.0.16  36;22  PLINK 1.06  
Health 2000 Illumina 610K Illuminus 0.95 0.95 1e10-6 0.01 
MDS-plot outliers 
removed (non-
European 
ancestry) 555388 MACH 1.0 36;22 ProbABEL 
Health ABC 
Illumina Human 
1M-Duo 
BeadStudio 
3.3.7 0.97 0.95 1e10-6 0.01 
No sex mismatch, 
and cryptic 
relatedness 914,263 
MACH 
1.0.16.a 36;22 R version 2.9.2 
KORA F4 Affymetrix 6.0 Birdseed2 0.93 No No No No 909622 
IMPUTE 
0.4.2 36;22 SNPTEST 1.1.5 
KORA S3  Affymetrix 500K  BRLMM  0.93 No  No  No  No  490033 MACH 1.0.9  35;21  MACH2QTL 1.0.4  
NFBC1966  Illumina 
HumanCNV370-
Beadstudio  none  0.95 1e10-4 0.01 No  328007 IMPUTE v1.0  35; 21  SNPTEST 1.1.5  
22 
 
Duo  
ORCADES  
Illumina 
HumanHap 300 v2  Beadstudio  
0.98 (for SNP of call rate 
>=0.98,MAF>=0.02,HWE>=E-
10)  0.98 1e10-6 0.01 No  306207 
MACH 
1.0.15  36;22  GenABEL 1.4.2, ProbABEL  
RS-I 
Illumina HapMap 
550K BeadStudio 0.98 0.98 1e10-6 0.01 
excess autosomal 
heterozygosity, 
sex mismatch or 
outlying identity-
by-state 
clustering 
estimates 512,349 
MACH 
1.0.15 36;22 
MACH2QTL as 
implemented in GRIMP 
RS-II 
Illumina 550K + 
610 Quad GenomeStudio 0.98 0.98 1e10-6 0.01 
excess autosomal 
heterozygosity, 
sex mismatch or 
outlying identity-
by-state 
clustering 
estimates 537,405 
MACH 
1.0.16 36;22 
MACH2QTL as 
implemented in GRIMP 
SHIP  Affymetrix 6.0  BirdseedV2  0.92 No  No  No  
QC callrate > 0.86 
each Chip  869224 
IMPUTE 
0.5.0  36;22  SNPTEST 1.1.5  
TwinsUK-I  Illumina 317K  Beadstudio  0.95 
0.95 if 
MAF>0.05; <0.99 
if 
0.01<=MAF<0.05  
5.7e10-
7 0.01 
unexpected 
relatedness 
based on pi_hat  296293 
IMPUTE 
0.5.0  36;22  GenABEL 1.4.2  
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 Supplementary Table 2 Literature search results for genes overlapping or proximal to novel lung function lead SNP and genes which contain a SNP with r2>0.3 with lead 
SNP.  
We systematically searched the scientific literature as catalogued by PubMed and refined our results using the PubMatrix text mining interface6. Additionally, we 
complemented our association findings by searching the Genetic Association Database—a comprehensive repository of published human genetic association studies7. 
Primers used for mRNA expression profiling are also included for each locus. 
Lead SNP,  
Chr: position, 
chromosomal 
band 
Genes containing SNP with r
2
>0.3 with 
sentinel SNP 
(HapMap release 22 CEU, functional 
annotation obtained using 
GeneCruiser). 
Description of genes in region and  
biological plausibility  
Animal model with lung 
function or pulmonary 
phenotype  
Lookup in 
NHGRI GWAS 
table by 
sentinel SNP +/- 
500kb and 
r
2
>0.3.  
(P<5x10
-8
  in 
reported GWAS 
study) 
rs2284746 
chr1: 
17179262 
1p36.13 
rs2284746; MFAP2 intron, sentinel. 
rs6657613; ATP13A2 intron, r
2
=0.84. 
rs2871775; SDHB intron, r
2
=0.66. 
rs2016693; PADI2 intron, r
2
=0.43. 
rs7513616; CROCC intron, r
2
=0.42. 
 
MFAP2: Microfibrillar-associated protein 2 is a major antigen of elastin-associated 
microfibrils
8
 and a candidate for involvement in the etiology of inherited connective tissue 
diseases.  
ATP13A2 encodes a member of the P5 subfamily of ATPases which transports inorganic 
cations as well as other substrates. Mutations in ATP13A2 are associated with a form of 
Parkinson’s Disease (PARK9, Kufor-Rakeb syndrome)
9
. 
SDHB is a component of the succinate dehydrogenase complex (II) of the respiratory chain 
and sporadic and familial mutations in this gene result in paragangliomas and 
pheochromocytoma
10
.  
PADI2 encodes a peptidyl arginine deiminase which catalyses the post-translational 
deimination of proteins by converting arginine residues into citrullines in the presence of 
calcium ions. PADI2 protein levels are increased in bronchial mucosa and bronchoalveolar 
lavage cells of smokers
11
. 
CROCC encodes rootletin, a component of the rootlet at the proximal end of a cilium
12
. 
 
mRNA expression profiling primers (MFAP2) 
MFAP2-E8F(TCTGTGTTCGTACAGTGTGTGC), MFAP2-E9R(ACAGAGAGGCCTGGGATACTC) 
Expected product size: 398bp 
Crocc-null mice develop 
photoreceptor 
degeneration and a 
lymphocytic lung 
infiltration consistent 
with impaired mucociliary 
clearance
13
. 
 
Sentinel SNP 
rs2284746 also 
associated with 
human height
14
 
(P=4x10
-29
). 
rs993925 
chr1: 
216926691 
1q41 
Sentinel SNP is 242.1kb downstream of 
TGFB2 and 487.1kb upstream of 
LYPLAL1 (no SNPs with r
2
>0.3 with 
sentinel SNP in either gene). 
This association signal is distal to TGFB2, transforming growth factor beta 2. TGFB2 is a 
member of a family of cytokines TGFB1-3 with a diverse repertoire of functions including 
regulating; cell proliferation, adhesion, migration and differentiation mediated via TGFB 
receptor 1 and 2 activation and smad signalling. TGFB2 has been suggested as a pro-fibrotic 
cytokine modulating epithelial repair mechanisms and extracellular matrix homeostasis 
including collagen deposition
15
. TGFB2 expression levels have been shown to be elevated in 
respiratory disease e.g. in bronchial epithelium in asthma
16
. 
 
mRNA expression profiling primers (TGFB2) 
Tgfb2-/- mice have 
multiple cardiac defects, 
and dilated conducting 
airways with collapsed 
terminal bronchioles 
postnatally
17
. Tgfb2 
contributes to airway 
remodeling and 
eosinophil recruitment in none 
24 
 
TGFB2F(CGATCCGCGGGCAGATCCTG), TGFB2R(TGGAGGTGCCATCAATACCTGCA) 
Expected product size: 741bp 
OVA-induced asthma 
model
18
  
rs12477314 
chr2: 
239542085 
2q37.3 
rs12477314 is 92.7kb downstream of 
HDAC4 and 29.2kb upstream of 
FLJ43879. 
HDAC4 (histone deacetylase 4) is a member of a family of proteins with enzymatic activity 
that removes acetylation from histone surrounding DNA thus influencing transcription factor 
access to the DNA. This deacetylase activity is thought to repress gene transcription.  
Reduced HDAC activity has been reported in lung tissue from subjects with COPD and this 
activity correlated with disease severity and inflammatory cytokine expression although 
HDAC2, 5 and HDAC8 differential expression levels were thought to mediate this 
observation
19
. Ongoing approaches to recover HDAC activity show potential for therapeutic 
intervention in COPD
20
 
 
mRNA expression profiling primers (HDAC4) 
HDAC4-E23F(CATGTGTTTCTGCCTTGCTG), HDAC4-E26R(GTCTGTCCCGTGTTCCCTGT)  
Expected product size: 523bp 
Hdac4-null mice die soon 
after birth, displaying 
significant skeletal 
defects and growth 
retardation that impair 
mobility and breathing
21
. none 
rs1529672 
chr3: 
25495586 
3p24.2 rs1529672; RARB intron, sentinel. 
RARB codes for retinoic acid receptor beta, a nuclear receptor responsive to retinoic acid, a 
vitamin A derivative. This receptor also controls cell proliferation and differentiation.  
Retinoic acid has been implicated in embryonic lung branching morphogenesis
22
. Epigenetic 
regulation of the RARB gene promoter has been linked to various cancers including non-small 
cell lung cancer
23
. 
 
mRNA expression profiling primers (RARB) 
RARB-E3F(GATGCCAATACTGTCGACTCC), RARB-E6R(CAGAGGACCAAATCCAGCAT) 
Expected product size: 500bp 
Rarb-null mice exhibit 
premature alveolar 
septation
24
. none 
rs1344555 
chr3: 
170782913 
3q26.2 rs1344555; EVI1 intron, sentinel 
EVI1, ecotropic viral integration site 1 codes for a zinc finger transcription factor and evidence 
suggests a proto-oncogenic role in proliferation in acute myeloid leukaemia
25,26
. The role of 
EVI1 in the lung is unclear at this time although increases in copy number have been reported 
in human squamous cell lung cancer
27
. Component of MECOM (MDS1 and EVI1 complex 
locus). 
 
mRNA expression profiling primers (EVI1) 
EVI1F(TGACCTGGAAACAACCTCGGGC), EVI1R(GCATTGGGAGGCGCCCTGAA) 
Expected product size: 951bp 
Evi1 is abundantly 
expressed in the 
bronchial epithelium of 
the developing mouse 
embryo
28
. none 
rs153916 
chr5: 
95062456 
5q15 
rs153916 is 17.9kb upstream of 
SPATA9 and 30.1kb upstream of 
RHOBTB3. 
rs34895; SPATA9 intron, r
2
=0.65. 
Little is known regarding SPATA9, spermatogenesis associated 9. However, this family of 
proteins were initially identified as mediators of spermatogenesis. Additional functions have 
now been identified for these proteins e.g. SPATA2 has been suggested to have a role in 
pancreatic development and β-cell proliferation
29
. 
RHOBTB3 encodes a Rho GTPase which is required for protein transport from endosomes to 
the trans Golgi network.  
 
mRNA expression profiling primers (SPATA9) 
SPATAF2(CGAGCAACATTAATTCGTGGAT), SPATAR2(CACCTTCAGCAAACATAGGCT) 
Expected product size: 406bp none none 
rs6903823 
chr6: 
rs6903823; ZKSCAN3 intron, sentinel. 
rs6912584; ZNF323 intron, r
2
=0.95. 
ZKSCAN3, zinc finger protein with KRAB and SCAN domains 3 is a transcription factor that has 
recently been identified as a regulator of many downstream targets including genes involved none 
SNP rs4324798 
(r
2
=0.42  with 
25 
 
28430275 
6p22.1 
rs7766356; ZSCAN23 3’ UTR, r
2
=0.80. 
rs7774981; ZSCAN12 3’UTR, r
2=
0.66. 
rs13215054; GPX6 intron, r
2
=0.60. 
rs6901575; PGBD1 intron, r
2
=0.51. 
rs13205911; ZNF192 3’UTR, r
2
=0.50. 
rs17763089; HIST1H1B exon 
(synonymous), r
2
=0.47. 
rs200981; HIST1H2AL exon 
(synonymous), r
2
=0.42. 
rs1150726; ZNF187 intron, r
2
=0.40. 
rs203878; ZNF165 5’UTR, r
2
=0.37. 
rs1654774; ZSCAN16 intron, r
2
=0.34. 
rs7206; ZNF193 3’UTR, r
2
=0.33. 
rs17720293; ZKSCAN4 intron, r
2
=0.31. 
 
Non-synonymous SNPs (gene, r
2
 >0.3 
with sentinel): 
rs13201753 (ZKSCAN3, r
2
=0.51). 
rs1997660 (PGBD1, r
2
=0.49). 
rs2232423 (ZSCAN12, r
2
=0.38). 
rs6456811 and rs3800325 (PGBD1, 
r
2
=0.34). 
rs853684 (ZNF323, r
2
=0.33). 
in; cell growth/cell cycle/signal transduction e.g. VEGF, FGF23, cyclin D1, extracellular matrix 
and proteolysis e.g. MMP26, integrin beta 4 and transcription regulators e.g. ELF3
30
. 
Importantly, these functions have been linked to tumour growth
30
 and proliferation in 
multiple myeloma
31
.  
ZNF323 (zinc finger 323) is a member of the subfamily of C2H2 Kruppel-like zinc finger 
transcription factors. Preliminary mRNA expression data for ZNF323 suggests a potential role 
in multiple organ embryogenesis including the lung
32
. 
ZNF192 (ZKSCAN8), ZNF187 (ZSCAN26),  ZNF165 (ZSCAN7), ZNF193(ZSCAN9),  ZSCAN23, 
ZSCAN12 and ZSCAN16 encode zinc finger and SCAN domain-containing proteins.  
GPX6 encodes a glutathione peroxidase. 
PGBD1 piggyBac transposable element derived 1 is within part of a haplotype linked to high 
CD8+ T-lymphocyte numbers and Hereditary Hemochromatosis
33
. 
HIST1H1B and HIST1H2AL encode members of the H1 histone protein family, basic nuclear 
proteins which form the nucleosome which wraps and compacts the DNA into chromatin and 
may play a role in transcription regulation, DNA repair, DNA replication and chromosomal 
stability. 
ZKSCAN4 encodes a zinc finger protein with KRAB and SCAN domains which may inhibit 
glucocorticoid receptor-mediated transactivation
34
. 
 
eQTL result: ZFP57 encodes a zinc finger protein with a KRAB domain with a role in 
methylation associated with imprinting
35
. Mutations in this gene have been implicated in 
transient neonatal diabetes
36
. 
ZSCAN12 (ZNF96) is described above. 
 
mRNA expression profiling primers (ZKSCAN3) 
ZKSCAN3F(GCGCCGCAGGTTTCAGGTGTT), ZKSCAN3R(CTGCTGTGTCCATTCAGGGGTGA) 
Expected product size: 300bp 
rs6903823) 
associated with 
lung cancer
37
 
(P=2x10
-8
). 
rs2857595 
Chr6: 
31676448 
6p21.33 
Sentinel SNP is 7.7kb upstream of NCR3 
(no SNP in NCR3 with r
2
>0.3 with 
sentinel SNP), 14.6kb upstream of AIF1.  
rs3093975; BAT1 intron, r
2
=0.95. 
rs1800629; TNFA promoter region 
(upstream), r
2
=0.86. 
rs3130614; MICB intron, r
2
=0.67. 
rs7750641; TCF19 exon (non-
synonymous), r
2
=0.54. 
rs2853975; MICA intron, r
2
=0.52. 
rs3130557; PSORS1C1(SEEK1) intron, 
r
2
=0.50. 
rs2233980; C6orf15 exon 
(synonymous), r
2
=0.50. 
rs1041981; LTA exon (non-
synonymous), r
2
=0.47. 
rs2071592; NFKBIL1 intron, r
2
=0.47. 
rs2071594; ATP6V1G2 3’UTR, r
2
=0.46. 
NCR3, natural cytotoxity triggering receptor 3, blocking antibodies in vitro have demonstrated 
that NCR3 is required for efficient cytotoxicity responses by natural killer cells against normal 
cells and tumours
38
. AIF1, allograft inflammatory factor 1, is induced by chemokines and 
interferon and is involved in the regulation of vascular smooth muscle growth. AIF1 has been 
implicated in the pulmonary vasculopathy that characterizes systemic sclerosis
39,40
.  
TNFA: rs1800629 (-308G/A) in the promoter region of TNFA (r
2
 0.86) has previously been 
associated with asthma susceptibility in European ancestry subjects
41
. rs1800629 (-308G/A) 
been associated with lung function in COPD cases
42
, but candidate gene studies reporting its 
association to COPD susceptibility have not provided consistent and conclusive evidence
43
 
and suggest publication bias.  
BAT1-BAT5 are HLA-B associated transcripts.  
MICA and MICB encode the MHC class I chain-related proteins A and B
44
. These proteins are 
stress-induced and ligands for the activation of the cytolytic response of NK cell receptors. 
They are similar to MHC class I molecules but do not associate with beta-2-microglobulin or 
bind peptides. Polymorphisms in MICB have been associated with airflow obstruction in 
asthmatics
45
. 
TCF19 encodes transcription factor 19. 
PSORS1C1(SEEK1) is a psoriasis susceptibility candidate gene
46
 and  overlaps CDSN. The 
Tnfa overexpression in 
mice results in increased 
lung volume, loss of small 
airspaces and thickened 
pleural septa
60
. 
Lta knockout mice have 
increased airway 
inflammation and 
remodelling, and elicit a 
severe Th1 response 
when challenged by 
allergens
61
 
Cfb-null mice infected 
with P. aeruginosa 
pneumonia exhibit 
increased mortality
62
 
SNP rs3117582 
(r
2
=0.38 with 
rs2857595) 
associated with 
lung 
cancer
37,57,63
 
(strongest 
P=5x10
-12
). 
SNP rs3099844 
(r
2
=0.67 with 
rs2857595) 
associated with 
neonatal 
lupus
64
 (P=5x10
-
10
).  
SNP rs3131379 
(r
2
=0.34 with 
rs2857595) 
26 
 
rs3132450; BAT2(PRRC2A) intron, 
r
2
=0.38. 
rs3117582; APOM intron, r
2
=0.38. 
rs9267531; CSNK2B intron, r
2
=0.38. 
rs3131383; CLIC1 5’UTR, r
2
=0.34. 
rs3131379; MSH5 intron, r
2
=0.34. 
rs915652; VARS intron, r
2
=0.34. 
rs3130679; C6orf48 3’UTR, r
2
=0.34. 
rs3132550; CDSN intron, r
2
=0.31. 
rs3130628; BAT3(BAG6) intron, 
r
2
=0.30. 
rs3130618; BAT4(GPANK1) exon (non-
synonymous), r
2
=0.30. 
rs1270942; CFB intron, r
2
=0.30. 
rs389884; STK19 intron, r
2
=0.30. 
 
 
 
 
Non-synonymous SNPs (gene, r
2
 >0.3 
with sentinel): 
rs7750641 (TCF19, r
2
=0.54). 
rs1041981 (LTA, r
2
=0.47). 
rs2233974 (C6orf15, r
2
=0.38). 
rs3130618 (BAT4, r
2
=0.30). 
 
function of PSORS1C1 is unknown. CDSN encodes a protein found in corneodesmosomes, 
structures found within human epidermis and other cornified squamous epithelia. 
C6orf15 (STG) No function is known for this gene in humans but the strongest signal of 
association in this region for a study of follicular lymphoma overlapped this gene
47
. 
LTA encodes lymphotoxin alpha, a cytokine produced by lymphocytes and a member of the 
tumour necrosis factor family. This gene has been associated with leprosy
48
 and psoriatic 
arthritis
49
. 
NFKBIL1 encodes a putative inhibitor of the NFκB complex which has a role in DNA 
transcription regulation and has shown association with rheumatoid arthritis
50
 and may 
confer susceptibility to chronic thromboembolic-induced pulmonary hyptertension
51
.  
ATP6V1G2 encodes a component of vacuolar ATPase (V-ATPase), a multisubunit enzyme that 
mediates acidification of intracellular compartments of eukaryotic cells. 
APOM encodes apolipoprotein M which may play a role in high density lipid metabolism
52
.  
CSNK2B encodes the beta subunit of casein kinase II which is believed to play a role in a wide 
range of cellular processes
53
 including Wnt/beta-catenin signalling
54
. 
CLIC1 encodes chloride intracellular channel 1 which may play a role in the maintenance of 
intracellular membranes
55
. 
MSH5 encode a MutS-homologous protein with roles in meiotic and mitotic DNA 
recombination
56
. Common variants in the MSH5 locus have been associated with risk of lung 
cancer
57
. 
VARS encodes valyl tRNA synthetase which binds the tRNA with valine for translation. Other 
aminoacyl tRNA synthetases have been associated with disease including 
neurodegeneration
58
. 
C6orf48 Function unknown. 
CFB encodes complement factor B, a component of the alternative pathway of complement 
activation. Complement factor B is cleaved into Ba and Bb with Bb being a serine protease 
that associates with C3b to form the alternative pathway C3 convertase. Polymorphisms in 
this gene have been associated with a reduced risk of age-related macular degeneration
59
. 
STK19 encodes serine/threonine kinase 19 and may be involved in transcription regulation. 
 
eQTL results: HLA-DRB1 and HLA-DQA1 encode  HLA beta and alpha chain class II paralogues, 
respectively, that play a key role in the immune system by presenting peptides derived from 
extracellular proteins.  
 
mRNA expression profiling primers (NCR3) 
NCR3-E2F(ATGCCAGCCAAGGGAGACT), NCR3-E4R(ACAGCCAGAAGAGGGTATGTGT) 
Expected product size: 577bp 
associated with 
SLE
65
 (P=2x10
-
52
). 
 
rs2798641 
chr6: 
109374743 
6q21 rs2798641; ARMC2 intron, sentinel. 
ARMC2, armadillo repeat containing 2 is a member of a protein family containing a repeating 
motif of ~42 amino acids consisting of three alpha helices. Protein family members have been 
identified as having roles in many diverse protein functions including; cell signalling, protein 
degradation and cytoskeleton functions
66
.  At this time little is known regarding the function 
of ARMC2. 
 
mRNA expression profiling primers (ARMC2) 
ARMC2F(GTGCTGCTTGCACACAACTTCAT), ARMC2R(TTCCATTGCCGTGCAGAGCTGG) none none 
27 
 
Expected product size: 578bp 
rs7068966 
chr10: 
12317998 
10p13 
rs7068966; CDC123 intron, sentinel. 
rs7072888; NUDT5 intron, r
2
=0.37. 
CDC123, cell division cycle 123 homolog shows high homology across species and has been 
shown to be a critical control protein modulating Eukaryotic initiation factor 2 in times of cell 
stress e.g. nutrition and growth in Saccharomyces cerevisiae
67
. 
NUDT5 Human NUDT5 (hNUDT5) is an ADP-ribose (ADPR) pyrophosphatase (ADPRase) that 
plays important roles in controlling the intracellular levels of ADPR and preventing non-
enzymatic ADP-ribosylation of proteins by hydrolyzing ADPR to AMP and ribose 5'-
phosphate
68
. 
 
eQTL results OSBPL1A (located on chromosome 18) encodes an oxysterol-binding protein. 
 
mRNA expression profiling primers (CDC123) 
CDC123-E1F(CGAGGCGTTACCATCAAGA), CDC123-E8R(ATTCACACCATTTTCGGAGAAC) 
Expected product size: 460bp none none 
rs11001819  
chr10: 
77985230 
10q22.3 
rs11001819; c10orf11 intron, sentinel 
rs7078013; KCNMA1 intron, r
2
=0.54. 
C10orf11 Individuals with a rare deletion that disrupts C10orf11 exhibit cognitive defects
69
. 
KCNMA1 encodes the potassium large conductance calcium-activated channel, subfamily M, 
alpha member 1 (also known as BKCa), is present on airway smooth muscle cells and 
pulmonary endothelium and its activation may lead to bronchial relaxation
70
 and pulmonary 
arterial vasodilation
71
. 
mRNA expression profiling primers (C10orf11): 
C10orf11-E2F(GGAGGAACTCATCTTGGACAAC), C10orf11-E6RB(TCCCATAGTAAACGTAGCGACA)  
Expected product size: 473bp none none 
rs11172113 
chr12: 
55813550 
12q13.3 
rs11172113; LRP1 intron, sentinel 
rs167769; STAT6 intron, r
2
=0.36 
LRP1, low density lipoprotein receptor-related protein 1 is a member of a family of receptors 
involved in cholesterol homeostasis
72
. However, this receptor interacts with a diverse number 
of ligands e.g. ApoE, MMP-2, MMP-9, uPA-uPAR pathway components, amyloid precursor 
protein, and mediates the cellular processes related to these proteins including cell signalling 
and migration
73
. Several of these ligands have been implicated via differential expression in 
disease progression in COPD including MMP-9, uPA and uPAR
74
.  
STAT6 encodes a signal transducer and activator of transcription 6, interleukin-4 induced 
protein and may play a role in allergic inflammation
75
 and pathways leading to pulmonary 
fibrosis
76
. 
 
mRNA expression profiling primers (LRP1) 
LRP1F(AACCGGTACTACCTGCGCAAGC), LRP1R(TGGCTAGCCGTGCAGTTGGACA) 
Expected product size: 911bp 
Stat6-null mice are 
protected from allergen-
induced airway 
inflammation and 
eosinophilia
77
. 
Pharmacologic inhibition 
of Stat6 ameliorates 
ovalbumin-induced 
bronchial constriction in 
mice
78
. none 
rs1036429 
chr12: 
94795559 
12q22 
rs1036429; CCDC38 intron, sentinel. 
rs4762633; SNRPF intron, r
2
=0.96. 
 
CCDC38, coiled-coil domain containing 38 is a member of a diverse protein family that contain 
two or more alpha helical domains that twist around each other forming a supercoil. These 
proteins are involved in a diverse array of functions and includes; skeletal proteins e.g. 
vimentin and motor proteins e.g. myosin
79
. At this time little is known regarding the function 
of CCDC38. 
SNRPF Small nuclear ribonucleoprotein F. The presence of anti-RNP antibodies has been 
associated with increased progression to pulmonary damage in individuals with Systemic 
Lupus Erythematosus
80
.  
 none none 
28 
 
mRNA expression profiling primers (CCDC38): 
CCDC38-E12F(AGAGAGCTGGAAGAGCAGAATC), CCDC38-E15R(TAGCCTTTCCTGTTGGTGTCTT) 
Expected product size: 498bp 
mRNA expression profiling primers (SNRPF): 
SNRPFF(CGGTACCTGCTGTAGTCACGA),SNRPFR(CTTCACCCAGATGTCCAGACA) 
Expected product size: 262bp 
rs12447804 
chr16: 
56632783 
16q13 
rs12447804; MMP15 intron, sentinel. 
 
 
Non-synonymous SNPs (gene, r
2
 >0.3 
with sentinel): 
rs3743563 (MMP15, r
2
=1). 
MMP15, matrix metalloproteinase 15 (also called membrane type matrix metalloproteinase 
2, MT2-MMP) is a member of a large protease family with diverse functional roles via 
protease activity and specificity including; tissue remodelling, wound healing, angiogenesis, 
and tumor invasion. MMP15 expression has been shown to be elevated in primary lung 
adenocarcinoma
81
 and MMP15 has demonstrated anti- apoptosis properties
82
.  MMP15 
substrates include Pro-MMP-2, gelatin, fibronectin and laminin
83
.  
 
mRNA expression profiling primers (MMP15) 
MMP15-E1F(CTGCTCCTGGTGCTTCTGG), MMP15-E4R(AGGTCAGTGCTGGAGAAGGTC) 
Expected product size: 650bp 
Mmp15 expression is 
increased in the lungs of 
mice exposed to 
particulate matter
84
. none 
rs2865531  
chr16: 
73947817 
16q23.1 
rs2865531; CFDP1 intron, sentinel 
rs12933281; TMEM170A intron, 
r
2
=0.97. 
rs3115960; CHST6 intron, r
2
=0.76. 
 
CFDP1 encodes Craniofacial Development Protein 1.  
TMEM170A unknown. 
CHST6 encodes carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6. Mutations in this 
gene have been associated with macular corneal dystrophy. 
 
mRNA expression profiling primers (CFDP1) 
CFDP1E1F(TGCGGTCTTGTGAGTTTGAC), CFDP1E4R(GCTCTTCTGCTTTTACCAACAA) 
Expected product size: 500bp 
Cfdp1 is highly expressed 
in developing mouse 
lung
85
 none 
rs9978142 
chr21: 
34574109 
21q22.11 
rs9978142 is 84.1kb upstream of 
KCNE2 and 90kb downstream of 
C21orf82. 
KCNE2, potassium channel, voltage-gated, ISK-related subfamily, member 2 has been 
associated with thyroid dysfunction using KCNE2-/- mice which exhibited; hypothyroidism, 
dwarfism, alopecia, goitre and cardiac abnormalities
86
. The authors concluded that the 
KCNQ1-KCNE2 TSH-stimulated thyrocyte K+ channel was crucial for normal thyroid I– 
accumulation
86
. KCNQ1-KCNE2 K+ channels may modulate transepithelial anion secretion in 
Calu3 airway epithelial cells
87
. 
C21orf82 unknown 
 
mRNA expression profiling primers (KCNE2) 
KCNE2F(ATTGGCGCCAGAACACAACAGCT), KCNE2R(GACATTTTGAACCCAGCCGCACC) 
Expected product size: 292bp none 
SNP rs9982601 
(r
2
=0.68 with 
rs9978142) 
associated with 
myocardial 
infarction
88
 
(P=6x10
-11
). 
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Supplementary Table 3 Association of the 16 novel regions, and previously reported regions, with A) FEV1 and 
FEV1/FVC in children, B) tobacco addiction, C) height and D) lung cancer. The effect of SNPs previously associated 
with height on lung function are also shown (E). 
A) Association of the 16 novel regions, and previously reported regions, with FEV1 and FEV1/FVC in children. 
Effects of the 16 novel SNPs, and effects of SNPs in regions previously reported as associated with lung 
function, on FEV1 and FEV1/FVC in children were looked up in ALSPAC (Avon Longitudinal Study of Parents 
and Children, N=5062, 50% males, age mean (s.d.)=8.6(0.3)) and in the Raine Study (N=1219, 52% males, age 
mean (s.d.)=8.1(0.3)). Effect sizes estimates for the children’s cohorts were meta-analysed using inverse 
variance weighting. P values still significant after applying a Bonferroni correction for 16 tests (P<0.003125) 
are shown in bold. To enable a comparison of effect sizes between children and adults, effect sizes in the 
SpiroMeta-CHARGE Stage 2 dataset only (to avoid potential winners’ curse bias) are given for the novel loci. 
Effect sizes in the SpiroMeta-CHARGE GWAS Stage 1 are provided for the previously reported regions.  
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Chr. Measure SNP_ID(NCBI36 position), function 
 
ALSPAC N=5062 Raine N=1219 ALSPAC+Raine meta-analysis 
SpiroMeta-CHARGE Stage 
2 
Coded 
allele  Beta Se P  Beta Se P  Beta Se P  Beta Se P  
Novel loci 
1 FEV1/FVC rs2284746 (17179262),  MFAP2(intron) G 0.005 0.028 8.58E-01 0.002 0.043 9.61E-01 0.004 0.023 8.60E-01 -0.038 0.007 2.640E-07 
1 FEV1 rs2284746 (17179262),  MFAP2(intron) G -0.064 0.029 2.70E-02 0.096 0.042 2.30 E-02 -0.013 0.024 5.93E-01 0.006 0.007 3.701E-01 
1 FEV1/FVC rs993925 (216926691),  TGFB2(downstream)  T 0.052 0.029 7.30E-02 0.015 0.05 7.67E-01 0.043 0.025 8.90E-02 0.023 0.01 1.758E-02 
1 FEV1 rs993925 (216926691),  TGFB2(downstream)  T 0.058 0.03 5.30E-02 -0.011 0.049 8.20E-01 0.039 0.026 1.26E-01 0.003 0.007 7.292E-01 
2 FEV1/FVC rs12477314 (239542085),  HDAC4(downstream) T 0.093 0.035 8.00E-03 0.063 0.048 1.93E-01 0.083 0.028 4.00E-03 0.031 0.008 8.410E-05 
2 FEV1 rs12477314 (239542085),  HDAC4(downstream) T 0.025 0.036 4.87E-01 0.058 0.048 2.31E-01 0.037 0.029 2.03E-01 0.025 0.007 1.816E-04 
3 FEV1/FVC rs1529672 (25495586),  RARB(intron) C -0.078 0.036 3.00E-01 -0.034 0.053 5.24E-01 -0.064 0.03 3.10E-02 -0.038 0.009 1.160E-05 
3 FEV1 rs1529672 (25495586),  RARB(intron) C 0.044 0.037 2.34E-01 0.011 0.053 8.41E-01 0.033 0.03 2.76E-01 -0.011 0.007 9.328E-02 
3 FEV1/FVC rs1344555 (170782913),  MECOM(intron) T 0.016 0.035 6.48E-01 -0.068 0.053 2.00E-01 -0.01 0.029 7.43E-01 -0.017 0.012 1.551E-01 
3 FEV1 rs1344555 (170782913),  MECOM(intron) T -0.013 0.036 7.18E-01 -0.064 0.052 2.19E-01 -0.03 0.03 3.20E-01 -0.025 0.009 6.436E-03 
5 FEV1/FVC rs153916 (95062456),  SPATA9(upstream) T 0.037 0.027 1.71E-01 0.019 0.04 6.31E-01 0.032 0.022 1.60E-01 -0.025 0.009 6.671E-03 
5 FEV1 rs153916 (95062456),  SPATA9(upstream) T 0.001 0.028 9.72E-01 0.05 0.04 2.19E-01 0.017 0.023 4.64E-01 0.004 0.007 6.220E-01 
6 FEV1/FVC rs6903823 (28430275),  ZKSCAN3(intron)/ZNF323(intron) G -0.037 0.032 2.48E-01 -0.131 0.049 7.00E-03 -0.065 0.027 1.40E-02 -0.013 0.011 2.337E-01 
6 FEV1 rs6903823 (28430275),  ZKSCAN3(intron)/ZNF323(intron) G 0.02 0.034 5.56E-01 -0.036 0.049 4.64E-01 0.002 0.028 9.51E-01 -0.029 0.008 4.750E-04 
6 FEV1/FVC rs2857595 (31676448),  NCR3(upstream) G 0.044 0.034 1.96E-01 0.08 0.05 1.09E-01 0.055 0.028 4.90E-02 0.028 0.008 5.364E-04 
6 FEV1 rs2857595 (31676448),  NCR3(upstream) G -0.013 0.035 7.10E-01 -0.076 0.05 1.30E-01 -0.034 0.029 2.41E-01 0.017 0.007 9.411E-03 
6 FEV1/FVC rs2798641 (109374743),  ARMC2(intron) T -0.102 0.036 5.00E-03 0.049 0.052 3.49E-01 -0.053 0.03 7.30E-02 -0.03 0.012 1.565E-02 
6 FEV1 rs2798641 (109374743),  ARMC2(intron) T -0.115 0.037 2.00E-03 -0.062 0.052 2.33E-01 -0.097 0.03 1.00E-03 -0.009 0.01 3.351E-01 
10 FEV1/FVC rs7068966 (12317998),  CDC123(intron) T 0.051 0.027     5.90E-02 -0.03 0.04 4.64E-01 0.026 0.022      2.45E-01 0.023 0.006 3.861E-04 
10 FEV1 rs7068966 (12317998),  CDC123(intron) T 0.041 0.029 1.57E-01 0.044 0.04 2.74E-01 0.042 0.024 7.40E-02 0.022 0.005 3.560E-05 
10 FEV1/FVC rs11001819 (77985230),  C10orf11(intron) G -0.048 0.028 8.60E-02 -0.018 0.041 6.62E-01 -0.038 0.023 9.70E-02 -0.006 0.006 3.174E-01 
10 FEV1 rs11001819 (77985230),  C10orf11(intron) G -0.04 0.029 1.68E-01 0.003 0.041 9.45E-01 -0.026 0.024     2.78E-01 -0.022 0.005 3.100E-05 
12 FEV1/FVC rs11172113 (55813550),  LRP1(intron) T -0.011 0.028      6.94E-01 -0.054 0.041 1.87E-01 -0.025 0.023 2.85E-01 -0.026 0.01 5.829E-03 
12 FEV1 rs11172113 (55813550),  LRP1(intron) T -0.039 0.029 1.79E-01 -0.032 0.041 4.34E-01 -0.037 0.024 1.21E-01 -0.003 0.007 6.940E-01 
12 FEV1/FVC rs1036429 (94795559),  CCDC38(intron) T 0.066 0.034 5.20E-02 0.014 0.052 7.82E-01 0.05 0.028 7.60E-02 0.028 0.008 3.348E-04 
12 FEV1 rs1036429 (94795559),  CCDC38(intron) T -0.015 0.036 6.77E-01 0.001 0.052 9.79E-01 -0.01 0.03 7.43E-01 0.004 0.006 5.381E-01 
16 FEV1/FVC rs12447804 (56632783),  MMP15(intron) T -0.06 0.033 6.90E-02 0.089 0.051 8.40E-02 -0.017 0.028 5.52E-01 -0.021 0.01 4.204E-02 
16 FEV1 rs12447804 (56632783),  MMP15(intron) T -0.074 0.034 3.00E-02 -0.006 0.051 9.12E-01 -0.053 0.028 6.10E-02 0.004 0.007 5.705E-01 
Contd. 
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ALSPAC N=5062 Raine N=1219 ALSPAC+Raine meta-analysis 
SpiroMeta-CHARGE Stage 
2 
Chr. Measure SNP_ID(NCBI36 position), function 
Coded 
allele  Beta Se P  Beta Se P  Beta Se P  Beta Se P  
16 FEV1/FVC rs2865531 (73947817),  CFDP1(intron) T -0.016 0.028 5.68E-01 0.023 0.041 5.85E-01 -0.004 0.023 8.67E-01 0.024 0.006 1.940E-04 
16 FEV1 rs2865531 (73947817),  CFDP1(intron) T -0.037 0.029 2.02E-01 -0.066 0.041 1.12E-01 -0.046 0.024 5.00E-02 0.011 0.005 3.888E-02 
21 FEV1/FVC rs9978142 (34574109),  KCNE2(upstream) T -0.031 0.04 4.38E-01 0.125 0.059 3.50E-02 0.018 0.033 5.90E-01 -0.031 0.013 1.749E-02 
21 FEV1 rs9978142 (34574109),  KCNE2(upstream) T -0.035 0.042 4.05E-01 0.095 0.059 1.12E-01 0.008 0.034 8.13E-01 -0.015 0.01 1.353E-01 
Previously reported regions 
2 FEV1/FVC rs2571445(218391399), TNS (ns) G 0.033 0.028 2.39E-01 -0.037 0.042 3.74E-01 0.011 0.023 6.31E-01 0.033 0.007 4.460E-06 
2 FEV1 rs2571445(218391399), TNS1(ns) G 0.05 0.029 8.47E-02 0.045 0.042 2.83E-01 0.048 0.024 4.25E-02 0.047 0.007 9.830E-11 
2 FEV1/FVC rs10498230(229210747), PID1(downstream) T 0.072 0.052 1.66E-01 -0.073 0.076 3.39E-01 0.026 0.043 5.44E-01 0.068 0.014 1.130E-06 
2 FEV1 rs10498230(229210747), PID1(downstream) T 0.078 0.054 1.49E-01 0.054 0.076 4.81E-01 0.07 0.044 1.13E-01 0.03 0.014 3.601E-02 
4 FEV1/FVC rs2045517(90089987), FAM13A(intron) T 0.004 0.028 8.86E-01 -0.03 0.042 4.72E-01 -0.007 0.023 7.78E-01 -0.047 0.007 2.000E-11 
4 FEV1 rs2045517(90089987), FAM13A(intron) T -0.035 0.029 2.27E-01 -0.013 0.042 7.57E-01 -0.028 0.024 2.43E-01 -0.012 0.007 8.933E-02 
4 FEV1/FVC rs7671167(90103002), FAM13A(intron) T 0.02 0.027 4.59E-01 -0.016 0.041 6.96E-01 0.009 0.023 6.85E-01 -0.042 0.007 1.270E-09 
4 FEV1 rs7671167(90103002), FAM13A(intron) T -0.024 0.028 3.91E-01 -0.017 0.041 6.74E-01 -0.022 0.023 3.44E-01 -0.017 0.007 1.635E-02 
4 FEV1/FVC rs10516526(106908353), GSTCD(intron) G 0.158 0.055 4.07E-03 -0.007 0.081 9.35E-01 0.106 0.045 1.98E-02 0.039 0.014 6.167E-03 
4 FEV1 rs10516526(106908353), GSTCD(intron) G 0.069 0.057 2.26E-01 0.169 0.081 3.66E-02 0.102 0.047 2.81E-02 0.108 0.014 4.750E-14 
4 FEV1/FVC rs17331332(107027556), NPNT(upstream) G -0.132 0.054 1.45E-02 0.031 0.08 6.95E-01 -0.081 0.045 7.14E-02 -0.057 0.014 5.300E-05 
4 FEV1 rs17331332(107027556), NPNT(upstream) G -0.074 0.056 1.86E-01 -0.177 0.079 2.57E-02 -0.108 0.046 1.79E-02 -0.102 0.014 1.110E-12 
4 FEV1/FVC rs6823809(107048244), NPNT(intron)  T 0.113 0.039 3.76E-03 0.101 0.101 3.16E-01 0.112 0.036 2.18E-03 0.056 0.011 2.200E-07 
4 FEV1 rs6823809(107048244), NPNT(intron)  T 0.043 0.041 2.94E-01 0.103 0.095 2.80E-01 0.052 0.038 1.64E-01 0.05 0.011 4.820E-06 
4 FEV1/FVC rs1032296(145654138), HHIP(upstream) T -0.012 0.029 6.79E-01 0.013 0.043 7.56E-01 -0.004 0.024 8.68E-01 -0.05 0.007 3.420E-12 
4 FEV1 rs1032296(145654138), HHIP(upstream) T 0.02 0.03 5.05E-01 -0.053 0.042 2.12E-01 -0.004 0.024 8.57E-01 -0.047 0.007 8.740E-11 
4 FEV1/FVC rs11100860(145698589), HHIP(upstream) G 0.016 0.029 5.81E-01 -0.02 0.041 6.25E-01 0.004 0.024 8.68E-01 0.064 0.007 6.810E-20 
4 FEV1 rs11100860(145698589), HHIP(upstream) G -0.015 0.03 6.17E-01 0.056 0.041 1.70E-01 0.01 0.024 6.82E-01 0.041 0.007 4.270E-09 
5 FEV1/FVC rs11168048(147822546), HTR4(intron) T -0.072 0.029 1.30E-02 0.011 0.041 7.86E-01 -0.044 0.024 6.08E-02 -0.047 0.007 5.970E-11 
5 FEV1 rs11168048(147822546), HTR4(intron) T -0.003 0.03 9.20E-01 0.057 0.041 1.71E-01 0.018 0.024 4.70E-01 -0.046 0.007 2.430E-10 
5 FEV1/FVC rs3995090(147826008), HTR4(intron) C 0.074 0.028 8.22E-03 -0.001 0.04 9.88E-01 0.049 0.023 3.12E-02 0.046 0.007 1.040E-10 
5 FEV1 rs3995090(147826008), HTR4(intron) C 0 0.029 1.00E+00 -0.042 0.04 2.98E-01 -0.014 0.023 5.41E-01 0.045 0.007 3.330E-10 
5 FEV1/FVC rs1985524(147827981), HTR4(intron) G -0.083 0.028 3.03E-03 0.04 0.04 3.21E-01 -0.043 0.023 6.10E-02 -0.045 0.007 2.900E-10 
5 FEV1 rs1985524(147827981), HTR4(intron) G -0.004 0.029 8.90E-01 0.052 0.041 2.05E-01 0.015 0.024 5.35E-01 -0.048 0.007 3.060E-11 
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ALSPAC N=5062 Raine N=1219 ALSPAC+Raine meta-analysis 
SpiroMeta-CHARGE Stage 
2 
Chr. Measure SNP_ID(NCBI36 position), function 
Coded 
allele  Beta Se P  Beta Se P  Beta Se P  Beta Se P  
5 FEV1/FVC rs11134779(156869344), ADAM19(intron) G 0.013 0.029 6.54E-01 -0.036 0.042 3.90E-01 -0.003 0.024 9.06E-01 -0.042 0.007 6.010E-09 
5 FEV1 rs11134779(156869344), ADAM19(intron) G -0.051 0.03 8.91E-02 0.039 0.042 3.60E-01 -0.021 0.024 3.93E-01 -0.027 0.007 2.396E-04 
6 FEV1/FVC rs2070600(32259421), AGER(ns) T 0.126 0.054 1.96E-02 0.192 0.081 1.83E-02 0.146 0.045 1.15E-03 0.126 0.016 9.070E-15 
6 FEV1 rs2070600(32259421), AGER(ns) T 0.05 0.056 3.72E-01 0.089 0.081 2.73E-01 0.063 0.046 1.75E-01 0.025 0.016 1.271E-01 
6 FEV1/FVC rs3817928(142792209), GPR126(intron) G 0.106 0.035 2.46E-03 0.045 0.05 3.68E-01 0.086 0.029 2.75E-03 0.059 0.008 2.270E-12 
6 FEV1 rs3817928(142792209), GPR126(intron) G -0.033 0.036 3.59E-01 0.032 0.05 5.26E-01 -0.011 0.029 7.11E-01 0.023 0.009 8.625E-03 
6 FEV1/FVC rs262129(142894837), LOC153910(unknown) G 0.118 0.03 8.38E-05 0.054 0.044 2.23E-01 0.098 0.025 8.19E-05 0.056 0.008 2.910E-13 
6 FEV1 rs262129(142894837), LOC153910(unknown) G -0.021 0.032 5.12E-01 0.017 0.044 6.98E-01 -0.008 0.026 7.61E-01 0.031 0.008 5.440E-05 
9 FEV1/FVC rs16909859(97244613), PTCH1(downstream) G 0.057 0.05 2.54E-01 0.022 0.09 8.12E-01 0.049 0.044 2.66E-01 0.08 0.013 7.450E-10 
9 FEV1 rs16909859(97244613), PTCH1(downstream) G 0.058 0.052 2.65E-01 -0.128 0.092 1.62E-01 0.013 0.045 7.80E-01 -0.014 0.013 2.933E-01 
9 FEV1/FVC rs16909898(97270829), PTCH1(intron) G -0.089 0.048 6.37E-02 0.002 0.088 9.77E-01 -0.068 0.042 1.06E-01 -0.072 0.012 3.940E-09 
9 FEV1 rs16909898(97270829), PTCH1(intron) G -0.022 0.049 6.53E-01 0.098 0.089 2.67E-01 0.006 0.043 8.85E-01 0.015 0.012 2.211E-01 
15 FEV1/FVC rs12899618(69432174), THSD4(intron) G 0.045 0.039 2.49E-01 0.092 0.057 1.02E-01 0.06 0.032 6.03E-02 0.076 0.01 1.860E-15 
15 FEV1 rs12899618(69432174), THSD4(intron) G -0.024 0.041 5.58E-01 -0.029 0.057 6.10E-01 -0.026 0.033 4.39E-01 0.036 0.01 1.567E-04 
15 FEV1/FVC rs8033889(69467134), THSD4(intron) T -0.051 0.034 1.34E-01 -0.104 0.051 4.09E-02 -0.067 0.028 1.70E-02 -0.072 0.008 2.030E-17 
15 FEV1 rs8033889(69467134), THSD4(intron) T 0.031 0.035 3.76E-01 0.094 0.051 6.30E-02 0.051 0.029 7.41E-02 -0.044 0.009 3.010E-07 
15 FEV1/FVC rs2568494(76528019), IREB2(intron) G 0.014 0.029 6.29E-01 0.028 0.043 5.22E-01 0.018 0.024 4.48E-01 0.029 0.007 5.250E-05 
15 FEV1 rs2568494(76528019), IREB2(intron) G -0.023 0.03 4.43E-01 0.015 0.043 7.27E-01 -0.011 0.025 6.68E-01 0.023 0.007 1.635E-03 
15 FEV1/FVC rs8034191(76593078), CHRNA3/5(intron) T 0.026 0.029 3.70E-01 -0.01 0.042 8.13E-01 0.014 0.024 5.47E-01 0.032 0.007 9.650E-06 
15 FEV1 rs8034191(76593078), CHRNA3/5(intron) T -0.03 0.03 3.17E-01 0.007 0.042 8.67E-01 -0.017 0.024 4.75E-01 0.031 0.007 2.070E-05 
15 FEV1/FVC rs2036527(76638670), CHRNA5(uptream) G 0.038 0.03 2.05E-01 -0.015 0.047 7.57E-01 0.023 0.025 3.66E-01 0.032 0.007 1.190E-05 
15 FEV1 rs2036527(76638670), CHRNA5(uptream) G -0.015 0.031 6.28E-01 0.04 0.047 3.97E-01 0.002 0.026 9.51E-01 0.036 0.008 2.400E-06 
15 FEV1/FVC rs8040868(76698236), CHRNA3(s)  T 0.039 0.028 1.64E-01 -0.027 0.042 5.19E-01 0.019 0.023 4.25E-01 0.04 0.008 1.140E-06 
15 FEV1 rs8040868(76698236), CHRNA3(s)  T 0.003 0.03 9.20E-01 0.041 0.042 3.21E-01 0.016 0.024 5.09E-01 0.039 0.008 2.980E-06 
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B) Relation of 16 novel lung function loci, and previously reported loci, with tobacco addiction. Effects of the 16 
novel SNPs associated with lung function on two smoking phenotypes (cigarettes per day and ever-smokers vs. 
never-smokers) were looked up in the Oxford-GlaxoSmithKline (Ox-GSK) study, a collaborative effort to investigate 
the genetic basis of smoking-related behavioral traits 89. Results for the SpiroMeta-CHARGE joint meta-analysis of 
Stage 1 and Stage 2 for the lung function measure that showed stronger association are reported for the novel loci. 
Results for the SpiroMeta-CHARGE GWAS stage (stage 1) for the lung function measure that showed stronger 
association are reported for the previously reported loci.  
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Lung function  
(Stage 1 and Stage 2 meta-analysis) 
Cigarettes per day Ever vs. Never smoking 
Chr. SNP ID(NCBI36 position),  function Coded allele Measure Beta Se P Beta Se P Beta Se P 
Novel loci 
1 rs2284746 (17179262),  MFAP2(intron) G FEV1/FVC -0.04 0.005 7.50E-16 0.004 0.01 6.85E-01 -0.015 0.018 3.99E-01 
1 rs993925 (216926691),  TGFB2(downstream) T FEV1/FVC 0.034 0.006 1.16E-08 -0.007 0.011 5.12E-01 -0.027 0.019 1.53E-01 
2 rs12477314 (239542085),  HDAC4(downstream) T FEV1/FVC 0.041 0.006 1.68E-12 -0.021 0.012 8.83E-02 0.014 0.022 5.20E-01 
3 rs1529672 (25495586),  RARB(intron) C FEV1/FVC -0.048 0.006 3.97E-14 -0.013 0.014 3.65E-01 0.024 0.025 3.38E-01 
3 rs1344555 (170782913),  MECOM(intron) T FEV1 -0.034 0.006 2.65E-08 0.011 0.013 3.86E-01 0.01 0.022 6.51E-01 
5 rs153916 (95062456),  SPATA9(upstream) T FEV1/FVC -0.031 0.005 2.12E-08 -0.021 0.01 3.70E-02 0.02 0.018 2.72E-01 
6 rs6903823 (28430275),  ZKSCAN3(intron)/ZNF323(intron) G FEV1 -0.037 0.006 2.18E-10 0.02 0.012 8.86E-02 -0.026 0.021 2.16E-01 
6 rs2857595 (31676448),  NCR3(upstream) G FEV1/FVC 0.037 0.006 2.28E-10 -0.002 0.014 8.55E-01 -0.009 0.025 7.12E-01 
6 rs2798641 (109374743),  ARMC2(intron) T FEV1/FVC -0.041 0.007 8.35E-09 0.007 0.013 5.69E-01 -0.036 0.025 1.39E-01 
10 rs7068966 (12317998),  CDC123(intron) T FEV1/FVC 0.033 0.005 6.13E-13 0.001 0.01 9.22E-01 0.02 0.018 2.74E-01 
10 rs11001819 (77985230),  C10orf11(intron) G FEV1 -0.029 0.004 2.98E-12 -0.011 0.01 2.70E-01 0.015 0.018 4.05E-01 
12 rs11172113 (55813550),  LRP1(intron) T FEV1/FVC -0.032 0.006 1.24E-08 -0.006 0.01 5.41E-01 0.022 0.019 2.44E-01 
12 rs1036429 (94795559),  CCDC38(intron) T FEV1/FVC 0.038 0.006 2.30E-11 0.006 0.012 6.35E-01 0.028 0.021 1.85E-01 
16 rs12447804 (56632783),  MMP15(intron) T FEV1/FVC -0.038 0.007 3.59E-08 -0.005 0.013 6.69E-01 -0.005 0.022 8.06E-01 
16 rs2865531 (73947817),  CFDP1(intron) T FEV1/FVC 0.031 0.005 1.77E-11 0.019 0.01 5.30E-02 0.002 0.018 9.13E-01 
21 rs9978142 (34574109),  KCNE2(upstream) T FEV1/FVC -0.043 0.008 2.65E-08 0.007 0.013 5.84E-01 0.007 0.024 7.59E-01 
Previously reported loci 
2 rs2571445(218391399), TNS1(ns) G FEV1 0.047 0.007 9.83E-11 -0.011 0.011 3.09E-01 0.023 0.02 2.47E-01 
2 rs10498230(229210747), PID1(downstream) T FEV1/FVC 0.068 0.014 1.13E-06 -0.061 0.019 1.62E-03 -0.05 0.033 1.38E-01 
4 rs2045517(90089987), FAM13A (intron) T FEV1/FVC -0.047 0.007 2.00E-11 -0.01 0.01 3.23E-01 0.004 0.018 8.40E-01 
4 rs7671167(90103002), FAM13A (intron) T FEV1/FVC -0.042 0.007 1.27E-09 -0.013 0.01 1.91E-01 0.014 0.018 4.35E-01 
4 rs10516526(106908353), GSTCD(intron) G FEV1 0.108 0.014 4.75E-14 0.03 0.02 1.23E-01 0.018 0.034 6.08E-01 
4 rs17331332(107027556), NPNT (upstream) G FEV1 -0.102 0.014 1.11E-12 -0.037 0.019 5.25E-02 -0.031 0.033 3.51E-01 
4 rs6823809(107048244), NPNT(intron) T FEV1/FVC 0.056 0.011 2.20E-07 0.011 0.026 6.77E-01 -0.045 0.066 5.02E-01 
4 rs1032296(145654138), HHIP(upstream) T FEV1/FVC -0.05 0.007 3.42E-12 0.007 0.01 4.97E-01 -0.002 0.018 9.01E-01 
4 rs11100860(145698589), HHIP(upstream) G FEV1/FVC 0.064 0.007 6.81E-20 -0.002 0.01 8.58E-01 0.001 0.017 9.32E-01 
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Lung function  
(Stage 1 and Stage 2 meta-analysis) 
Cigarettes per day Ever vs. Never smoking 
Chr. SNP ID(NCBI36 position),  function Coded allele Measure Beta Se P Beta Se P Beta Se P 
5 rs11168048(147822546), HTR4(intron) T FEV1/FVC -0.047 0.007 5.97E-11 0.003 0.01 7.34E-01 -0.012 0.018 5.04E-01 
5 rs3995090(147826008), HTR4(intron) C FEV1/FVC 0.046 0.007 1.04E-10 -0.002 0.01 8.69E-01 0.014 0.018 4.25E-01 
5 rs1985524(147827981), HTR4(intron) G FEV1 -0.048 0.007 3.06E-11 0 0.01 9.97E-01 -0.027 0.018 1.32E-01 
5 rs11134779(156869344), ADAM19(intron) G FEV1/FVC -0.042 0.007 6.01E-09 -0.015 0.01 1.43E-01 0.012 0.019 5.27E-01 
6 rs2070600(32259421), AGER(ns) T FEV1/FVC 0.126 0.016 9.07E-15 0.033 0.026 1.98E-01 0.056 0.044 2.03E-01 
6 rs3817928(142792209), GPR126(intron) G FEV1/FVC 0.059 0.008 2.27E-12 -0.004 0.012 7.16E-01 0.005 0.021 8.10E-01 
6 rs262129(142894837), LOC153910(unknown) G FEV1/FVC 0.056 0.008 2.91E-13 0.005 0.011 6.56E-01 0.019 0.02 3.39E-01 
9 rs16909859(97244613), PTCH1(downstream) G FEV1/FVC 0.08 0.013 7.45E-10 -0.005 0.02 7.81E-01 -0.012 0.033 7.09E-01 
9 rs16909898(97270829), PTCH1(intron) G FEV1/FVC -0.072 0.012 3.94E-09 0.024 0.018 1.91E-01 0.019 0.031 5.45E-01 
15 rs12899618(69432174), THSD4(intron) G FEV1/FVC 0.076 0.01 1.86E-15 -0.013 0.014 3.36E-01 -0.012 0.024 6.31E-01 
15 rs8033889(69467134), THSD4(intron) T FEV1/FVC -0.072 0.008 2.03E-17 -0.004 0.012 7.57E-01 -0.02 0.022 3.59E-01 
15 rs2568494(76528019), IREB2(intron) G FEV1/FVC 0.029 0.007 5.25E-05 -0.082 0.01 2.15E-15 -0.016 0.018 3.62E-01 
15 rs8034191(76593078), CHRNA3/5(intron) T FEV1/FVC 0.032 0.007 9.65E-06 -0.09 0.011 1.59E-17 -0.02 0.018 2.75E-01 
15 rs2036527(76638670), CHRNA5(uptream) G FEV1 0.036 0.008 2.40E-06 -0.091 0.011 6.34E-18 -0.016 0.018 3.86E-01 
15 rs8040868(76698236), CHRNA3(coding-synon) T FEV1/FVC 0.04 0.008 1.14E-06 -0.09 0.011 2.53E-17 -0.023 0.019 2.26E-01 
 
36 
 
C) Relation of16 novel lung function loci, and previously reported loci, with height. Effects of the 16 novel SNPs, 
and previously reported SNPs, associated with lung function on height were looked up in the GIANT 
dataset90. Directions of effect for height have been flipped to refer to the same coded allele as lung function. 
Both effect sizes for lung and for height can be interpreted as proportion of a standard deviation. P values 
still significant after applying a Bonferroni correction for 16 tests (P<0.003125) are shown in bold. Results for 
the SpiroMeta-CHARGE Stage 1 and Stage 2 meta-analysis for the lung function measure that showed 
stronger association are reported for the novel loci. Results from the GWAS Stage 1 for the lung function 
measure that showed stronger association are reported for the previously reported loci. A column indicating 
whether the effect of each SNP on height is on the same direction as the effect on lung is included. 
Abbreviations: ns=nonsynonymous, s= synonymous. 
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Chr. SNP ID(NCBI36 position),  function 
Coded 
allele  Measure 
Lung function  
(Stage 1+ Stage 2 meta-analysis) 
Height   
(GIANT consortium) 
Relationship of direction of 
effect on height to direction 
of effect on lung function 
  Beta  Se  P  Beta Se P  
Novel loci 
1 rs2284746 (17179262),  MFAP2(intron) G FEV1/FVC -0.04 0.005 7.50E-16 0.0354 0.0045 5.638E-15 different 
1 rs993925 (216926691),  TGFB2(downstream) T FEV1/FVC 0.034 0.006 1.16E-08 0.0105 0.005 3.605E-02 same 
2 rs12477314 (239542085),  HDAC4(downstream) T FEV1/FVC 0.041 0.006 1.68E-12 -0.0029 0.0057 6.124E-01 different 
3 rs1529672 (25495586),  RARB(intron) C FEV1/FVC -0.048 0.006 3.97E-14 0.0012 0.0063 8.494E-01 different 
3 rs1344555 (170782913),  MECOM(intron) T FEV1 -0.034 0.006 2.65E-08 -0.0145 0.0056 9.681E-03 same 
5 rs153916 (95062456),  SPATA9(upstream) T FEV1/FVC -0.031 0.005 2.12E-08 0.0027 0.0045 5.513E-01 different 
6 rs6903823 (28430275),  ZKSCAN3(intron)/ZNF323(intron) G FEV1 -0.037 0.006 2.18E-10 -0.0017 0.0056 7.617E-01 same 
6 rs2857595 (31676448),  NCR3(upstream) G FEV1/FVC 0.037 0.006 2.28E-10 -0.0148 0.006 1.306E-02 different 
6 rs2798641 (109374743),  ARMC2(intron) T FEV1/FVC -0.041 0.007 8.35E-09 -0.0042 0.0058 4.723E-01 same 
10 rs7068966 (12317998),  CDC123(intron) T FEV1/FVC 0.033 0.005 6.13E-13 0.0078 0.0045 8.521E-02 same 
10 rs11001819 (77985230),  C10orf11(intron) G FEV1 -0.029 0.004 2.98E-12 0.0024 0.0045 5.964E-01 different 
12 rs11172113 (55813550),  LRP1(intron) T FEV1/FVC -0.032 0.006 1.24E-08 0.003 0.0047 5.189E-01 different 
12 rs1036429 (94795559),  CCDC38(intron) T FEV1/FVC 0.038 0.006 2.30E-11 -0.0053 0.0056 3.444E-01 different 
16 rs12447804 (56632783),  MMP15(intron) T FEV1/FVC -0.038 0.007 3.59E-08 0.0077 0.0075 3.054E-01 different 
16 rs2865531 (73947817),  CFDP1(intron) T FEV1/FVC 0.031 0.005 1.77E-11 -0.0129 0.0045 4.418E-03 different 
21 rs9978142 (34574109),  KCNE2(upstream) T FEV1/FVC -0.043 0.008 2.65E-08 -0.0122 0.0062 4.914E-02 same 
Previously reported loci  
2 rs2571445 (218391399), TNS1(ns) G FEV1 0.047 0.007 9.83E-11 -0.0032 0.0047 4.914E-01 different 
2 rs10498230 (229210747), PID1(downstream) T FEV1/FVC 0.068 0.014 1.13E-06 -0.0111 0.0087 2.023E-01 different 
4 rs2045517 (90089987), FAM13A(intron) T FEV1/FVC -0.047 0.007 2.00E-11 0.0058 0.0045 2.006E-01 different 
4 rs7671167 (90103002), FAM13A(intron) T FEV1/FVC -0.042 0.007 1.27E-09 0.0072 0.0045 1.121E-01 different 
4 rs10516526 (106908353), GSTCD(intron) G FEV1 0.108 0.014 4.75E-14 0.0032 0.0092 7.275E-01 same 
4 rs17331332 (107027556), NPNT(upstream) G FEV1 -0.102 0.014 1.11E-12 -0.002 0.0093 8.298E-01 same 
4 rs6823809 (107048244), NPNT(intron) T FEV1/FVC 0.056 0.011 2.20E-07 -0.0001 0.0072 9.888E-01 different 
4 rs1032296 (145654138), HHIP(upstream) T FEV1/FVC -0.05 0.007 3.42E-12 -0.0152 0.0047 1.082E-03 same 
4 rs11100860 (145698589), HHIP(upstream) G FEV1/FVC 0.064 0.007 6.81E-20 0.0151 0.0045 8.618E-04 same 
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Lung function  
(Stage 1+ Stage 2 meta-analysis) 
Height   
(GIANT consortium) 
Relationship of direction of 
effect on height to direction 
of effect on lung function 
 Chr. SNP ID(NCBI36 position),  function 
Coded 
allele  Measure Beta  Se  P  Beta Se P  
5 rs11168048 (147822546), HTR4(intron) T FEV1/FVC -0.047 0.007 5.97E-11 -0.0133 0.0049 6.524E-03 same 
5 rs3995090 (147826008), HTR4(intron) C FEV1/FVC 0.046 0.007 1.04E-10 0.0143 0.0049 3.448E-03 same 
5 rs1985524 (147827981), HTR4(intron) G FEV1 -0.048 0.007 3.06E-11 -0.015 0.0049 2.156E-03 same 
5 rs11134779 (156869344), ADAM19(intron) G FEV1/FVC -0.042 0.007 6.01E-09 -0.0092 0.0047 4.791E-02 same 
6 rs2070600 (32259421), AGER(ns) T FEV1/FVC 0.126 0.016 9.07E-15 0.0094 0.0114 4.116E-01 same 
6 rs3817928 (142792209), GPR126(intron) G FEV1/FVC 0.059 0.008 2.27E-12 -0.0368 0.0055 1.967E-11 different 
6 rs262129 (142894837), LOC153910(unknown) G FEV1/FVC 0.056 0.008 2.91E-13 -0.0443 0.005 9.173E-19 different 
9 rs16909859 (97244613), PTCH1(downstream) G FEV1/FVC 0.08 0.013 7.45E-10 -0.0266 0.0082 1.226E-03 different 
9 rs16909898 (97270829), PTCH1(intron) G FEV1/FVC -0.072 0.012 3.94E-09 0.0313 0.0078 5.392E-05 different 
15 rs12899618 (69432174), THSD4(intron) G FEV1/FVC 0.076 0.01 1.86E-15 -0.0075 0.0061 2.175E-01 different 
15 rs8033889 (69467134), THSD4(intron) T FEV1/FVC -0.072 0.008 2.03E-17 0.0015 0.0054 7.798E-01 different 
15 rs2568494 (76528019), IREB2(intron) G FEV1/FVC 0.029 0.007 5.25E-05 0.0021 0.0047 6.516E-01 same 
15 rs8034191 (76593078), CHRNA3/5(intron) T FEV1/FVC 0.032 0.007 9.65E-06 -0.0002 0.0047 9.657E-01 different 
15 rs2036527 (76638670), CHRNA5(uptream) G FEV1 0.036 0.008 2.40E-06 -0.0005 0.0048 9.165E-01 different 
15 rs8040868 (76698236), CHRNA3(s)  T FEV1/FVC 0.04 0.008 1.14E-06 -0.006 0.0064 3.515E-01 different 
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D) Relation of 16 novel lung function loci, and previously reported loci, with lung cancer. Effects of the 16 novel 
SNPs, and previously reported SNPs, associated with lung function on lung cancer were assessed in the 
International Lung Cancer Consortium (ILCCO) GWAS meta-analysis37. Directions of effect for lung cancer 
have been flipped to refer to the same coded allele as lung function. P values still significant after applying a 
Bonferroni correction for 16 tests (P<0.003125) are shown in bold. The ILCCO GWAS meta-analysis only had 
genotyped data, for this reason proxy SNPs were given when the top SNP was not included in their data. 
Leading SNP, region name and r2 between leading SNP and proxy SNP are also provided. Results for the 
SpiroMeta-CHARGE Stage 1 and Stage 2 meta-analysis are reported for the SNPs that were followed up in 
Stage 2 and were included in the lung cancer dataset (rs1529672, rs2857595, rs2798641, rs11001819, 
rs11172113, rs1036429) and results from the GWAS Stage 1 only are provided for the other loci, for the lung 
function measure that showed stronger association.  
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Chr. Proxy SNP ID (NCBI36 position), function 
Leading SNP (region name), r
2
 with 
proxy 
Coded 
allele 
Lung function Lung cancer 
Measure Beta  Se  P  Beta Se P 
Novel loci 
1 rs761423 (17174259), MFAP2 (intron) rs2284746 (MFAP2), 0.63 T FEV1/FVC 0.038 0.007 8.72E-08 0.033 0.017 6.24E-02 
1 rs2871775 (17218492), SDHB (intron) rs2284746 (MFAP2), 0.66 G FEV1/FVC -0.040 0.007 9.08E-09 -0.015 0.017 3.81E-01 
2 rs4591362 (239542675), HDAC4(downstream) rs12477314 (HDAC4), 0.94 G FEV1/FVC -0.049 0.009 8.29E-09 -0.020 0.021 3.49E-01 
3 rs1529672 (25495586), RARB (intron) rs1529672 (RARB), 1 C FEV1/FVC -0.048 0.006 3.97E-14 -0.013 0.027 6.33E-01 
3 rs2056777 (25515395), RARB (intron) rs1529672 (RARB), 0.77 T FEV1/FVC -0.050 0.009 5.31E-08 -0.011 0.027 6.80E-01 
3 rs1362772 (170739927), MECOM(intron) rs1344555 (MECOM), 1 T FEV1 -0.040 0.009 3.24E-06 -0.010 0.022 6.63E-01 
3 rs7642776 (170753972), MECOM(intron) rs1344555 (MECOM), 0.94 G FEV1 0.038 0.008 5.38E-06 0.013 0.021 5.37E-01 
5 rs2548125 (95037182), SPATA9 (intron) rs153916 (SPATA9), 0.61 G FEV1/FVC -0.029 0.007 3.50E-05 -0.012 0.018 5.08E-01 
6 rs209181 (28900456), LOC401242 (downstream) rs6903823 (ZKSCAN3/ZNF323), 0.69 G FEV1 0.035 0.012 2.25E-03 -0.106 0.026 3.41E-05 
6 rs3099844 (31556955), HCG26 (downstream) rs2857595 (NCR3), 0.67 C FEV1 0.058 0.011 1.92E-07 -0.141 0.027 2.21E-07 
6 rs2857595 (31676448), NCR3(upstream) rs2857595 (NCR3), 1 G FEV1/FVC 0.037 0.006 2.28E-10 -0.051 0.022 1.91E-02 
6 rs1475055 (109350925), ARMC2 (intron) rs2798641 (ARMC2), 0.73 T FEV1/FVC 0.027 0.008 7.67E-04 -0.011 0.020 5.87E-01 
6 rs2798641 (109374743), ARMC2 (intron) rs2798641 (ARMC2), 1 T FEV1/FVC -0.041 0.007 8.35E-09 0.006 0.022 7.72E-01 
10 rs1317549 (12285320), CDC123 (intron) rs7068966 (CDC123), 0.68 T FEV1/FVC -0.038 0.007 8.95E-08 0.013 0.018 4.78E-01 
10 rs4478891 (12307660), CDC123 (intron) rs7068966 (CDC123), 0.85 G FEV1/FVC 0.043 0.007 8.71E-10 -0.005 0.018 7.61E-01 
10 rs2130800 (77944824), C10orf11 (intron) rs11001819 (C10orf11), 0.73 T FEV1 0.038 0.007 5.45E-08 0.031 0.017 7.80E-02 
10 rs11001819 (77985230), C10orf11 (intron) rs11001819 (C10orf11), 1 G FEV1 -0.029 0.004 2.98E-12 -0.051 0.020 1.21E-02 
10 rs2637260 (77990352), C10orf11 (downstream) rs11001819 (C10orf11), 0.72 T FEV1 0.035 0.007 7.38E-07 0.024 0.017 1.72E-01 
12 rs11172113 (55813550), LRP1 (intron) rs11172113 (LRP1), 1 T FEV1/FVC -0.032 0.006 1.24E-08 -0.010 0.018 5.84E-01 
12 rs1466535 (55820737), LRP1 (intron) rs11172113 (LRP1), 0.72 G FEV1/FVC -0.025 0.007 5.76E-04 0.004 0.018 8.45E-01 
12 rs7307510 (94761701), SNRPF (upstream) rs1036429 (CCDC38), 0.96 T FEV1/FVC 0.049 0.009 3.49E-08 0.009 0.023 6.82E-01 
12 rs1036429 (94795559), CCDC38 (intron) rs1036429 (CCDC38), 1 T FEV1/FVC 0.038 0.006 2.30E-11 0.011 0.022 6.06E-01 
16 rs2304488 (56631711), MMP15 (intron) rs12447804 (MMP15), 0.88 G FEV1/FVC -0.040 0.008 9.45E-07 0.019 0.021 3.62E-01 
16 rs12597233 (56657709), MMP15 (downstream) rs12447804 (MMP15), 0.87 G FEV1/FVC 0.038 0.008 4.80E-06 -0.012 0.022 5.85E-01 
16 rs4243111 (73878328), CFDP1(downstream) rs2865531 (CFDP1), 0.93 T FEV1/FVC -0.037 0.007 1.52E-07 -0.036 0.018 4.22E-02 
16 rs1424013 (74053487), TMEM170 (intron) rs2865531 (CFDP1), 0.82 T FEV1/FVC 0.033 0.007 3.92E-06 0.046 0.018 1.00E-02 
21 rs973754 (34555400), C21orf82 (downstream) rs9978142 (KCNE2), 0.81 G FEV1/FVC -0.043 0.010 2.09E-05 -0.010 0.025 6.78E-01 
Previously reported regions 
2 rs1035672 (218383444), TNS1 (intron) rs2571445 (TNS1), 0.96 G FEV1 -0.046 0.007 3.03E-10 -0.020 0.018 2.66E-01 
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Chr. Proxy SNP ID (NCBI36 position), function 
Leading SNP (region name), r
2
 with 
proxy 
Coded 
allele 
Lung function Lung cancer 
Measure Beta  Se  P  Beta Se P 
2 rs2571445 (218391399), TNS1 (non synonymous) rs2571445 (TNS1), 1 G FEV1 0.047 0.007 9.83E-11 0.016 0.018 3.72E-01 
4 rs2869967 (90088355), FAM13A (intron) rs2045517 (FAM13A), 1 T FEV1/FVC 0.047 0.007 2.08E-11 0.026 0.018 1.36E-01 
4 rs6849143 (90147512), FAM13A (intron) rs2045517 (FAM13A), 0.75 T FEV1/FVC -0.038 0.007 5.99E-08 -0.020 0.018 2.51E-01 
4 rs11727735 (106851319), GSTCD (intron) rs10516526 (GSTCD), 1 G FEV1 0.105 0.014 1.65E-13 -0.029 0.036 4.19E-01 
4 rs10516526 (106908353), GSTCD (intron) rs10516526 (GSTCD), 1 G FEV1 0.108 0.014 4.75E-14 -0.029 0.036 4.31E-01 
4 rs1828591 (145700230), HHIP (upstream) rs11100860 (HHIP), 1 G FEV1/FVC 0.063 0.007 1.44E-19 -0.005 0.018 7.82E-01 
4 rs1512288 (145710731), HHIP (upstream) rs11100860 (HHIP), 1 G FEV1/FVC -0.062 0.007 3.46E-19 0.000 0.018 9.89E-01 
5 rs2277027 (156864954), ADAM19 (intron) rs11134779 (ADAM19), 1 C FEV1/FVC -0.042 0.007 6.65E-09 0.007 0.018 6.93E-01 
5 rs1422795 (156868942), ADAM19 (non synonymous) rs11134779 (ADAM19), 1 T FEV1/FVC 0.041 0.007 1.05E-08 -0.007 0.018 7.11E-01 
6 rs2070600 (32259421), AGER (non synonymous) rs2070600 (AGER), 1 T FEV1/FVC 0.126 0.016 9.07E-15 -0.004 0.044 9.27E-01 
6 rs2854050 (32293583), NOTCH4 (intron) rs2070600 (AGER), 1 G FEV1/FVC -0.083 0.016 9.34E-08 0.022 0.040 5.80E-01 
6 rs6570507 (142721265), GPR126 (intron) rs262129 (GPR126), 0.72 G FEV1/FVC -0.051 0.008 2.25E-11 0.006 0.019 7.49E-01 
6 rs11155242 (142733242), GPR126 (non synonymous) rs3817928 (GPR126), 1 C FEV1/FVC 0.055 0.009 1.88E-10 0.003 0.022 8.99E-01 
6 rs3748069 (142809326), GPR126 (downstream) rs262129 (GPR126), 0.84 G FEV1/FVC 0.053 0.008 2.02E-12 -0.007 0.019 7.01E-01 
6 rs7776356 (142818722), GPR126 (downstream) rs3817928 (GPR126), 1 G FEV1/FVC 0.059 0.008 4.16E-12 -0.001 0.021 9.69E-01 
9 rs10512249 (97296130), PTCH1 (intron) rs16909859 (PTCH1), 0.84 G FEV1/FVC 0.066 0.012 1.54E-08 -0.067 0.029 1.90E-02 
15 rs1913768 (69436598), THSD4 (intron) rs8033889 (THSD4), 0.673 G FEV1/FVC 0.075 0.009 2.77E-15 -0.014 0.024 5.49E-01 
15 rs8033889 (69467134), THSD4 (intron) rs8033889 (THSD4), 1 T FEV1/FVC -0.072 0.008 2.03E-17 0.014 0.025 5.85E-01 
15 rs8034191 (76593078), AGPHD1 (intron) rs8040868 (CHRNA3), 0.70 T FEV1/FVC 0.032 0.007 9.65E-06 -0.258 0.018 2.19E-46 
15 rs1051730 (76681394), CHRNA3 (synonymous) rs8040868 (CHRNA3), 0.76 G FEV1/FVC 0.032 0.007 1.46E-05 -0.273 0.018 1.91E-51 
42 
 
E) Association of published height SNPs with FEV1 and FEV1/FVC. Effects sizes and P values for the 180 loci that 
reached genome-wide significance (P <5x10-8) in the combined Stage1 and 2 analysis of height reported by 
the GIANT consortium90 are shown, together with the effect sizes, standard errors and P values for FEV1 and 
FEV1/FVC in the SpiroMeta-CHARGE GWAS dataset. Directions of effect for height have been flipped to refer 
to the same coded allele as lung function. Both effect sizes for lung and for height can be interpreted as 
proportion of a standard deviation. P values still significant after applying a Bonferroni correction for 180 
tests (P <2.8x10-4) are shown in bold. Columns indicating whether the effect of each SNP on height is on the 
same direction as the effect on lung are included. 
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Chr. 
SNP ID(NCBI36 position),  
Nearest_OMIM_height_gene 
Coded 
allele 
Height FEV1 FEV1/FVC 
Beta P Beta Se P 
Direction of 
effect for 
FEV1 relative 
to height Beta Se P 
Direction of 
effect for 
FEV1/FVC 
relative to 
height 
1 rs425277(2059032),  PRKCZ T 0.022 2.10E-08 0.004 0.008 5.88E-01 same -0.007 0.008 3.68E-01 different 
1 rs2284746(17179262),  MFAP2 G 0.04 3.90E-29 0.008 0.007 2.78E-01 same -0.042 0.007 2.47E-09 different 
1 rs1738475(23409478),  HTR1D G -0.025 3.00E-12 -0.002 0.007 7.73E-01 same -0.004 0.007 5.76E-01 same 
1 rs4601530(24916698),  CLIC4 T -0.028 2.20E-12 0.03 0.008 1.47E-04 different 0.019 0.008 1.32E-02 different 
1 rs7532866(26614131),  LIN28 G -0.021 3.40E-08 -0.017 0.008 2.19E-02 same -0.001 0.007 8.94E-01 same 
1 rs2154319(41518357),  SCMH1 T -0.03 1.80E-12 -0.008 0.009 3.57E-01 same -0.003 0.008 6.80E-01 same 
1 rs17391694(78396214),  GIPC2 T 0.042 1.70E-11 0.013 0.013 3.16E-01 same 0.007 0.012 5.90E-01 same 
1 rs6699417(88896031),  PKN2 T 0.021 5.00E-09 0.001 0.007 8.44E-01 same -0.011 0.007 1.04E-01 different 
1 rs10874746(93096559),  RPL5 T -0.024 6.70E-11 0.005 0.007 4.69E-01 different 0.015 0.007 3.10E-02 different 
1 rs9428104(118657110),  SPAG17 G 0.041 5.60E-23 -0.013 0.008 1.26E-01 different 0.015 0.008 6.91E-02 same 
1 rs11205277(148159496),  SF3B4 G 0.046 4.80E-32 -0.021 0.008 9.16E-03 different -0.011 0.008 1.76E-01 different 
1 rs17346452(170319910),  DNM3 T -0.04 1.40E-23 -0.014 0.008 7.77E-02 same 0.002 0.008 8.09E-01 different 
1 rs1325598(175058872),  PAPPA2 G 0.022 1.10E-09 -0.008 0.007 2.76E-01 different -0.003 0.007 6.59E-01 different 
1 rs1046934(182290152),  TSEN15 C 0.044 2.10E-31 -0.001 0.007 8.97E-01 different 0.01 0.007 1.75E-01 same 
1 rs10863936(210304421),  DTL G 0.021 1.90E-09 -0.003 0.007 6.47E-01 different -0.011 0.007 1.11E-01 different 
1 rs6684205(216676325),  TGFB2 G 0.028 1.50E-12 0.002 0.008 7.94E-01 same -0.007 0.008 3.75E-01 different 
1 rs11118346(217810342),  LYPLAL1 T -0.025 1.90E-12 0.008 0.007 2.61E-01 different 0.004 0.007 5.67E-01 different 
1 rs10799445(225978506),  JMJD4 C -0.032 2.40E-13 0.001 0.008 9.45E-01 different -0.005 0.008 5.67E-01 same 
2 rs4665736(25041103),  DNAJC27 T 0.029 7.30E-16 -0.008 0.007 2.67E-01 different -0.012 0.007 9.28E-02 different 
2 rs6714546(33214929),  LTBP1 G 0.026 1.60E-09 0.004 0.008 6.48E-01 same 0.002 0.008 8.24E-01 same 
2 rs17511102(37814117),  CDC42EP3 T 0.06 1.60E-18 0.004 0.014 7.88E-01 same 0.015 0.013 2.69E-01 same 
2 rs2341459(44621706),  C2orf34 T 0.025 7.90E-10 -0.006 0.008 4.53E-01 different -0.003 0.008 7.13E-01 different 
2 rs12474201(46774789),  SOCS5 G -0.028 2.60E-13 0.001 0.008 9.37E-01 different 0.003 0.007 6.68E-01 different 
2 rs3791675(55964813),  EFEMP1 T -0.053 2.50E-35 -0.02 0.008 1.28E-02 same 0.025 0.008 1.88E-03 different 
2 rs11684404(88705737),  EIF2AK3 T -0.028 9.90E-14 0.02 0.007 7.65E-03 different 0.002 0.007 8.34E-01 different 
2 rs7567288(134151294),  NCKAP5 T -0.032 2.10E-12 0.008 0.009 3.75E-01 different 0.016 0.009 7.32E-02 different 
2 rs7567851(178392966),  PDE11A G -0.037 3.30E-08 -0.009 0.013 4.86E-01 same 0.019 0.013 1.47E-01 different 
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2 rs1351164(217980143),  TNS1 T 0.034 2.10E-14 -0.017 0.009 5.42E-02 different -0.015 0.009 8.06E-02 different 
2 rs12470505(219616613),  CCDC108/IHH T 0.041 8.90E-12 0.007 0.012 5.81E-01 same -0.009 0.012 4.59E-01 different 
2 rs2629046(224755988),  SERPINE2 T 0.024 7.90E-12 -0.009 0.007 1.96E-01 different -0.006 0.007 4.08E-01 different 
2 rs2580816(232506210),  NPPC T -0.045 5.80E-22 0.007 0.009 4.49E-01 different -0.007 0.009 4.75E-01 same 
2 rs12694997(241911659),  SEPT2 G 0.024 1.20E-08 0.004 0.008 5.94E-01 same -0.001 0.008 8.59E-01 different 
3 rs2597513(13530836),  HDAC11 T -0.036 7.40E-10 0.014 0.012 2.45E-01 different 0.025 0.011 2.66E-02 different 
3 rs13088462(51046753),  DOCK3 T -0.052 3.80E-10 -0.011 0.016 5.18E-01 same -0.026 0.016 1.07E-01 same 
3 rs2336725(53093779),  RTF1 T -0.027 9.70E-13 0.002 0.007 7.52E-01 different 0.009 0.007 2.41E-01 different 
3 rs9835332(56642722),  C3orf63 G 0.026 5.30E-13 0.005 0.007 4.41E-01 same 0.006 0.007 3.99E-01 same 
3 rs17806888(67499012),  SUCLG2 T 0.036 2.10E-09 -0.018 0.011 1.16E-01 different -0.02 0.011 8.55E-02 different 
3 rs9863706(72520103),  RYBP T -0.031 4.10E-13 -0.011 0.009 2.00E-01 same 0.002 0.008 8.02E-01 different 
3 rs6439167(130533446),  C3orf47 T -0.034 8.90E-15 -0.014 0.009 9.99E-02 same 0 0.008 9.68E-01 different 
3 rs9844666(137456906),  PCCB G 0.024 3.50E-09 -0.01 0.008 2.04E-01 different -0.001 0.008 9.08E-01 different 
3 rs724016(142588260),  ZBTB38 G 0.07 3.10E-86 -0.003 0.007 6.26E-01 different 0.002 0.007 7.52E-01 same 
3 rs572169(173648421),  GHSR T 0.033 2.80E-18 0.011 0.008 1.64E-01 same 0.008 0.007 2.73E-01 same 
3 rs720390(187031377),  IGF2BP2 G -0.029 1.90E-14 0.004 0.007 5.75E-01 different 0.013 0.007 7.13E-02 different 
4 rs2247341(1671115),  SLBP/FGFR3 G -0.025 1.50E-11 0.017 0.007 1.99E-02 different 0.01 0.007 1.88E-01 different 
4 rs6449353(17642586),  LCORL T 0.075 7.10E-46 0.013 0.01 2.07E-01 same 0.003 0.01 7.57E-01 same 
4 rs17081935(57518233),  POLR2B T 0.03 3.70E-11 0.007 0.009 4.07E-01 same 0.015 0.009 7.98E-02 same 
4 rs7697556(73734177),  ADAMTS3 T 0.028 2.00E-14 -0.007 0.007 3.36E-01 different 0.007 0.007 3.32E-01 same 
4 rs788867(82369030),  PRKG2/BMP3 T -0.043 8.90E-28 0.005 0.008 4.86E-01 different 0.002 0.008 8.03E-01 different 
4 rs10010325(106325802),  TET2 C -0.024 3.90E-11 -0.009 0.007 2.16E-01 same -0.014 0.007 4.05E-02 same 
4 rs7689420(145787802),  HHIP T -0.073 6.20E-51 -0.008 0.009 4.21E-01 same -0.008 0.009 3.84E-01 same 
4 rs955748(184452669),  WWC2 G 0.023 4.40E-08 -0.003 0.008 7.19E-01 different -0.011 0.008 1.54E-01 different 
5 rs1173727(32866278),  NPR3 T 0.034 1.60E-21 -0.009 0.007 1.82E-01 different -0.002 0.007 7.23E-01 different 
5 rs11958779(55037656),  SLC38A9 G 0.027 1.80E-12 0.005 0.008 4.73E-01 same -0.008 0.007 2.65E-01 different 
5 rs10037512(88390431),  MEF2C T 0.032 2.00E-18 0.002 0.007 7.77E-01 same 0.003 0.007 7.19E-01 same 
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5 rs13177718(108141243),  FER T -0.04 3.00E-08 0.002 0.014 8.90E-01 different 0.021 0.014 1.33E-01 different 
5 rs1582931(122685098),  CEP120 G 0.023 1.50E-10 0.005 0.007 4.54E-01 same 0.002 0.007 7.95E-01 same 
5 rs274546(131727766),  SLC22A5 G 0.029 7.30E-16 -0.007 0.007 3.13E-01 different 0.001 0.007 8.87E-01 same 
5 rs526896(134384604),  PITX1 T 0.03 2.30E-13 0 0.008 9.51E-01 different 0.007 0.008 3.83E-01 same 
5 rs4282339(168188818),  SLIT3 G 0.036 6.60E-16 0.003 0.009 7.55E-01 same 0.006 0.009 4.97E-01 same 
5 rs12153391(171136043),  FBXW11 C 0.03 3.60E-12 -0.001 0.008 8.96E-01 different -0.007 0.008 3.99E-01 different 
5 rs889014(172916720),  BOD1 T -0.03 9.40E-16 0.008 0.007 2.83E-01 different 0.004 0.007 5.72E-01 different 
5 rs422421(176449932),  FGFR4/NSD1 T -0.031 1.10E-12 0.005 0.009 5.76E-01 different 0.018 0.008 3.90E-02 different 
5 rs6879260(179663620),  GFPT2 T -0.022 1.60E-09 0.003 0.007 7.20E-01 different -0.014 0.007 5.38E-02 same 
6 rs3812163(7670759),  BMP6 T 0.036 1.20E-23 -0.026 0.007 2.14E-04 different -0.001 0.007 9.33E-01 different 
6 rs1047014(19949472),  ID4 T -0.032 1.80E-13 0.005 0.009 5.44E-01 different -0.011 0.008 1.78E-01 same 
6 rs806794(26308656),  Histone cluster G -0.052 1.20E-39 0.006 0.008 4.67E-01 different -0.013 0.008 9.67E-02 same 
6 rs3129109(29192211),  OR2J3 T -0.032 2.40E-17 -0.01 0.007 1.61E-01 same 0.001 0.007 8.49E-01 different 
6 rs2256183(31488508),  MICA G -0.04 7.80E-29 0.007 0.007 3.11E-01 different 0.01 0.007 1.46E-01 different 
6 rs6457620(32771977),  HLA locus G 0.029 2.10E-16 -0.002 0.007 7.58E-01 different -0.025 0.007 2.92E-04 different 
6 rs2780226(34307070),  HMGA1 T -0.076 8.10E-28 -0.015 0.014 2.63E-01 same 0.023 0.014 8.63E-02 different 
6 rs6457821(35510783),  PPARD/FANCE C 0.104 2.10E-12 -0.007 0.029 7.96E-01 different 0.058 0.028 3.97E-02 same 
6 rs9472414(45054484),  SUPT3H/RUNX2 T 0.026 1.80E-09 -0.002 0.008 7.97E-01 different 0.003 0.008 7.01E-01 same 
6 rs9360921(76322362),  SENP6 T -0.042 2.60E-13 0.015 0.011 1.81E-01 different 0.011 0.011 3.36E-01 different 
6 rs310405(81857081),  FAM46A G -0.026 2.20E-13 -0.007 0.007 3.14E-01 same -0.012 0.007 9.00E-02 same 
6 rs7759938(105485647),  LIN28B T -0.045 8.30E-31 0.016 0.008 3.93E-02 different -0.006 0.008 4.26E-01 same 
6 rs1046943(109890634),  ZBTB24 G -0.02 2.50E-08 -0.012 0.007 8.88E-02 same 0 0.007 9.46E-01 different 
6 rs961764(117628849),  VGLL2 G 0.024 1.30E-11 -0.003 0.007 6.42E-01 different 0.009 0.007 2.23E-01 same 
6 rs1490384(126892853),  C6orf173 T 0.034 3.90E-21 0.022 0.007 2.07E-03 same -0.002 0.007 7.46E-01 different 
6 rs6569648(130390812),  L3MBTL3 T -0.04 1.10E-21 -0.002 0.008 8.41E-01 same 0.013 0.008 1.13E-01 different 
6 rs7763064(142838982),  GPR126 G 0.048 1.10E-33 -0.03 0.008 1.33E-04 different -0.052 0.008 6.80E-12 different 
6 rs543650(152152636),  ESR1 T -0.034 1.20E-17 0.002 0.008 7.58E-01 different 0.002 0.008 8.44E-01 different 
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6 rs9456307(158849430),  TULP4 T 0.048 2.20E-09 0.001 0.016 9.38E-01 same -0.007 0.016 6.76E-01 different 
7 rs798489(2768329),  GNA12 T -0.048 1.90E-33 0.006 0.008 4.72E-01 different -0.002 0.008 7.93E-01 same 
7 rs4470914(19583047),  TWISTNB T 0.029 9.20E-10 -0.008 0.01 4.25E-01 different -0.014 0.009 1.39E-01 different 
7 rs12534093(23469499),  IGF2BP3 T 0.034 2.00E-14 0.008 0.008 3.46E-01 same -0.003 0.008 7.43E-01 different 
7 rs1708299(28156471),  JAZF1 G -0.04 5.80E-25 0.014 0.008 6.07E-02 different 0.002 0.008 8.31E-01 different 
7 rs6959212(38094851),  STARD3NL T -0.024 1.60E-09 0.003 0.008 7.21E-01 different 0.002 0.008 7.68E-01 different 
7 rs42235(92086012),  CDK6 T 0.057 7.70E-47 0 0.008 9.50E-01 different -0.007 0.008 3.52E-01 different 
7 rs822552(148281567),  PDIA4 G 0.025 2.60E-08 -0.023 0.009 8.01E-03 different -0.003 0.009 7.28E-01 different 
7 rs2110001(150147955),  TMEM176A G 0.031 3.30E-13 0.019 0.008 1.86E-02 same 0.007 0.008 4.03E-01 same 
8 rs1013209(24172249),  ADAM28 T -0.025 1.60E-09 0.021 0.008 1.03E-02 different -0.002 0.008 8.37E-01 same 
8 rs7460090(57356717),  SDR16C5 T 0.058 8.20E-27 0.012 0.011 2.52E-01 same -0.003 0.01 8.07E-01 different 
8 rs6473015(78341040),  PEX2 C 0.029 6.90E-13 0.011 0.008 1.72E-01 same -0.002 0.008 8.42E-01 different 
8 rs6470764(130794847),  GSDMC T -0.05 1.70E-28 -0.004 0.009 6.39E-01 same -0.002 0.009 8.34E-01 same 
8 rs12680655(135706519),  ZFAT G -0.028 1.60E-14 0.016 0.007 2.15E-02 different 0.014 0.007 4.40E-02 different 
9 rs7864648(16358732),  BNC2 T 0.022 2.10E-08 0 0.008 9.87E-01 different 0.004 0.008 6.30E-01 same 
9 rs11144688(77732106),  PCSK5 G 0.049 9.60E-12 0.001 0.015 9.29E-01 same 0.009 0.015 5.31E-01 same 
9 rs7853377(85742025),  C9orf64 G 0.024 4.50E-08 0.007 0.009 4.29E-01 same 0.008 0.009 3.38E-01 same 
9 rs8181166(88306448),  ZCCHC6 G -0.026 2.70E-12 0.014 0.007 5.36E-02 different 0.003 0.007 6.68E-01 different 
9 rs2778031(90025546),  SPIN1 T 0.031 9.00E-13 0.005 0.008 5.62E-01 same 0.01 0.008 2.16E-01 same 
9 rs9969804(94468941),  IPPK C -0.03 7.70E-17 0.003 0.007 6.58E-01 different 0.015 0.007 3.15E-02 different 
9 rs1257763(95933766),  PTPDC1 G -0.069 9.90E-10 -0.003 0.022 8.98E-01 same -0.005 0.022 8.13E-01 same 
9 rs473902(97296056),  PTCH1/FANCC T 0.065 2.30E-17 -0.012 0.016 4.26E-01 different -0.024 0.015 1.16E-01 different 
9 rs7027110(108638867),  ZNF462 G -0.031 2.30E-13 0.024 0.008 3.80E-03 different 0.01 0.008 2.35E-01 different 
9 rs1468758(112846903),  LPAR1 T -0.026 1.40E-09 -0.004 0.008 6.21E-01 same -0.006 0.008 4.26E-01 same 
9 rs751543(118162163),  PAPPA T 0.026 6.50E-10 -0.005 0.008 5.47E-01 different -0.003 0.008 7.14E-01 different 
9 rs7466269(132453905),  FUBP3 G -0.032 2.60E-17 -0.012 0.007 1.11E-01 same -0.02 0.007 6.62E-03 same 
9 rs7849585(138251691),  QSOX2 T 0.029 4.70E-14 0.014 0.008 7.84E-02 same -0.002 0.008 8.08E-01 different 
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10 rs7909670(12958770),  CCDC3 T -0.021 3.20E-09 0.002 0.007 7.78E-01 different -0.001 0.007 8.76E-01 same 
10 rs2145998(80791702),  PPIF T 0.026 3.60E-13 0 0.007 9.72E-01 different 0.006 0.007 3.59E-01 same 
10 rs11599750(101795432),  CPN1 T -0.028 1.60E-13 -0.01 0.007 1.55E-01 same -0.012 0.007 9.58E-02 same 
11 rs2237886(2767307),  KCNQ1 T 0.046 2.20E-13 -0.005 0.012 7.13E-01 different -0.008 0.012 5.31E-01 different 
11 rs7926971(12654616),  TEAD1 G 0.023 4.40E-10 -0.017 0.007 1.41E-02 different 0.006 0.007 3.59E-01 same 
11 rs1330(17272605),  NUCB2 T 0.022 4.90E-09 -0.007 0.008 3.32E-01 different 0.003 0.007 7.11E-01 same 
11 rs10838801(48054856),  PTPRJ/SLC39A13 G 0.027 3.50E-12 -0.01 0.008 1.94E-01 different -0.008 0.008 2.87E-01 different 
11 rs1814175(49515748),  FOLH1 T 0.022 1.60E-08 -0.006 0.008 4.80E-01 different 0.002 0.008 8.07E-01 same 
11 rs5017948(51270794),  OR4A5 T -0.027 3.10E-08 -0.002 0.01 8.63E-01 same 0 0.009 9.70E-01 different 
11 rs3782089(65093395),  SSSCA1 T -0.058 3.60E-13 -0.019 0.016 2.45E-01 same 0.009 0.016 5.74E-01 different 
11 rs7112925(66582736),  RHOD T -0.023 9.00E-10 0.003 0.007 7.14E-01 different -0.001 0.007 8.98E-01 same 
11 rs634552(74959700),  SERPINH1 T 0.039 3.50E-13 -0.024 0.01 2.15E-02 different -0.007 0.01 4.72E-01 different 
11 rs494459(118079885),  TREH T 0.02 1.70E-08 0.003 0.007 6.23E-01 same -0.003 0.007 6.39E-01 different 
11 rs654723(128091365),  FLI1 C -0.025 3.60E-11 0.003 0.007 6.98E-01 different 0.002 0.007 7.78E-01 different 
12 rs2856321(11747040),  ETV6 G 0.029 4.50E-15 -0.008 0.007 2.50E-01 different -0.013 0.007 6.49E-02 different 
12 rs10770705(20748734),  SLCO1C1 C -0.033 8.00E-18 0.014 0.008 6.45E-02 different 0.004 0.007 6.38E-01 different 
12 rs2638953(28425682),  CCDC91 G -0.032 6.70E-17 0.018 0.007 1.70E-02 different -0.003 0.007 6.80E-01 same 
12 rs2066807(55026949),  STAT2 G 0.054 1.00E-13 0.018 0.014 2.07E-01 same -0.001 0.014 9.16E-01 different 
12 rs1351394(64638093),  HMGA2 T 0.06 1.70E-65 0.012 0.007 8.47E-02 same 0.016 0.007 2.12E-02 same 
12 rs10748128(68113925),  FRS2 T 0.038 2.10E-20 -0.009 0.008 2.63E-01 different -0.005 0.008 5.37E-01 different 
12 rs11107116(92502635),  SOCS2 T 0.052 1.40E-34 0.008 0.008 3.14E-01 same -0.006 0.008 4.67E-01 different 
12 rs7971536(100897919),  CCDC53/GNPTAB T 0.028 8.20E-14 0.012 0.007 9.22E-02 same 0.003 0.007 7.20E-01 same 
12 rs11830103(122389499),  SBNO1 G 0.035 3.90E-15 -0.01 0.009 2.67E-01 different -0.015 0.009 7.90E-02 different 
13 rs7332115(32045548),  PDS5B/BRCA2 T -0.023 5.50E-10 -0.006 0.007 4.16E-01 same 0.007 0.007 3.49E-01 different 
13 rs3118905(50003335),  DLEU7 G 0.056 1.10E-45 -0.024 0.008 2.40E-03 different -0.004 0.008 6.44E-01 different 
13 rs7319045(90822575),  GPC5 G -0.025 1.20E-11 -0.01 0.007 1.70E-01 same -0.012 0.007 1.09E-01 same 
14 rs1950500(23900690),  NFATC4 T 0.034 2.20E-18 -0.011 0.008 1.62E-01 different -0.004 0.008 6.24E-01 different 
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14 rs2093210(60027032),  SIX6 T -0.032 6.20E-17 -0.007 0.008 3.77E-01 same 0.011 0.008 1.30E-01 different 
14 rs1570106(67882868),  RAD51L1 T -0.026 8.10E-09 -0.018 0.009 4.56E-02 same -0.021 0.009 1.46E-02 same 
14 rs862034(74060499),  LTBP2 G 0.028 7.30E-14 -0.013 0.007 8.64E-02 different -0.003 0.007 6.97E-01 different 
14 rs7155279(91555634),  TRIP11 T -0.024 1.40E-10 0.019 0.007 1.01E-02 different 0.008 0.007 2.81E-01 different 
15 rs16964211(49317787),  CYP19A1 G 0.05 1.70E-09 0.012 0.016 4.66E-01 same -0.009 0.016 5.85E-01 different 
15 rs7178424(60167551),  C2CD4A T -0.021 5.60E-09 -0.012 0.007 8.08E-02 same -0.007 0.007 2.93E-01 same 
15 rs10152591(67835211),  TLE3 C -0.041 2.70E-10 -0.002 0.013 8.45E-01 same -0.002 0.012 8.65E-01 same 
15 rs12902421(69948457),  MYO9A T -0.062 2.90E-08 0.01 0.023 6.75E-01 different 0.026 0.023 2.51E-01 different 
15 rs5742915(72123686),  PML T -0.031 1.00E-15 0.002 0.008 8.21E-01 different 0.017 0.008 2.85E-02 different 
15 rs11259936(82371586),  ADAMTSL3 C 0.044 1.70E-35 0.009 0.007 1.90E-01 same 0.021 0.007 2.77E-03 same 
15 rs16942341(87189909),  ACAN T -0.13 3.80E-27 0.004 0.024 8.80E-01 different -0.002 0.023 9.38E-01 same 
15 rs2871865(97012419),  IGF1R G -0.057 2.90E-21 -0.004 0.012 7.61E-01 same 0.017 0.012 1.35E-01 different 
15 rs4965598(98577137),  ADAMTS17 T -0.028 4.30E-13 -0.003 0.008 7.15E-01 same 0.015 0.007 4.02E-02 different 
16 rs11648796(732191),  NARFL G 0.034 1.20E-13 -0.01 0.01 3.22E-01 different 0.002 0.01 8.69E-01 same 
16 rs26868(2189377),  CASKIN1 T -0.034 9.00E-17 0.004 0.008 6.11E-01 different 0 0.008 9.87E-01 different 
16 rs1659127(14295806),  MKL2 G -0.027 1.10E-11 -0.008 0.008 3.08E-01 same 0.005 0.008 5.47E-01 different 
16 rs8052560(87304743),  CTU2/GALNS C -0.029 3.30E-08 0.002 0.011 8.43E-01 different -0.001 0.011 9.52E-01 same 
17 rs4640244(21224816),  KCNJ12 G -0.024 2.30E-08 -0.004 0.008 6.03E-01 same 0.003 0.008 7.20E-01 different 
17 rs3110496(24941897),  ANKRD13B G 0.022 7.30E-09 -0.006 0.008 4.54E-01 different -0.012 0.007 1.05E-01 different 
17 rs3764419(26188149),  ATAD5/RNF135 C 0.035 1.80E-21 -0.016 0.007 2.56E-02 different 0.002 0.007 8.21E-01 same 
17 rs17780086(27367395),  LRRC37B G -0.028 2.60E-08 -0.002 0.01 8.22E-01 same -0.025 0.01 1.31E-02 same 
17 rs1043515(34175722),  PIP4K2B G 0.023 2.90E-10 -0.005 0.007 4.46E-01 different -0.027 0.007 1.22E-04 different 
17 rs4986172(40571807),  ACBD4 T -0.032 2.30E-16 -0.009 0.008 2.55E-01 same -0.008 0.007 2.76E-01 same 
17 rs2072153(44745013),  ZNF652 G -0.021 3.50E-08 -0.002 0.008 7.84E-01 same -0.007 0.007 3.54E-01 same 
17 rs4605213(46599746),  NME2 G -0.021 2.70E-08 0.013 0.008 9.69E-02 different -0.002 0.007 8.19E-01 same 
17 rs227724(52133816),  NOG T 0.03 7.40E-15 -0.001 0.007 8.41E-01 different -0.001 0.007 8.74E-01 different 
17 rs2079795(56851431),  TBX2 T 0.04 2.10E-24 -0.023 0.008 2.78E-03 different -0.006 0.008 4.24E-01 different 
Contd. 
Contd. 
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Chr. 
SNP ID(NCBI36 position),  
Nearest_OMIM_height_gene 
Coded 
allele 
Height FEV1 FEV1/FVC 
Beta P Beta Se P 
Direction of 
effect for 
FEV1 relative 
to height Beta Se P 
Direction of 
effect for 
FEV1/FVC 
relative to 
height 
17 rs2665838(59320197),  CSH1/GH1 G 0.042 5.10E-25 0.006 0.008 4.31E-01 same 0 0.008 9.82E-01 different 
17 rs11867479(65601802),  KCNJ16/KCNJ2 T 0.025 1.50E-10 -0.007 0.008 3.65E-01 different 0.006 0.008 4.25E-01 same 
18 rs4800452(18981609),  CABLES1 T 0.051 4.20E-30 -0.023 0.009 7.84E-03 different 0 0.009 9.98E-01 different 
18 rs9967417(45213498),  DYM G 0.038 9.30E-25 -0.004 0.007 6.04E-01 different -0.002 0.007 7.65E-01 different 
18 rs17782313(56002077),  MC4R T -0.028 3.80E-11 -0.016 0.008 5.22E-02 same 0 0.008 9.59E-01 different 
19 rs12982744(2128193),  DOT1L G 0.03 3.40E-16 -0.01 0.007 1.80E-01 different -0.002 0.007 7.38E-01 different 
19 rs7507204(3379834),  NFIC G -0.036 4.30E-16 -0.006 0.009 5.22E-01 same -0.007 0.009 3.90E-01 same 
19 rs891088(7135762),  INSR G 0.029 2.40E-12 0 0.008 9.59E-01 different 0.002 0.008 8.30E-01 same 
19 rs4072910(8550031),  ADAMTS10 G 0.031 3.60E-13 0.002 0.009 8.23E-01 same -0.003 0.009 6.93E-01 different 
19 rs2279008(17144303),  MYO9B T 0.025 2.50E-08 -0.004 0.009 6.89E-01 different 0.004 0.009 6.61E-01 same 
19 rs17318596(46628935),  ATP5SL G -0.032 5.00E-16 0.006 0.008 4.39E-01 different 0.003 0.008 6.73E-01 different 
20 rs1741344(4049800),  SMOX T -0.023 3.30E-09 0.012 0.007 1.09E-01 different 0 0.007 9.82E-01 different 
20 rs2145272(6574218),  BMP2 G 0.039 2.10E-24 -0.018 0.007 1.84E-02 different 0.016 0.007 2.60E-02 same 
20 rs7274811(31796842),  ZNF341 T -0.041 5.90E-22 -0.003 0.008 7.03E-01 same -0.004 0.008 5.87E-01 same 
20 rs143384(33489170),  GDF5 G 0.063 1.00E-58 0.004 0.008 1.54E-01 same 0.018 0.008 1.45E-02 same 
20 rs237743(47336426),  ZNFX1 G -0.041 1.30E-20 0.008 0.007 3.65E-01 different 0.008 0.008 3.41E-01 different 
21 rs2834442(34612656),  KCNE2 T -0.026 5.10E-12 -0.002 0.007 1.82E-01 same -0.024 0.007 9.36E-04 same 
22 rs4821083(31386341),  SYN3 T 0.031 3.10E-10 0.03 0.008 1.93E-01 same -0.014 0.01 1.54E-01 different 
Contd. 
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Supplementary Table 4 Associations in never-smokers and ever-smokers in the Stage 1 and 2 data, and tests for 
interaction with smoking.  
Each of the SNPs included in the table showed genome-wide significant association (P<5x10-8) with either FEV1 or 
FEV1/FVC in the Stage 1 and 2 data. The stratum-specific estimates are shown for Stage 1 (GWAS), Stage 2 and Stage 
1 + 2 data for the trait with the strongest association. P values for the interaction between ever-smokers and never-
smokers in the combined Stage 1 + 2 meta-analysis are shown.  
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Chr. 
SNP_ID 
(NCBI36 
position), 
function 
Measure 
Stage 1 Stage 2 Stage 1 + Stage 2 meta-analysis 
Interaction Ever-smokers 
 
Never-smokers 
 
Ever-smokers 
 
Never-smokers 
 
Ever-smokers Never-smokers 
Beta Se P Beta Se P Beta Se P Beta Se P Beta Se Beta Se P 
1 rs2284746 
(17179262),  
MFAP2 
(intron) 
FEV1/FVC -0.046 0.009 5.82E-07 -0.036 0.010 3.43E-04 -0.039 0.010 1.04E-04 -0.037 0.011 7.02E-04 -0.043 0.007 -0.036 0.007 5.12E-01 
1 rs993925 
(216926691),  
TGFB2 
(downstream) 
FEV1/FVC 0.047 0.010 4.85E-06 0.032 0.011 4.59E-03 0.031 0.014 2.29E-02 0.016 0.014 2.43E-01 0.041 0.008 0.026 0.009 1.91E-01 
2 rs12477314 
(239542085),  
HDAC4 
(downstream) 
FEV1/FVC 0.054 0.012 3.58E-06 0.049 0.013 1.14E-04 0.042 0.011 1.90E-04 0.019 0.011 9.56E-02 0.048 0.008 0.032 0.008 1.88E-01 
3 rs1529672 
(25495586),  
RARB 
(intron) 
FEV1/FVC -0.072 0.013 1.64E-08 -0.044 0.014 1.97E-03 -0.047 0.012 7.44E-05 -0.025 0.012 3.80E-02 -0.059 0.009 -0.033 0.009 4.29E-02 
3 rs1344555 
(170782913),  
MECOM 
(intron) 
FEV1 -0.053 0.012 5.13E-06 -0.029 0.012 2.05E-02 -0.022 0.013 8.79E-02 -0.029 0.012 1.57E-02 -0.040 0.009 -0.029 0.009 3.81E-01 
5 rs153916 
(95062456),  
SPATA9 
(upstream) 
FEV1/FVC -0.041 0.009 6.39E-06 -0.022 0.010 2.81E-02 -0.022 0.013 9.55E-02 -0.028 0.013 3.31E-02 -0.035 0.008 -0.024 0.008 3.28E-01 
6 rs6903823 
(28430275),  
ZKSCAN3 
(intron)/ 
ZNF323 
(intron) 
FEV1 -0.043 0.012 3.30E-04 -0.051 0.012 4.20E-05 -0.033 0.012 5.79E-03 -0.027 0.011 1.63E-02 -0.038 0.008 -0.037 0.008 9.64E-01 
6 rs2857595 
(31676448),  
NCR3 
(upstream) 
FEV1/FVC 0.053 0.012 9.43E-06 0.045 0.013 7.01E-04 0.035 0.011 1.91E-03 0.020 0.012 7.59E-02 0.043 0.008 0.031 0.009 3.11E-01 
6 rs2798641 
(109374743),  
ARMC2 
(intron) 
FEV1/FVC -0.056 0.012 2.97E-06 -0.036 0.013 6.55E-03 -0.038 0.017 2.70E-02 -0.020 0.017 2.45E-01 -0.050 0.010 -0.030 0.010 1.67E-01 
 
 
                
 
 
Contd. 
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Chr. SNP_ID 
(NCBI36 
position), 
function 
Measure Stage 1 Stage 2 Stage 1 + Stage 2 meta-analysis 
Interaction 
Ever-smokers Never-smokers Ever-smokers Never-smokers Ever-smokers Never-smokers 
Beta Se P Beta Se P Beta Se P Beta Se P Beta Se Beta Se P 
10 rs7068966 
(12317998),  
CDC123 
(intron) 
FEV1/FVC 0.053 0.009 4.55E-09 0.034 0.010 7.48E-04 0.029 0.009 1.31E-03 0.016 0.009 7.72E-02 0.041 0.006 0.024 0.007 7.15E-02 
10 rs11001819 
(77985230),  
C10orf11 
(intron) 
FEV1 -0.036 0.010 1.61E-04 -0.047 0.010 2.99E-06 -0.020 0.008 9.85E-03 -0.023 0.007 1.23E-03 -0.026 0.006 -0.031 0.006 5.56E-01 
12 rs11172113 
(55813550),  
LRP1 (intron) 
FEV1/FVC -0.036 0.010 1.66E-04 -0.034 0.010 1.01E-03 -0.033 0.013 1.31E-02 -0.020 0.013 1.40E-01 -0.035 0.008 -0.029 0.008 5.97E-01 
12 rs1036429 
(94795559),  
CCDC38 
(intron) 
FEV1/FVC 0.049 0.011 1.76E-05 0.050 0.012 6.28E-05 0.039 0.011 3.91E-04 0.019 0.011 8.77E-02 0.044 0.008 0.033 0.008 3.45E-01 
16 rs12447804 
(56632783),  
MMP15 
(intron) 
FEV1/FVC -0.058 0.013 7.47E-06 -0.047 0.014 6.79E-04 -0.029 0.014 4.77E-02 -0.011 0.014 4.31E-01 -0.045 0.010 -0.030 0.010 2.71E-01 
16 rs2865531 
(73947817),  
CFDP1 (intron) 
FEV1/FVC 0.034 0.009 2.23E-04 0.045 0.010 9.48E-06 0.033 0.009 2.19E-04 0.014 0.009 1.20E-01 0.034 0.006 0.028 0.007 5.42E-01 
21 rs9978142 
(34574109),  
KCNE2 
(upstream) 
FEV1/FVC -0.055 0.013 1.61E-05 -0.040 0.014 5.06E-03 -0.046 0.019 1.34E-02 -0.018 0.019 3.25E-01 -0.052 0.011 -0.032 0.011 1.94E-01 
Contd. 
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Supplementary Table 5 Lung function associations (FEV1 and FEV1/FVC) in Stage 1 for all previously reported loci (A) 
and all SNPs taken forward to follow-up in Stage 2 (B). 
A) Effects in the SpiroMeta-CHARGE dataset of loci previously reported to be associated with FEV1, FEV1/FVC, or 
COPD1,2,91-94 providing that they also showed association with lung function, are shown for both lung function 
measures. Details of the selection of these SNPs are shown in the Online Methods. P values below 5x10-8 for 
FEV1 and FEV1/FVC are shown in bold. The sample sizes (N) shown are the effective sample sizes. Effective 
sample size within each study is the product of sample size and imputation quality metric. For each locus, 
the most significant SNP for either FEV1 or FEV1/FVC (as indicated in the third column) in the SpiroMeta-
CHARGE dataset (SpiroMeta-CHARGE in 2nd column) is also included. Abbreviations: ns=nonsynonymous, s= 
synonymous. 
Previous studies which report these loci are Cho et al. (2010)91, DeMeo et al. (2009)94, Hancock et al. (2010)1, 
Pillai et al. (2009)92, Repapi et al. (2010)2 and Wilk et al. (2009)93. 
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Chr. Paper reported Measure SNP ID (NCBI36 position),  function Region name 
Coded 
allele 
FEV1 FEV1/FVC N 
Beta  
(Se)  
P 
Beta  
(Se)  
P 
2 Repapi et al. FEV1 rs2571445(218391399), TNS1(ns) TNS1 G 
0.047 
(0.007) 
9.83E-11 
0.033 
(0.007) 
4.46E-06 45839 
2 Hancock et al. FEV1/FVC rs10498230(229210747), PID1(downstream) PID1 T 
0.03 
(0.014) 
3.60E-02 
0.068 
(0.014) 
1.13E-06 44957 
4 Hancock et al. FEV1/FVC rs2869967(90088355), FAM13A FAM13A T 
0.012 
(0.007) 
9.38E-02 
0.047 
(0.007) 
2.08E-11 47710 
4 SpiroMeta-CHARGE FEV1/FVC rs2045517(90089987), FAM13A (intron) FAM13A T 
-0.012 
(0.007) 
8.93E-02 
-0.047 
(0.007) 
2.00E-11 47675 
4 Cho et al. COPD rs7671167(90103002), FAM13A FAM13A T 
-0.017 
(0.007) 
1.64E-02 
-0.042 
(0.007) 
1.27E-09 47723 
4 Repapi et al. FEV1 rs10516526(106908353), GSTCD(intron) GSTCD-NPNT G 
0.108 
(0.014) 
4.75E-14 
0.039 
(0.014) 
6.17E-03 47970 
4 Hancock et al. FEV1 rs17331332(107027556), NPNT (upstream) GSTCD-NPNT G 
-0.102 
(0.014) 
1.11E-12 
-0.057 
(0.014) 
5.30E-05 39503 
4 SpiroMeta-CHARGE FEV1/FVC rs6823809(107048244), NPNT(intron) GSTCD-NPNT T 
0.050 
(0.011) 
4.82E-06 
0.056 
(0.011) 
2.20E-07 23656 
4 SpiroMeta-CHARGE FEV1 rs1032296(145654138), HHIP(upstream) HHIP T 
-0.047 
(0.007) 
8.74E-11 
-0.050 
(0.007) 
3.42E-12 45318 
4 Repapi et al. FEV1/FVC rs12504628(145655774), HHIP HHIP T 
-0.044 
(0.007) 
1.03E-09 
-0.063 
(0.007) 
5.54E-19 46204 
4 Wilk et al. FEV1/FVC rs11100860(145698589), HHIP(upstream) HHIP G 
0.041 
(0.007) 
4.27E-09 
0.064 
(0.007) 
6.81E-20 47876 
4 Hancock et al. FEV1/FVC rs1980057(145705188), HHIP HHIP T 
0.042 
(0.007) 
4.07E-09 
0.063 
(0.007) 
1.06E-19 47865 
5 Hancock et al. FEV1/FVC rs11168048(147822546), HTR4(intron) HTR4 T 
-0.046 
(0.007) 
2.43E-10 
-0.047 
(0.007) 
5.97E-11 44976 
5 Repapi et al. FEV1 rs3995090(147826008), HTR4 HTR4 C 
0.045 
(0.007) 
3.33E-10 
0.046 
(0.007) 
1.04E-10 47607 
5 SpiroMeta-CHARGE FEV1 rs1985524(147827981), HTR4 HTR4 G 
-0.048 
(0.007) 
3.06E-11 
-0.045 
(0.007) 
2.90E-10 45623 
5 Hancock et al. FEV1/FVC rs2277027(156864954), ADAM19 ADAM19 C 
-0.026 
(0.007) 
3.10E-04 
-0.042 
(0.007) 
6.65E-09 48023 
5 SpiroMeta-CHARGE FEV1/FVC rs11134779(156869344), ADAM19(intron) ADAM19 G 
-0.027 
(0.007) 
2.40E-04 
-0.042 
(0.007) 
6.01E-09 48075 
6 
Hancock et al. and 
Repapi et al. FEV1/FVC rs2070600(32259421), AGER(ns) AGER T 
0.025 
(0.016) 
1.27E-01 
0.126 
(0.016) 
9.07E-15 46314 
6 Repapi et al. FEV1/FVC rs2395730(39892343), DAAM2 (intron) DAAM2 C 
-0.004 
(0.007) 
5.95E-01 
0.022 
(0.007) 
1.39E-03 47256 
6 SpiroMeta-CHARGE FEV1/FVC rs11756622(39898021), DAAM2 (intron) DAAM2 T 
0.047 
(0.019) 
1.23E-02 
0.064 
(0.019) 
5.48E-04 28276 
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Chr. Paper reported Measure SNP ID (NCBI36 position),  function Region name 
Coded 
allele 
FEV1 FEV1/FVC N 
Beta  
(Se)  
P 
Beta  
(Se)  
P 
6 Hancock et al. FEV1/FVC rs3817928(142792209), GPR126 
GPR126- 
LOC153910 G 
0.023 
(0.009) 
8.63E-03 
0.059 
(0.008) 
2.27E-12 46730 
6 SpiroMeta-CHARGE FEV1/FVC 
rs262129(142894837), 
LOC153910(unknown) 
GPR126- 
LOC153910 G 
0.031 
(0.008) 
5.44E-05 
0.056 
(0.008) 
2.91E-13 47014 
9 SpiroMeta-CHARGE FEV1/FVC 
rs16909859(97244613), 
PTCH1(downstream) PTCH1 G 
-0.014 
(0.013) 
2.93E-01 
0.08 
(0.013) 
7.45E-10 43353 
9 Hancock et al. FEV1/FVC rs16909898(97270829), PTCH1 PTCH1 G 
0.015 
(0.012) 
2.21E-01 
-0.072 
(0.012) 
3.94E-09 42486 
15 Repapi et al. FEV1/FVC rs12899618(69432174), THSD4 THSD4 G 
0.036 
(0.01) 
1.57E-04 
0.076 
(0.01) 
1.86E-15 46657 
15 SpiroMeta-CHARGE FEV1/FVC rs8033889(69467134), THSD4 (intron) THSD4 T 
-0.044 
(0.009) 
3.01E-07 
-0.072 
(0.008) 
2.03E-17 46995 
15 DeMeo et al (2009) COPD rs2568494(76528019), IREB2(intron) 
CHRNA3-CHRNA5-
IREB2-LOC123688 G 
0.023 
(0.007) 
1.64E-03 
0.029 
(0.007) 
5.25E-05 47919 
15 Pillai et al. (2009) COPD rs8034191(76593078), LOC123688 
CHRNA3-CHRNA5-
IREB2-LOC123688 T 
0.031 
(0.007) 
2.07E-05 
0.032 
(0.007) 
9.65E-06 47954 
15 SpiroMeta-CHARGE FEV1 rs2036527(76638670), CHRNA5(uptream) 
CHRNA3-CHRNA5-
IREB2-LOC123688 G 
0.036 
(0.008) 
2.40E-06 
0.032 
(0.007) 
1.19E-05 45038 
15 SpiroMeta-CHARGE FEV1/FVC rs8040868(76698236), CHRNA3(s)  
CHRNA3-CHRNA5-
IREB2-LOC123688 T 
0.039 
(0.008) 
2.98E-06 
0.04 
(0.008) 
1.14E-06 35121 
Contd. 
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B) Tests for association with lung function for all SNPs followed up in Stage 2. 34 SNPs which showed novel evidence 
of association (P < 3x10-6) were followed up for both lung function measures in Stage 2. The sample sizes (N) shown 
are the effective sample sizes for Stage 1, Stage 2 and the joint analysis of Stage 1 and 2. Effective sample size within 
each study is the product of sample size and imputation quality metric. P< 5x10-8 for Stage 1 and 2 are shown in bold. 
Abbreviations: ns=nonsynonymous, s= synonymous. For the CHRNA3/5 and MMP15 regions, the lead SNP had an 
effective sample size ≥70 but <80% and so a proxy SNP was also included. For the CHRNA3/5, MICB/NCR3 and 
CDC123 regions, there were different top SNPs for FEV1 and FEV1/FVC and so both lead SNPs were taken forward. 
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Chr. Measure SNP_ID (NCBI36 position), function 
Coded 
allele 
Stage 1 Stage 2 Stage 1 + Stage 2 meta-analysis 
Beta (Se)  P N Beta (Se)  P N Beta (Se) P N 
1 FEV1/FVC rs2284746 (17179262), MFAP2(intron) G -0.042 (0.007) 2.47E-09 45944 -0.038 (0.007) 2.64E-07 35310 -0.04 (0.005) 7.50E-16 81254 
1 FEV1 rs2284746 (17179262), MFAP2(intron) G 0.008 (0.007) 2.78E-01 45944 0.006 (0.007) 3.70E-01 35310 0.007 (0.005) 1.48E-01 81254 
1 FEV1/FVC rs993925 (216926691), TGFB2(downstream) T 0.04 (0.007) 2.54E-07 42402 0.023 (0.01) 1.76E-02 21162 0.034 (0.006) 1.16E-08 63564 
1 FEV1 rs993925 (216926691), TGFB2(downstream) T 0.025 (0.007) 1.51E-03 42402 0.003 (0.007) 7.29E-01 21162 0.014 (0.005) 8.71E-03 63564 
2 FEV1/FVC rs2544527 (15843619), DDX1(downstream) T -0.04 (0.007) 1.08E-07 45352 0 (0.01) 9.75E-01 21115 -0.026 (0.006) 8.73E-06 66467 
2 FEV1 rs2544527 (15843619), DDX1(downstream) T -0.024 (0.007) 1.55E-03 45352 -0.017 (0.007) 1.95E-02 21115 -0.021 (0.005) 5.53E-05 66467 
2 FEV1/FVC rs3769124 (239014101), ASB1(intron) G -0.038 (0.01) 1.95E-04 44924 -0.032 (0.02) 1.11E-01 10579 -0.036 (0.009) 2.83E-05 55503 
2 FEV1 rs3769124 (239014101), ASB1(intron) G -0.053 (0.01) 2.76E-07 44924 -0.023 (0.02) 2.44E-01 10579 -0.047 (0.009) 6.50E-08 55503 
2 FEV1/FVC rs12477314 (239542085), HDAC4(downstream) T 0.052 (0.008) 4.48E-09 45585 0.031 (0.008) 8.41E-05 45704 0.041 (0.006) 1.68E-12 91289 
2 FEV1 rs12477314 (239542085), HDAC4(downstream) T 0.032 (0.008) 2.77E-04 45585 0.025 (0.007) 1.82E-04 45704 0.028 (0.005) 1.02E-07 91289 
3 FEV1/FVC rs1529672 (25495586), RARB(intron) C -0.06 (0.009) 7.75E-10 40624 -0.038 (0.009) 1.16E-05 45386 -0.048 (0.006) 3.97E-14 86010 
3 FEV1 rs1529672 (25495586), RARB(intron) C -0.037 (0.009) 1.78E-04 40624 -0.011 (0.007) 9.33E-02 45386 -0.02 (0.006) 2.16E-04 86010 
3 FEV1/FVC rs9310995 (32904119), TRIM71(intron) T 0.017 (0.007) 1.70E-02 44835 -0.013 (0.009) 1.60E-01 21070 0.007 (0.006) 2.36E-01 65905 
3 FEV1 rs9310995 (32904119), TRIM71(intron) T 0.035 (0.007) 1.28E-06 44835 0.009 (0.007) 2.00E-01 21070 0.023 (0.005) 3.60E-06 65905 
3 FEV1/FVC rs1344555 (170782913), MECOM(intron) T -0.019 (0.008) 2.61E-02 46067 -0.017 (0.012) 1.55E-01 21104 -0.018 (0.007) 6.65E-03 67171 
3 FEV1 rs1344555 (170782913), MECOM(intron) T -0.042 (0.008) 1.91E-06 46067 -0.025 (0.009) 6.44E-03 21104 -0.034 (0.006) 2.65E-08 67171 
4 FEV1/FVC rs1541374 (106267809), TET2(upstream) T -0.026 (0.007) 5.56E-04 45221 -0.014 (0.01) 1.72E-01 20516 -0.022 (0.006) 2.05E-04 65737 
4 FEV1 rs1541374 (106267809), TET2(upstream) T -0.036 (0.007) 2.43E-06 45221 -0.015 (0.007) 4.36E-02 20516 -0.026 (0.005) 5.80E-07 65737 
5 FEV1/FVC rs1551943 (52230790), ITGA1(intron) G 0.048 (0.008) 1.20E-08 43787 0.007 (0.008) 3.71E-01 45914 0.026 (0.006) 2.43E-06 89701 
5 FEV1 rs1551943 (52230790), ITGA1(intron) G 0.022 (0.008) 9.93E-03 43787 -0.006 (0.006) 3.53E-01 45914 0.004 (0.005) 3.61E-01 89701 
5 FEV1/FVC rs153916 (95062456), SPATA9(upstream) T -0.033 (0.007) 2.06E-06 47530 -0.025 (0.009) 6.67E-03 21428 -0.031 (0.005) 2.12E-08 68958 
5 FEV1 rs153916 (95062456), SPATA9(upstream) T -0.001 (0.007) 8.91E-01 47530 0.004 (0.007) 6.22E-01 21428 0.001 (0.005) 8.20E-01 68958 
5 FEV1/FVC rs10067603 (131831767), C5orf56(downstream) G -0.04 (0.008) 1.60E-06 44134 -0.006 (0.011) 6.03E-01 21167 -0.028 (0.006) 1.46E-05 65301 
5 FEV1 rs10067603 (131831767), C5orf56(downstream) G -0.007 (0.008) 3.83E-01 44134 0.013 (0.008) 1.14E-01 21167 0.002 (0.006) 6.74E-01 65301 
6 FEV1/FVC rs1928168 (22125717), AK026189(intron) T 0.037 (0.007) 8.99E-08 47936 0.011 (0.009) 2.40E-01 21323 0.028 (0.005) 1.69E-07 69259 
6 FEV1 rs1928168 (22125717), AK026189(intron) T 0.025 (0.007) 2.61E-04 47936 0.002 (0.007) 7.69E-01 21323 0.015 (0.005) 2.25E-03 69259 
6 FEV1/FVC rs6903823 (28430275), ZKSCAN3(intron)/ZNF323(intron) G -0.027 (0.008) 2.28E-03 47057 -0.013 (0.011) 2.34E-01 21428 -0.021 (0.007) 1.19E-03 68485 
6 FEV1 rs6903823 (28430275), ZKSCAN3(intron)/ZNF323(intron) G -0.046 (0.008) 2.00E-07 47057 -0.029 (0.008) 4.75E-04 21428 -0.037 (0.006) 2.18E-10 68485 
Contd. 
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Chr. Measure SNP_ID(NCBI36 position), function 
Coded 
allele 
Stage 1 Stage 2 Stage 1 + Stage 2 meta-analysis 
Beta (Se)  P N Beta (Se)  P N Beta (Se) P N 
6 FEV1/FVC rs3094548 (29463181), OR12D2(upstream) G -0.027 (0.008) 1.15E-03 42516 -0.015 (0.01) 1.37E-01 20733 -0.022 (0.006) 3.39E-04 63249 
6 FEV1 rs3094548 (29463181), OR12D2(upstream) G -0.042 (0.008) 4.11E-07 42516 -0.016 (0.008) 3.60E-02 20733 -0.029 (0.005) 1.45E-07 63249 
6 FEV1/FVC rs2855812 (31580699), MICB(intron) T -0.034 (0.008) 5.11E-05 46921 -0.015 (0.011) 1.59E-01 21190 -0.027 (0.006) 2.45E-05 68111 
6 FEV1 rs2855812 (31580699), MICB(intron) T -0.045 (0.008) 8.57E-08 46921 -0.013 (0.008) 1.06E-01 21190 -0.03 (0.006) 1.80E-07 68111 
6 FEV1/FVC rs2857595 (31676448), NCR3(upstream) G 0.049 (0.009) 7.86E-08 45540 0.028 (0.008) 5.36E-04 45657 0.037 (0.006) 2.28E-10 91197 
6 FEV1 rs2857595 (31676448), NCR3(upstream) G 0.04 (0.009) 1.46E-05 45540 0.017 (0.007) 9.41E-03 45657 0.025 (0.005) 1.30E-06 91197 
6 FEV1/FVC rs2647044 (32775888), HLA-DQB1(upstream) G 0.053 (0.011) 2.71E-06 44610 0.007 (0.022) 7.63E-01 8381 0.044 (0.01) 5.95E-06 52991 
6 FEV1 rs2647044 (32775888), HLA-DQB1(upstream) G 0.031 (0.011) 6.71E-03 44610 0.009 (0.022) 6.71E-01 8381 0.027 (0.01) 5.62E-03 52991 
6 FEV1/FVC rs2798641 (109374743), ARMC2(intron) T -0.047 (0.009) 2.81E-07 46369 -0.03 (0.012) 1.57E-02 20999 -0.041 (0.007) 8.35E-09 67368 
6 FEV1 rs2798641 (109374743), ARMC2(intron) T -0.046 (0.009) 5.39E-07 46369 -0.009 (0.01) 3.35E-01 20999 -0.03 (0.006) 4.69E-06 67368 
6 FEV1/FVC rs3734729 (150612560), PPP1R14C(untranslated-3) G -0.045 (0.017) 8.71E-03 43680 -0.058 (0.023) 1.00E-02 20998 -0.05 (0.013) 1.93E-04 64678 
6 FEV1 rs3734729 (150612560), PPP1R14C(untranslated-3) G -0.085 (0.016) 1.08E-06 43680 -0.021 (0.017) 2.24E-01 20998 -0.055 (0.012) 4.48E-06 64678 
10 FEV1/FVC rs1878798 (12283489), CDC123(intron) G 0.042 (0.007) 3.48E-09 46164 0.024 (0.009) 1.15E-02 21086 0.035 (0.005) 9.56E-11 67250 
10 FEV1 rs1878798 (12283489), CDC123(intron) G 0.042 (0.007) 3.11E-09 46164 0.015 (0.007) 3.65E-02 21086 0.029 (0.005) 1.84E-09 67250 
10 FEV1/FVC rs7068966 (12317998), CDC123(intron) T 0.045 (0.007) 1.28E-10 47085 0.023 (0.006) 3.86E-04 45892 0.033 (0.005) 6.13E-13 92977 
10 FEV1 rs7068966 (12317998), CDC123(intron) T 0.04 (0.007) 1.19E-08 47085 0.022 (0.005) 3.56E-05 45892 0.029 (0.004) 2.82E-12 92977 
10 FEV1/FVC rs11001819 (77985230), C10orf11(intron) G -0.019 (0.007) 6.50E-03 45546 -0.006 (0.006) 3.17E-01 45677 -0.012 (0.005) 7.58E-03 91223 
10 FEV1 rs11001819 (77985230), C10orf11(intron) G -0.041 (0.007) 1.42E-08 45546 -0.022 (0.005) 3.10E-05 45677 -0.029 (0.004) 2.98E-12 91223 
12 FEV1/FVC rs4762767 (19757396), AEBP2(downstream) G -0.036 (0.007) 2.42E-06 48016 -0.008 (0.011) 4.47E-01 21324 -0.027 (0.006) 8.15E-06 69340 
12 FEV1 rs4762767 (19757396), AEBP2(downstream) G -0.028 (0.007) 3.85E-04 48016 -0.012 (0.008) 1.34E-01 21324 -0.021 (0.005) 1.52E-04 69340 
12 FEV1/FVC rs11172113 (55813550), LRP1(intron) T -0.035 (0.007) 1.36E-06 45387 -0.026 (0.01) 5.83E-03 20256 -0.032 (0.006) 1.24E-08 65643 
12 FEV1 rs11172113 (55813550), LRP1(intron) T -0.021 (0.007) 3.55E-03 45387 -0.003 (0.007) 6.94E-01 20256 -0.013 (0.005) 1.19E-02 65643 
12 FEV1/FVC rs1036429 (94795559), CCDC38(intron) T 0.049 (0.008) 1.24E-08 47814 0.028 (0.008) 3.35E-04 46183 0.038 (0.006) 2.30E-11 93997 
12 FEV1 rs1036429 (94795559), CCDC38(intron) T 0.01 (0.008) 2.67E-01 47814 0.004 (0.006) 5.38E-01 46183 0.006 (0.005) 2.26E-01 93997 
15 FEV1/FVC rs2036527 (76638670), CHRNA5(uptream) G 0.032 (0.007) 1.19E-05 45038 0 (0.01) 9.82E-01 20874 0.022 (0.006) 1.81E-04 65912 
15 FEV1 rs2036527 (76638670), CHRNA5(uptream) G 0.036 (0.007) 2.40E-06 45038 0.015 (0.008) 5.44E-02 20874 0.026 (0.005) 6.90E-07 65912 
15 FEV1/FVC rs12914385 (76685778), CHRNA3(intron) T -0.03 (0.007) 2.28E-05 47226 0.002 (0.01) 8.08E-01 21327 -0.019 (0.006) 5.17E-04 68553 
15 FEV1 rs12914385 (76685778), CHRNA3(intron) T -0.034 (0.007) 2.95E-06 47226 -0.015 (0.007) 4.10E-02 21327 -0.025 (0.005) 4.72E-07 68553 
15 FEV1/FVC rs8040868 (76698236), CHRNA3(s) T 0.04 (0.008) 1.14E-06 35121 -0.005 (0.01) 6.10E-01 21131 0.022 (0.006) 3.01E-04 56252 
15 FEV1 rs8040868 (76698236), CHRNA3(s) T 0.039 (0.008) 2.98E-06 35121 0.012 (0.007) 9.86E-02 21131 0.025 (0.005) 4.06E-06 56252 
Contd. 
Contd. 
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Chr. Measure SNP_ID(NCBI36 position), function 
Coded 
allele 
Stage 1 Stage 2 Stage 1 + Stage 2 meta-analysis 
Beta (Se)  P N Beta (Se)  P N Beta (Se) P N 
16 FEV1/FVC rs12447804 (56632783), MMP15(intron) T -0.053 (0.009) 7.12E-08 35123 -0.021 (0.01) 4.20E-02 23693 -0.038 (0.007) 3.59E-08 58816 
16 FEV1 rs12447804 (56632783), MMP15(intron) T -0.017 (0.009) 8.02E-02 35123 0.004 (0.007) 5.71E-01 23693 -0.004 (0.006) 4.73E-01 58816 
16 FEV1/FVC rs3743563 (56636666), MMP15(missense) G 0.043 (0.008) 1.80E-07 47179 0.013 (0.008) 1.22E-01 43190 0.028 (0.006) 6.76E-07 90369 
16 FEV1 rs3743563 (56636666), MMP15(missense) G 0.015 (0.008) 8.52E-02 47179 -0.001 (0.007) 8.74E-01 43190 0.006 (0.005) 2.79E-01 90369 
16 FEV1/FVC rs2865531 (73947817), CFDP1(intron) T 0.039 (0.007) 2.30E-08 47594 0.024 (0.006) 1.94E-04 46286 0.031 (0.005) 1.77E-11 93880 
16 FEV1 rs2865531 (73947817), CFDP1(intron) T 0.024 (0.007) 6.30E-04 47594 0.011 (0.005) 3.89E-02 46286 0.016 (0.004) 1.09E-04 93880 
16 FEV1/FVC rs12716852 (76746239), WWOX(intron) G 0.011 (0.007) 1.24E-01 47510 -0.004 (0.009) 6.85E-01 21228 0.006 (0.005) 2.81E-01 68738 
16 FEV1 rs12716852 (76746239), WWOX(intron) G 0.036 (0.007) 3.45E-07 47510 0.013 (0.007) 7.11E-02 21228 0.025 (0.005) 1.92E-07 68738 
21 FEV1/FVC rs9978142 (34574109), KCNE2(upstream) T -0.048 (0.009) 8.23E-07 44577 -0.031 (0.013) 1.75E-02 20693 -0.043 (0.008) 2.65E-08 65270 
21 FEV1 rs9978142 (34574109), KCNE2(upstream) T -0.012 (0.009) 2.47E-01 44577 -0.015 (0.01) 1.35E-01 20693 -0.013 (0.007) 5.57E-02 65270 
Contd. 
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Supplementary Table 6 Estimated number of undiscovered variants and proportion of variance explained.  
Effect sizes and standard errors estimated using non-discovery data are shown for genome-wide significant loci in 
SpiroMeta-CHARGE Stage 1 or Stage1 + 2 data. Sample sizes (N) are effective sample sizes for the non-discovery 
data. Estimates of discovery power for the 26 loci associated with lung function, estimates of the number of variants 
with similar effect sizes, and the proportion of the variance for FEV1 and FEV1/FVC that each individual discovered 
variant explains are shown. The total r2 accounted for by discovered and putative undiscovered variants in 
combination is calculated as the sum of the products of r2 multiplied by the number of estimated variants.   
Chr. 
SNP ID (NCBI36 position),  
function 
FEV1 excluding 
winners' curse bias 
FEV1/FVC 
excluding winners' 
curse bias     
N  
   
Power 
     
Estimated 
variants 
R2 
(%) 
FEV1 
R2 (%) 
FEV1/FVC Beta Se Beta Se 
1 
rs2284746(17179262),  
MFAP2(intron) 0.006 0.007 -0.038 0.007 35371
n2
 0.707 1.4 0.002 0.072 
1 
rs993925(216926691),  
TGFB2(downstream) 0.003 0.007 0.023 0.01 21414
n2
 0.214 4.7 0 0.024 
2 rs2571445(218391399), TNS1(ns) 0.041 0.009 0.034 0.009 29130
s
 0.863 1.2 0.082 0.055 
2 
rs12477314(239542085),  
HDAC4(downstream) 0.025 0.007 0.031 0.008 45821
n2
 0.341 2.9 0.02 0.031 
3 
rs1529672(25495586),  
RARB(intron) -0.011 0.007 -0.038 0.009 45466
n2
 0.376 2.7 0.003 0.041 
3 
rs1344555(170782913),  
MECOM(intron) -0.025 0.009 -0.017 0.012 21313
n2
 0.207 4.8 0.021 0.01 
4 
rs2045517(90089987), FAM13A 
(intron) -0.006 0.009 -0.037 0.009 25736
c
 0.654 1.5 0.002 0.067 
4 
rs10516526(106908353), 
GSTCD(intron) 0.07 0.034 0.035 0.033 7587
sc
 0.627 1.6 0.062 0.016 
4 
rs11100860(145698589), 
HHIP(upstream) 0.042 0.008 0.058 0.007 40202
f
 0.996 1 0.085 0.163 
5 
rs153916(95062456),  
SPATA9(upstream) 0.004 0.007 -0.025 0.009 21647
n2
 0.252 4 0.001 0.031 
5 rs1985524(147827981), HTR4 -0.047 0.017 -0.052 0.017 7204
sc
 0.961 1 0.107 0.134 
5 
rs11134779(156869344), 
ADAM19(intron) -0.03 0.01 -0.023 0.01 25917
c
 0.495 2 0.04 0.024 
6 
rs6903823(28430275),  
ZKSCAN3(intron)/ZNF323(intron) -0.029 0.008 -0.013 0.011 21489
n2
 0.248 4 0.031 0.006 
6 
rs2857595(31676448),  
NCR3(upstream) 0.017 0.007 0.028 0.008 46107
n2
 0.129 7.8 0.009 0.025 
6 rs2070600(32259421), AGER(ns) 0.012 0.04 0.093 0.04 7226
sc
 0.695 1.4 0.001 0.084 
6 
rs2798641(109374743),  
ARMC2(intron) -0.009 0.01 -0.03 0.012 21173
n2
 0.214 4.7 0.002 0.026 
6 
rs262129(142894837), 
LOC153910(unknown) 0.014 0.01 0.045 0.01 25317
c
 0.319 3.1 0.008 0.081 
9 
rs16909859(97244613), 
PTCH1(downstream) -0.021 0.018 0.062 0.017 22923
c
 0.539 1.9 0.006 0.058 
10 
rs7068966(12317998),  
CDC123(intron) 0.022 0.005 0.023 0.006 46067
n2
 0.209 4.8 0.024 0.026 
10 
rs11001819(77985230),  
C10orf11(intron) -0.022 0.005 -0.006 0.006 45932
n2
 0.108 9.3 0.024 0.002 
12 
rs11172113(55813550),  
LRP1(intron) -0.003 0.007 -0.026 0.01 20509
n2
 0.292 3.4 0 0.033 
12 
rs1036429(94795559),  
CCDC38(intron) 0.004 0.006 0.028 0.008 46311
n2
 0.204 4.9 0.001 0.026 
15 
rs8033889(69467134), THSD4 
(intron) -0.039 0.011 -0.072 0.011 28974
s
 0.996 1 0.05 0.174 
16 
rs12447804(56632783),  
MMP15(intron) 0.004 0.007 -0.021 0.01 24398
n2
 0.059 16.8 0.001 0.015 
16 
rs2865531(73947817),  
CFDP1(intron) 0.011 0.005 0.024 0.006 46304
n2
 0.175 5.7 0.006 0.028 
21 
rs9978142(34574109),  
KCNE2(upstream) -0.015 0.01 -0.031 0.013 20944
n2
 0.253 3.9 0.006 0.024 
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Total variants 
 
101.5 
  Total % variance explained by estimated 
variants 
 
1.355 3.016 
Total % polygenic variance explained by 
estimated variants 
 
3.388 7.538 
 
n2 no exclusions in SpiroMeta-CHARGE Stage 2 
s excluding SpiroMeta consortium discovery GWAS of Repapi et al. (2010)  
c excluding CHARGE consortium discovery GWAS of Hancock et al. (2010) 
sc excluding SpiroMeta consortium discovery GWAS of Repapi et al. (2010) and CHARGE consortium discovery GWAS 
of Hancock et al. (2010)  
f excluding FHS from SpiroMeta-CHARGE Stage 1 
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Supplementary Note 
 
PCR expression profiling 
Peripheral blood mononuclear cells were isolated from whole blood using 6% (w/v) dextran and 42%–51% (v/v) 
Percoll gradients (Sigma). Ethical approval for the use of primary cells was obtained from the local ethics 
committees. Total RNA was extracted from samples using an RNeasy kit (Qiagen) as directed by the manufacturer. 
cDNA was generated from 1 μg of RNA template using random hexamers and a SuperScript kit (Invitrogen) as 
directed by the manufacturer. PCR assays were designed to cross intron-exon boundaries and where splice variation 
was known, in order to detect all variants. Primer sequences are given in Supplementary Table 2. All PCR was done 
using Platinum Taq High Fidelity (Invitrogen) with 100 ng of cDNA template in a 25-μl reaction. Cycling conditions 
were as follows: 94 °C for 3 min, 35 cycles of 94 °C for 45 s, 55 °C for 30 s, and 72 °C for 90 s. GAPDH gene was used 
as a positive control for the cDNA quality, and water (H2O) as a negative control. 
 
Linkage disequilibrium at 6p21.32-22.1 region of association with FEV1 and FEV1/FVC. 
The novel signal of association with FEV1/FVC at SNP rs2857595 (upstream of NCR3) is independent (r
2<0.01) of the 
previously reported association of rs2070600 (non-synonymous SNP in AGER).   
The novel signal of association with FEV1 at SNP rs6903823 (intron of ZKSCAN3/ZNF323) is also independent (r
2=0.01) 
of SNP rs2070600 (non-synonymous SNP in AGER) and is in low LD (r2=0.31) with rs2857595 (novel signal upstream 
of NCR3) which show association with FEV1/FVC.  
 
Interaction analysis 
The analysis carried out to test for Gene x Smoking interaction (Supplementary Table 4) was a Z-test comparing the 
effect of a given SNP in ever-smokers and in never-smokers. 
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Effect of pack-years adjustment 
To assess the sensitivity of the results to the amount of cigarettes smoked, an analysis was undertaken on ever-
smokers adjusting for smoking status (current or ex smoker) and pack-years. The cohorts that were included in this 
analysis (BHS2, CARDIA, Gedling, HCS, LBC1936, LifeLines, MESA-Lung, Nottingham Smokers, NSHD, SAPALDIA and 
TwinsUK-II) were a subset of the follow-up studies that were chosen because of the availability of pack-years data. 
As represented below, effect size estimates for ever-smokers adjusted for smoking status and pack years and effect 
sizes for ever-smokers without any smoking adjustment were very similar across the novel loci.  
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Estimation of the number of undiscovered variants and calculation of the proportion of 
variance explained  
Our approach to estimate the number of independent variants associated with lung function measures that have 
similar effect sizes to the 26 variants reported here is based on the approach developed by Park et al.95. We 
estimated winners’ curse bias free effect sizes, and obtained the number of undiscovered variants using the 
discovery power to detect the unbiased effect sizes. 
To calculate the unbiased effect sizes for the 26 genome-wide significant (P<5x10-8) variants we excluded discovery 
data for each variant. Effect size estimates for the 16 novel loci reported here were obtained using SpiroMeta-
CHARGE Stage 2 data. The discovery data for HHIP92,93 included the data from FHS, therefore we excluded this study 
in our estimation of effect size estimates. For the remaining 9 loci previously discovered, effect sizes were calculated 
excluding studies involved in discovery GWAS of Repapi et al. 2010, or discovery GWAS of  Hancock et al. 2010, or 
discovery GWAS  of any of them, as indicated in Supplementary Table 6.  
To estimate the power for discovered associations we followed the approach used by the ICBP consortium for 
systolic and diastolic blood pressure96.This approach takes into account that two phenotypes were analysed in 
parallel and it also takes into account uncertainty about true effect sizes of discovered variants. The discovery power 
is expressed as a function of the true effect sizes and it is then integrated with respect to a joint probability 
distribution for true effect sizes on FEV1 and FEV1/FVC. The unbiased estimates of effect sizes are used as the means 
for the true effect size distributions. 
We followed Park et al. 2010 to obtain the proportion of variance explained by the inferred number of variants. First, 
the number of variants of a given effect size was obtained as the inverse of the power to detect them. Then, the 
proportion of variance explained by a variant of effect size β2i and allele frequency pi was calculated as  
2 pi(i-pi) β
2
i 
V 
where V is the phenotypic variance. Finally, the proportion of variance explained by the inferred number of variants 
is obtained summing the product of the number of variants of a given effect size by the proportion of variance 
explained by one of them, over each of the 26 genome-wide significant (P<5x10-8) variants. We assumed a 
heritability of 40%97-100 to estimate the proportion of the additive polygenic variance of each trait. 
The confidence interval for the total number of variants was obtained using bootstrapping, as in Park et al. 2010.  
MAGENTA analysis 
We tested whether the Stage 1 GWAS results were enriched for known biological pathways using MAGENTA v2101. 
Briefly, MAGENTA defines a P value for each gene that is the lowest SNP P value within 110kb upstream and 40kb 
downstream of the gene and is corrected for gene size, number of SNPs per gene and linkage disequilibrium within 
the region. For each gene set, the null hypothesis that there is a random distribution of gene association score ranks 
within the gene set is tested against the alternative hypothesis that there are more gene association score ranks 
above a given rank cut-off (75th percentile cut-off is recommended for polygenic traits) compared to random 
sampling of 10,000 gene sets of identical size. For each gene set, a false discovery rate (FDR) is calculated as the 
fraction of all randomly sampled gene sets (10,000 x number of gene sets tested) that have more genes with P value 
below the cut off (75th percentile) than in the gene set being tested, divided by the fraction of real gene sets that 
have more genes with P value below the cut off (75th percentile) than in the gene set being tested. 
 
Six databases of biological pathways were tested: including Ingenuity Pathway (June 2008, number of pathways 
n=92), KEGG (2010, n=186), PANTHER Molecular Function (January 2010, n=276), PANTHER Biological Processes 
(January 2010, n=254), PANTHER Pathways (January 2010, n=141) and Gene Ontology (April 2010, n=9542). 
Significance thresholds were Bonferroni corrected for each database. 
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Genes which contain a SNP with r2>0.3 with any of our sentinel SNPs were flagged in the analysis. Genes in the HLA 
region on chromosome 6 were included. 
 
No gene sets were significant for FEV1/FVC.  Two gene sets were significant for FEV1 after multiple testing correction 
for the number of gene sets tested within the database.  
From the KEGG database, a Systemic Lupus Erythematosus (SLE) was significant (P=1x10-3, FDR=0.03). This gene set 
contains 140 genes with an effective number of genes of 74 in this analysis. Flagged genes for this gene set were TNF 
and HIST1H2AL. 
From the PANTHER Biological Processes database, the MHC-I mediated immunity pathway was significant (P=2x10-3, 
FDR=0.019). This gene set contains 22 genes with an effective number of genes of 16 in this analysis. Flagged genes 
for this gene set were MICA and MICB. 
 
GRAIL analysis 
The previously described GRAIL102 algorithm was used to mine PubMed abstracts (prior to 2006), the Gene Ontology 
database and the Novartis Gene Expression Analysis for evidence of functional connections between genes in the 27 
regions associated with lung function.  For each lung function locus, boundaries were defined for testing in GRAIL 
such that all genes containing a SNP with r2>0.3 (see Supplementary Table 2) with the leading SNP in the region 
were included. 
 
No genes were identified that were connected by the literature, Gene Ontology or Expression Atlas to genes in the 
other associated loci (P<0.01). 
 
CNV analysis 
All lead 16 SNPs plus all SNPs with r2>0.8 with any lead SNP were checked for correlation with known CNVs. 192 SNP 
genotypes from HapMap release 24 were compared to 5238 GSV CNV genotypes103 and 1319 McCarroll et al104 CNV 
genotypes  for the same CEU individuals. No SNP had r2>0.3 with any of the CNVs tested. 
 
eQTL analysis  
Within each of the 16 novel regions, the lead SNPs and any SNPs with r2>0.8 with the lead SNP were searched 
against a database of expression SNPs (eSNPs) from lymphoblastoid cell lines105. We report eSNP associations 
exceeding a threshold of P<1.2x10-7.   
SNP rs3130805, a proxy for rs6903823 in ZKSCAN3/ZNF323 (r2=0.69), was significantly associated (P=1.3x10-15) with 
transcript levels of ZFP57. The two top eSNPs in this region showing association with ZFP57 were rs2535238 
(P=2.8x10-34) and rs2747457 (P=3.3x10-34) which were ~350kb away from, and not independent of, rs3130805 
(r2=0.43 and 0.38, respectively). 
SNP rs3799499, another proxy for rs6903823 (r2=0.66), was significantly associated with transcript levels of ZSCAN12 
(P=7.8x10-10). This SNP is 7.3Kb away from, and in strong linkage disequilibrium (r2=1) with, the top eSNP for 
transcript levels of ZSCAN12 (rs7774981, P=4.1x10-10). 
SNP rs2857595, upstream of NCR3, showed significant association with transcript levels of HLA-DRB1 (3 probes, 
strongest P=1x10-10) and HLA-DQA1 (P=3.9x10-9). The top eSNP associated with transcript levels of both of these 
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genes was rs3129763 (P=2x10-36 for HLA-DRB1 and P=2.8x10-39 for HLA-DQA1) which is 1.02Mb away from, and in 
weak LD (r2= 0.30) with, rs2857595. 
SNP rs1424013, a proxy for rs2865531 (r2=0.82), is one of two top eSNPs for transcript levels of CFDP1 (P=3.3x10-10). 
The other top eSNP is rs999675 (P=2.9x10-10) is 190Kb from rs1424013, downstream of CFDP1, and in linkage 
disequilibrium with rs1424013 (r2=0.78). 
SNP rs4478891, a proxy for rs7068966 in CDC123 on chromosome 10, showed significant association with transcript 
levels of OSBPL1A on chromosome 18 (P=1x10-7) suggesting a possible trans regulatory effect of rs4478891. No other 
SNP in the eSNP database showed significant association with transcript levels of OSBPL1A. 
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Individual study descriptions 
Stage 1 GWAS samples and phenotype measurement 
This section describes study-specific characteristics that are not presented in the tables. All participants provided 
written informed consent and studies were approved by local Research Ethics Committees and/or Institutional 
Review boards. 
The Reykjavik Study cohort originally comprised a random sample of 30,795 men and women born in 1907-1935 and 
living in Reykjavik in 1967. A total of 19,381 attended, resulting in 71% recruitment rate. The study sample was 
divided into six groups by birth year and birth date within month. One group was designated for longitudinal follow-
up and was examined in all stages. One group was designated a control group and was not included in examinations 
until 1991. Other groups were invited to participate in specific stages of the study. Between 2002 and 2006, the 
AGES-Reykjavik study re-examined 5,764 survivors of the original cohort who had participated before in the 
Reykjavik Study. Pulmonary function was obtained by spirometry (Vitalograph). Testing was conducted with the 
participant in a standing position and a disposable mouthpiece. Participants were shown how to perform the 
maneuver by the technician before testing. A successful test session was defined as at least three acceptable 
maneuvers. 
Atherosclerosis Risk in Communities (ARIC), is a population based study of risk factors for atherosclerosis and its 
sequelae106 in adults from four U.S. field centers aged 45-64 at recruitment in 1987-1989. ARIC spirometry 
measurements were made with a Collins Survey II water-seal spirometer (Collins Medical, Inc.) and Pulmo-Screen II 
software (PDS Healthcare Products, Inc.). Genotyping was done using the Affymetrix GeneChip SNP Array 6.0 and 
imputation was performed using MACH. Quality control steps for genotyping data included exclusions for call rate 
<95%, minor allele frequency <1%, HWE P<10-5, no chromosomal location, suspected first-degree relative of an 
included individual based on genotype data, or more than 8 standard deviations for any of the first ten principal 
components. The current analysis includes 9,078 Caucasian subjects with genotyping data, pulmonary function 
measures and complete covariate information.  
Details of the British 1958 Birth Cohort biomedical follow-up have been previously reported107 and a full technical 
report is available online (http://www.b58cgene.sgul.ac.uk/report.php). Spirometry at age 44–45 years was done in 
the standing position without nose clips, using a Vitalograph handheld spirometer as previously described108,109. In 
the analysis, all readings with a best-test variation greater than 10% were excluded. 
The Busselton Health Study (BHS) is a longitudinal survey of the town of Busselton in the south-western  
region of Western Australia that began in 1966. In 1994/1995 a cross-sectional community follow-up  
study was undertaken where blood was taken for DNA extraction. A sample of 1,168 European-ancestry  
individuals were genotyped using the Illumina 610-Quad BeadChip (BHS1), and subsequent genotyping  
was carried out on an independent group of 3,038 European-ancestry individuals (BHS2). Spirometric  
measures of forced expired volume in one second (FEV1) and forced vital capacity (FVC) were  
assessed as described previously110,111. 
 
The CHS is a population-based cohort study of risk factors for CHD and stroke in adults > 65 years conducted across 
four U.S. field centers112. CHS spirometry measurements were made with a Collins Survey I water-seal spirometer 
(Collins Medical, Inc.) and software from S&M Instruments. CHS genotyped 3,980 participants free of cardiovascular 
disease at baseline with available DNA and consent to genetic testing. After exclusions for call rate < 95%, sex 
mismatch or discordance with prior genotyping, 3,291 self-identified white participants remained. Of these, 3,140 
had pulmonary function measures and complete covariate information. 
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The CROATIA-Korcula study is a family-based, cross-sectional study in the isolated island of Korcula that included about 
1,000 examinees aged 18-95. Spirometry was performed in the sitting upright position without nose clips, using a Jaegger 
Toennisen spirometer. Three readings were taken for each examinee, at least 15 seconds apart113. Population 
stratification was partially taken into account after adjusting the measures for the 3 first principal components 
drawn from the population genomic kinship matrix computed using the ibs function of the GenABEL114. Additional 
correction of the standard error of effect estimates was undertaken by genomic control115. Effect estimates were 
obtained using the palinear function of the ProbABEL package. 
The CROATIA-Vis study is a family-based, cross-sectional study in the isolated island of Vis that included about 1,000 
examinees aged 18-93. Spirometry was performed in the sitting upright position without nose clips, using a Jaegger 
Toennisen spirometer. Three readings were taken for each examinee, at least 15 seconds apart113. Population 
stratification was partially taken into account after adjusting the measures for the 3 first principal components 
drawn from the population genomic kinship matrix computed using the ibs function of the GenABEL114. Additional 
correction of the standard error of effect estimates was undertaken by genomic control115. Effect estimates were 
obtained using the palinear function of the ProbABEL package. 
Details of the methods of ECRHS I and ECRHS II, a multicentre international cohort study, have been published 
elsewhere116,117. Participants within the ECRHS were eligible for inclusion in this analysis if they were identified by 
random sampling of those who fulfilled the following criteria 1) lived in centres that took part in genome-wide 
genotyping initiative under the auspices of GABRIEL118 AND 2) were initially selected to take part in the ECRHS clinical 
measurements as part of the random sample (ie not specifically selected for inclusion because of any pre-existing 
disease).  Participants were included in this analyses if they also provided a technically satisfactory forced expiratory 
manoeuvre, compliant with ATS spirometry criteria, at the time of the first survey (aged 20-48). Most centres used 
the BIOMEDIN water-sealed spirometer for lung function measures and all centres conducted manoeuvres in the 
sitting position with nose clips on. Further details are available in119. 
The EPIC Norfolk GWA cohort includes 2,566 participants randomly selected from the EPIC-Norfolk Study, a 
population-based cohort study of 25,663 men and women of European descent aged 39-79 years recruited in 
Norfolk, UK between 1993 and 1997109. Respiratory function was assessed by spirometry120,121. Forced expiratory 
volume in 1 second (FEV1) and forced vital capacity (FVC) were measured twice using a portable spirometer (Micro 
Medical, Rochester, United Kingdom). The higher values of the two readings for FEV1 and FVC were used for the 
analyses. 
The FHS is a longitudinal community-based family study that originated in 1948 with the recruitment of adults from 
the town of Framingham, MA.  The offspring of the original cohort were recruited to participate in 1971, and the 
third generation (Gen3) was recruited starting in 2002.  Spirometry has been measured on all three generations of 
the participating families as part of the clinical examinations.  For the original and offspring cohorts, spirometry was 
performed using a 6-L water-filled Collins survey spirometer connected to an Eagle II microprocessor (Collins 
Medical, Braintree, MA) or in later offspring examinations to a personal computer running software developed by 
S&M Instruments, Doylestown, PA. For the Gen3 cohort, spirometry was performed using the CPL System (Collins 
Medical, Braintree, MA) with a dry rolling-seal spirometer. All of these systems provided an automatic correction for 
body temperature and pressure, saturated, and provided quality assurance information.  Each Framingham 
participant’s latest examination with acceptable pulmonary function data was used in this analysis. Eligible 
examinations included original cohort examinations 19, 17, 16 and 13; offspring cohort examinations 7, 6, 5, and 3; 
and Gen3 cohort examination 1. A total of 9,274 subjects were genotyped and exclusions were based on a call rate < 
97%, heterozygosity more than 5 standard deviations from the mean, or excessive non-inheritance.  A total of 8,481 
participants passed the genotyping quality control criteria.  Of these, 7,914 participants with complete spirometry 
and covariate data were used in the final analysis data set.  
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The subjects for the Finnish Twin Cohort (FTC) came from two clinical substudies of twins in Finland: 1. The 
FinnTwin16 study is a nationwide longitudinal cohort study of health behaviors in twins and their families122. The 
participants were 34 MZ twin pairs, who were a subset of 347 twins recruited from the FinnTwin16 study of five 
consecutive birth cohorts (1975–1979) of twins (n = 4929 individuals), and who participated in a clinical study of 
body composition and cardiorespiratory fitness. The study protocol included a bicycle ergometer exercise test with 
gas exchange analysis. A mass flow sensor of the gas exchange device (Sensormedics Co) was used to measure 
forced expiratory volume in one second and forced vital capacity before exercise. 2. The Finnish Twin Study on 
Ageing (FITSA). Participants were recruited from the older Finnish Twin Cohort for a clinical study of functional 
limitations in older women. Clinical assessment was conducted in 2000-2001 at the University of Jyväskylä. The final 
sample consisted of 103 monozygotic (MZ) and 114 dizygotic (DZ) twin pairs. Lung function was measured in the 
standing position using an electronic spirometer (Medikro 202, Kuopio, Finland). The subject was asked to inhale 
maximally and to exhale as fast as possible into a mouthpiece connected to a flow transducer and a flow-volume 
curve was created. At least two tests were performed and the best result taken for the analyses. Spirometer was 
calibrated daily with a three-litre pump and was accurate to within 1%. Both substudies were mainly genotyped as 
part of the GenomEUtwin project of female MZ pairs 123. To avoid taking into account the statistical dependence of 
two related individuals in a family, we selected one twin at random for inclusion in the analysis if both of the MZ 
twins in a pair had the phenotype. 
The Health Aging and Body Composition (Health ABC) study is a prospective observational cohort of well functioning 
individuals aged 70–79 years. The Health ABC study recruited 3,075 community-dwelling African and European 
Americans, men and women, at two field centers at the University of Pittsburgh, Pennsylvania and the University of 
Tennessee, Memphis. Spirometry was performed with a horizontal dry rolling seal spirometer (SensorMedics 
Corporation, Yorba Linda, CA) connected to a computer. Pulmonary function testing followed ATS guidelines for the 
standardization of spirometry, and is described in detail elsewhere124. Health ABC genotyped 1,794 self-described 
white participants at baseline with available DNA and consent to genetics testing; of these 1,661 passed quality 
control benchmarks (call rate > 97%, no sex mismatch, and cryptic relatedness), and 1,472 had pulmonary function 
measurements and complete data on covariates. 
The DNA archive established from the Health 2000 Survey Cohort was used. Details of this study population and 
phenotyping procedures have been previously reported125. Spirometry was done in the standing position without 
nose clips, using a Vitalograph 2150 spirometer. In the analysis, the maximum permissible difference between the 
two highest FEV1 and FVC values was 10%. 
The KORA F4 study (Cooperative Health Research in the Region of Augsburg) is a follow-up study to the KORA-Survey 
2000 (S4, 10/1999 – 7/2001)126. Lung function tests were performed in a subsample of the KORA F4 cohort 
corresponding to a random population sample of subjects born between 1946 and 1965 (age range 41 – 63 years). A 
total of 1321 individuals (618 men, 703 women) were examined. Age was 51.6 ± 5.7 years (mean ± SD), weight was 
79.2 ± 16.8 kg, and height was 1.70 ± 0.09 m. Spirometry was performed in line with the ATS recommendations 127 
using a pneumotachograph-type spirometer (Masterscreen PC, CardinalHealth, Würzburg, Germany) before and 
after inhalation of 200 µg salbutamol. The spirometer was calibrated daily using a 1L-calibration pump 
(CardinalHealth, Würzburg, Germany), and additionally, an internal control was used to ensure constant 
instrumental conditions. The participants performed at least three forced expiratory lung function manoeuvres in 
order to obtain a minimum of two acceptable and reproducible values. The final values of FVC and FEV1 were 
determined based on the best maneuver as defined by the highest sum of FVC and FEV1. For participants who did 
not manage to perform at least two acceptable and reproducible values out of nine trials no lung function 
measurements were recorded. The presence of acute or chronic respiratory diseases as well as medication was 
assessed by a standardized questionnaire. 
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The KORA S3 study (Cooperative Health Research in the Region of Augsburg) is also known as the third MONICA 
survey, which was performed 1994-95 in Augsburg, Germany. The objective and protocol of this survey have been 
published earlier126. The third MONICA survey consisted of a random sample of all registered residents of the city of 
Augsburg aged 25–74 years. For all participants younger than 60, who did not smoke or use inhalers one hour before 
the test, FEV1 and FVC were determined by spirometry in 1997-98. All spirometric tests were performed strictly 
adhering to the ECRHS protocol 116. Tests were accounted valid if at least two technically satisfactory manoeuvres 
could be obtained throughout a maximum of nine trials. Based on the best manoeuvre, which was defined as the 
trail with the highest sum of FVC and FEV1, the values of FVC and FEV1 were determined. 
The Northern Finland Birth Cohort (NFBC) study programme was initiated in the 1960s. The cohort of women and 
their offspring was established  in the provinces of Oulu and Lapland and had an expected date of birth in 1966 
comprising 12231 children (NFBC1966, 15). The NFBC1966 had spirometry and other measurements done at the age 
of 31 years. In NFBC1966, we used a Vitalograph P-model spirometer (Vitalograph Ltd., Buckingham, UK), with a 
volumetric accuracy of ±2% or ±50 mL whichever was greater. The spirometer was calibrated regularly using a 1-Litre 
precision syringe. The spirometric manoeuvre was performed three times but was repeated if the coefficient of 
variation between two maximal readings was >4%. 
The Orkney Complex Disease Study (ORCADES) is an ongoing family-based, cross-sectional study in the isolated 
Scottish archipelago of Orkney. Spirometry was performed in the sitting position without nose clips, using a Spida 
handheld spirometer. Measurements were repeated once and the better reading was used for analysis. Population 
stratification was partially taken into account after adjusting the measures for the 3 first principal components 
drawn from the population genomic kinship matrix computed using the ibs function of the GenABEL114. Additional 
correction of the standard error of effect estimates was undertaken by genomic control115. Effect estimates were 
obtained using the palinear function of the ProbABEL package. 
The Rotterdam Study is a prospective population-based cohort study founded in 1990 in a suburb of Rotterdam, the 
Netherlands. The first cohort (RS I) consists of 7,983 participants, aged 55 years and over. The second cohort (RS II) 
was recruited in 2000 with the same inclusion criteria. Performing of spirometry was introduced in 2004. Spirometry 
was performed by trained paramedical personnel using a SpiroPro® portable spirometer (Erich Jaeger, Hoechberg, 
Germany), according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines. FEV1, FVC 
and FEV1/FVC ratio were measured. A total of 6,240 subjects were genotyped in RS I and a total of 2,516 in RS II. 
Exclusions were based on a call rate < 98%, Hardy-Weinberg p-value < 10-6 and MAF < 0.01%. A total of 5,974 for RS I 
and 2,157 for RS II passed genotyping quality control. Since spirometry was introduced in only 2004, full data with 
regard to spirometry and covariate data was available in 1,224 participants and 852 for RS II and were used in the 
final analysis dataset. Further details can be found in Hofman A et al., 2009128 and Estrada K et al., 2009129. 
The Study of Health in West Pomerania (SHIP) is a cross-sectional, population based survey in a region in the 
Northeast of Germany. Study details are given elsewhere130,131. The examinations were conducted using a 
bodyplethysmograph equipped with a pneumotachograph (VIASYS Healthcare, JAEGER, Hoechberg, Germany) which 
meets the American Thoracic Society (ATS) criteria132. The volume signal of the equipment was calibrated with a 3.0 
litre syringe connected to the pneumotachograph in accordance with the manufacturer´s recommendations and at 
least once on each day´s testing. Barometric pressure, temperature and relative humidity were registered every 
morning. Calibration of reference gas and volume was examined under ATS-conditions (Ambient Temperature 
Pressure) and the integrated volumes were BTPS (Body Temperature Pressure Saturated) corrected132,133. Lung 
function variables were measured continuously throughout the baseline breathing and the forced manoeuvres using 
a VIASYS HEALTHCARE system (MasterScreen Body/Diff.). Spirometry flow volume loops were conducted in 
accordance with ATS recommendations133 in a sitting position and with wearing noseclips. The participants 
performed at least three forced expiratory lung function manoeuvres in order to obtain a minimum of two 
acceptable and reproducible values134. Immediate on-screen error codes indicating the major acceptability (including 
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start, duration and end of test) and reproducibility criteria supported the attempt for standardised procedures. The 
procedure was continuously monitored by a physician. The best results for forced vital capacity (FVC), forced 
expiratory volume in one second (FEV 1), peak expiratory flow (PEF) and expiratory flow at 75%, 50%, 25% of FVC 
(MEF 75, MEF 50, MEF 25) were taken. The ratio of FEV 1 to FVC was calculated from the largest FEV 1 and FVC. 
The TwinsUK cohort consisted of a group of twins ascertained to study the heritability and genetics of age-related 
diseases (www.twinsUK.ac.uk). These unselected twins were recruited from the general population through national 
media campaigns in the UK and shown to be comparable to age-matched population singletons in terms of disease-
related and lifestyle characteristics135. Spirometry (Vitalograph model 2150, Buckingham, England) was conducted at 
the clinical centre during a visit. Twins were instructed before the test and forced vital capacity (FVC) manoeuvres 
were performed in a standing position, without the use of nose clips. Three manoeuvres were performed and the 
maximum obtained values for FEV1 were obtained. Because of the relatedness in the TwinsUK cohort, we utilized 
the GenABEL software package114 which incorporates a pair-wise kinship matrix calculated using genotyping data in 
the polygenic model to correct for relatedness and hidden population stratification. The score test implemented in 
the software was used to test the association between a given SNP and the lung function phenotypes. Two sets of 
the samples (TwinsUK-I and TwinsUK-II) derived from the TwinsUK were genotyped. The first set – TwinsUK-I, was 
genotyped using the Infinium assay (Illumina, San Diego, USA) with four fully compatible SNP arrays as previously 
described136. Normalised intensity data were pooled and genotypes called on the basis of the Illluminus algorithm137. 
No calls were assigned if the most likely call was less than a posterior probability of 0.95. Validation of pooling was 
done by visual inspection of 100 random, shared SNPs for overt batch effects; none were observed. Quality checks 
similar to those for the WTCCC Study 138 were applied. The second set – TwinsUK-II, were typed with the Infinium 
610k assay (Illumina, San Diego, USA) at two different centres, namely the Centre for Inherited Diseases Research 
(USA) and the Wellcome Trust Sanger Institute. The same pooling procedure used for the TwinsUK-I was applied to 
the TwinsUK-II. Further, we excluded SNPs that had a low call rate (<95%), Hardy-Weinberg p values < 10−4 and 
minor allele frequencies < 1%. We also removed subjects if the sample call rate was less than 95%, autosomal 
heterozygosity was outside the expected range, genotype concordance was over 97% with another sample and the 
sample was of lesser call rate, non-Caucasian ancestry either self-identified or identified by cluster analysis in 
STRUCTURE 139 or multidimensional scaling by comparison to the three HapMap phase 2 reference populations (CEU, 
YRI, CHB+JPT), or unexplained relatedness (estimated proportion of allele shared identical by descent >0.05) to >120 
other samples where genotyping failed for >2 % of SNPs 140. The overall genotyping efficiency of the GWA was 98.7 
%. Imputation of genotypes was carried out using the software IMPUTE 141 for both TwinsUK-I and TwinsUK-II. 
Stage 2 follow-up samples and phenotype measurement 
The ADONIX study was established in 2001, and for the period 2001-2004 the study base was established in 
cooperation with the INTERGENE study. Details of the ADONIX study142,143 and INTERGENE study144,145 have been 
previously reported. Spirometry was done in the standing position with nose clips, using a Vitalograph dry-wedge 
spirometer as previously described143. All readings fulfilled the ATS requirements for standardization of spirometry. 
Details of the British Regional Heart Study (BRHS) design have been previously reported 146. Spirometry was done at 
age 60-79 years. A minimum of 3 measurements of FVC and FEV1 were obtained standing and without noseclips, 
using a Vitalograph Compact II instrument (Vitalograph Ltd, Buckingham, United Kingdom) as previously 
described147. FEV1 and FVC were recorded for the best test, which was defined in accordance with American 
Thoracic Society recommendations148. 
Full details of the selection of participants and measurements used in the British Women’s Heart and Health Study 
(BWHHS) have been previously reported149,150. Lung function tests were carried out using a digital meter Vitalograph 
with an attached printout of forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), peak expiratory 
flow (PEF) and forced mid expiratory flow rate (FEF25–75). The Vitalograph was calibrated each day using a 1 litre 
syringe and automated so that results were adjusted for ambient temperature. The women then performed some 
72 
 
practice efforts. They were then required to perform a minimum of three reproducible FVC measures (within 5% of 
maximum FVC produced). The output that produced the highest sum of FVC and FEV1 were used in the analyses. 
Women who could not perform three reproducible measures or who were unable to attempt the lung function 
assessment were excluded. 
Cross-sectional analyses of data from year 0 examination of the Coronary Artery Risk Development in Young Adults 
(CARDIA) cohort was performed. During 1985-1986, CARDIA randomly recruited 5,115 black and white men and 
women, aged 18 to 30 years, from the general population at Birmingham, Alabama; Chicago, Illinois; and 
Minneapolis, Minnesota; and from the membership of the Oakland Kaiser-Permanente Health Plan in Oakland, 
California. Detailed methods, instruments, and quality control procedures are described at the CARDIA website 
(http://www.cardia.dopm.uab.edu/ex_mt.htm) and in other published reports151,152. Spirometric pulmonary function 
testing were performed using the Collins survey 8-liter water-sealed spirometer and the Eagle II microprocessor 
(Warren E. Collins, Inc., Braintree, MA) in a sitting position with noseclips, as per the 1979 American Thoracic Society 
criteria153. Specifically, each subject performed a minimum of three trials with expirations recorded to the FVC 
plateau, which occurs after six seconds of expiration in adult males and was maintained for at least one second 
before terminating the forced expiratory maneuver. If, at the end of the three trials, there were at least three 
acceptable tracings, and with the maximum FVC and FEV1  reproduced to within 5% or 100 mL, whichever is greater, 
no more trials were performed. 
 The CROATIA-Split study,is an ongoing population-based, cross-sectional study in the Dalmatian City of Split for 
which 499 of the examinees, aged 18-95, have genotype data available. Spirometry was performed in the sitting 
upright position without nose clips, using a Jaegger Toennisen spirometer. Three readings were taken for each 
examinee, at least 15 seconds apart 12. Population stratification was partially taken into account after adjusting 
themeasures for the3 first principal components drawn from the population genomic kinship matrix computed using 
the ibs function of the GenABEL package.  Additional correction of the standard error of effect estimates due to 
related individuals was undertaken using the mmscore function in GenABEL Effect estimates were obtained using 
the palinear function of the ProbABEL package. 
The Gedling cohort is a general population sample recruited in Nottingham in 1991 (18 to 70 yr of age, n=2,633)154 
and was then followed-up in 2000 (n=1346) when blood samples were taken for DNA extraction and FEV1 and FVC 
were measured using a calibrated dry bellows spirometer (Vitalograph, Buckingham, UK), recording the best of three 
satisfactory attempts155. 
Details of the Generation Scotland: Scottish Family Health Study (GS:SFHS) population and phenotyping procedures 
have been previously reported156. Spirometry was performed without nose clips using the Ndd Easy One Spirometer 
(Model 2001). Spirometry was performed a maximum of 4 times until satisfactory readings were obtained, all 
readings with a best test variation of greater than 10% were excluded. Generalised Estimating Equations (GEE) with 
robust standard errors were used to adjust for familial correlations. 
The Hertfordshire Cohort Study (HCS) comprises a nationally unique study of 3,000 men and women born during the 
period 1931-39 in the English county of Hertfordshire and still resident there157. Lung function was measured using a 
Micro Spirometer (Micro Medical Ltd) in the seated position without noseclips. After at least one practice blow, 
three FEV1 and FVC readings were recorded. The highest FEV1 and FVC values from satisfactory manoeuvres were 
used in the analyses - these did not necessarily come from the same blow. DNA on all participants has been collected 
and is stored in the MRC Epidemiology Resource Centre, University of Southampton. 
Details of the Lothian Birth Cohort 1936 have been previously reported158. Lung function assessing peak expiratory 
flow rate, forced expiratory volume in 1 s, and forced vital capacity (each the best of three), using a Micro Medical 
Spirometer was assessed, sitting down without nose clips, at age 70 years. The accuracy of the spirometer is ±3% (to 
ATS recommendations Standardisation of Spirometry 1994 update for flows and volumes). 
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LifeLines is an observational follow-up study in a large representative sample of the population of the northern 
provinces of the Netherlands covering three generations159. Firstly, a random sample of persons aged between 25 
and 50 years are invited to participate. Subsequently their family members if present are invited to also take part 
(parents, partner, parents in law, children), resulting in a three-generation study. The core of the LifeLines project 
consists of dedicated data collection and biological sample storage, including genetic samples (‘‘biobank’’). All 
participants receive a number of questionnaires and a basic medical examination and are followed for many years 
with extensive standardized measurements. Spirometry was performed following ATS guidelines using a Welch Allyn 
Version 1.6.0.489, PC-based SpiroPerfect with Ca Workstation software. Genotyping was performed on 3078 
unrelated individuals with IlluminaCytoSNP-12 arrays160. 
 
Details of the Multi-Ethnic Study of Atherosclerosis (MESA) and MESA Lung Study have been previously reported 
161,162 and a full technical report of MESA procedures is available online (www.mesa-nhlbi.org). Spirometry was 
conducted in 2004-2006 in accordance with the 2005 ATS/ERS recommended guidelines127 using a dry-rolling-sealed 
spirometer with automated quality control software (Occupational Marketing, Inc. Houston, TX). All spirometry 
exams were centrally reviewed by at least one (JLH) of the authors163. 
 
The Nottingham Smokers cohort is an ongoing collection in Nottingham using the following criteria; Caucasian, > 40 
years of age and smoking history of > 10 pack years (currently n=538). Lung function measurements (FEV1 and FVC) 
were recorded at enrolment using a MicroLab ML3500 spirometer (Micro Medical Ltd, UK) recording the best of 
three satisfactory attempts. 
 
The DNA archive established from the MRC National Survey of Health and Development (NSHD, also known as the 
British 1946 Birth Cohort) was used. Details of this study population have been previously reported164. In brief, NSHD 
is an ongoing prospective birth cohort study consisting of a stratified sample of all births in England, Scotland and 
Wales in one week in March 1946. The cohort is ethnically homogeneous and initially consisted of 2,547 females and 
2,815 males who have been followed up over 20 times since their birth, mostly by means of home interviews. During 
1999 when cohort members were all aged 53 years, all those still in contact with the study team and living in the UK 
were invited to be examined by a trained research nurse at home: 3,035 were successfully contacted164 and 
adequate blood samples for DNA extraction obtained from 2,756. Spirometry at age 53 years was done in the 
standing position without nose clips, using a Micromedical turbine electronic spirometer (Cardinal Health UK 232 
Ltd, Basingstoke, UK) as previously described165,166. Two measurements were taken and the maximum reading with 
recorded satisfactory technique (as assessed by the nurse conducting the test) was used for these analyses. 
 
The Rotterdam Study is a prospective population-based cohort study founded in 1990 in a suburb of Rotterdam, the 
Netherlands. The third cohort (RS IIII) consists of 3,932 participants, aged 45 years and over and was recruited in 
2006. Spirometry was performed by trained paramedical personnel using a SpiroPro® portable spirometer (Erich 
Jaeger, Hoechberg, Germany), according to American Thoracic Society (ATS)/European Respiratory Society (ERS) 
guidelines. FEV1, FVC and FEV1/FVC ratio were measured. A total of 2,420 subjects were genotyped in RS II. 
Exclusions were based on a call rate < 98%, Hardy-Weinberg p-value < 10-6 and MAF < 0.01%. A total of 2,082 passed 
genotyping quality control. Of these, 1,247 participants with complete spirometry and covariate data were used in 
the final analysis data set. Further details can be found in Hofman A et al., 2009128 and Estrada K et al., 2009129. 
Details of the SAPALDIA Cohort have been previously reported118,167-169 and technical details are available online 
(http://www.sapaldia.net/en/content/view/88/305/). SAPALDIA is a cohort study initiated in 1991 recruiting adults 
aged 18-60 years from the general population in eight areas of Switzerland. A first follow-up examination was done 
in 2002 and included the establishment of a DNA- and blood biobank, a second follow-up is currently under way. All 
participants were administered a detailed health questionnaire. Spirometry was done using a Sensormedics 2200 
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spirometer and complying to the ATS quality criteria as previously described 167,170. High quality genotype data was 
available on up to 5646 participants with complete spirometry and smoking information at baseline. 
Look up samples and phenotype measurement 
The Avon Longitudinal Study of Parents and their Children (ALSPAC) is a population-based birth cohort study 
consisting initially of over 13 000 women and their children recruited in the county of Avon, UK in the early 1990s171. 
At 8–9 years of age, children’s lung function was measured by spirometry (Vitalograph 2120, Maids Moreton, UK) 
according to American Thoracic Society criteria. Flow-volume curves were reviewed by a respiratory physician to 
ensure adherence to standards. GWA data and lung function measurements were available on 5062 of the children 
from this study. 
The GIANT consortium study description can be found in Lango Allen, H. et al90. 
The International Lung Cancer Consortium (ILCC) GWAS meta-analysis was conducted based on 14 lung cancer 
genomewide association studies with a total of 13,300 lung cancer patients and 19,666 controls37. The GWAS studies 
included in this meta-analysis are the Environment and Genetics in Lung Cancer Etiology (EAGLE), the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Prostate, Lung, Colon, Ovary Screening Trial (PLCO), 
the Cancer Prevention Study II Nutrition Cohort (CPS-II), the UK study from the Institute for Cancer Research, the 
International Agency for Research on Cancer (IARC) study in central Europe, the MD Anderson study in Texas, the 
DeCODE study in Iceland, the Helmholtz-Gemeinschaft Deutscher Forschungszentren (HGF) study in Germany, the 
Carotene and Retinol Efficacy Trial (CARET) cohort, the HUNG2/Tromso study, the Canadian study from the Samuel 
Lunenfeld Research Institute, the lung cancer study in France and lung cancer study in Estonia.  The detailed study 
methods and descriptions have been published previously37. 
The Oxford-GlaxoSmithKline study (OX-GSK) is a collaborative effort to investigate the genetic basis of smoking-
related behavioral traits89. The study combines genome-wide chip and imputed genotype from 20 disease, 
population and control cohorts totaling 41,150 samples. Three smoking related behavioural traits were measured on 
these samples (a) a smoking quantity phenotype, defined as a semi-quantitative trait based on the self-reported 
variable of cigarettes smoked per day (N = 15,574) , (b) a smoking initiation binary phenotype, defined as Ever 
smoker (N=18,598) versus Never smoker (N=15,041), and (c) a smoking cessation phenotype, defined as Current 
smoker (N=10,123) versus Non-current smoker (N=19,903). Association analyses separately within each cohort 
under an additive model using covariate effects for age, sex, disease case or control status where applicable, and 
other cohort-specific covariates. A meta-analysis was then carried out by combining study-specific regression 
coefficient estimates using a fixed effects model.    
 
Recruitment of the Western Australian Pregnancy (Raine) cohort has previously been described in detail172-174. In 
brief, between 1989 and 1991 2,900 pregnant women were recruited prior to 18-weeks gestation into a randomised 
controlled trial to evaluate the effects of repeated ultrasound in pregnancy. Children have been comprehensively 
phenotyped from birth to 21 years of age (average ages of one, two, three, six, eight, ten, fourteen, seventeen and 
twenty-one) by trained members the Raine research team. Most of the children are of Caucasian ethnicity. Data 
collection included questionnaires completed by the child’s primary care and by the adolescent from age 14, physical 
assessments by trained assessors at all follow up years, DNA collection from year 14 follow-up. The study was 
conducted with appropriate institutional ethics approval, and written informed consent was obtained from all 
mothers. Study individual genotype data was extracted from the genome-wide Illumina 660 Quad Array.  
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Stage 1 GWAS studies 
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data management: T.A., data analysis: G.K.G., A.V.S. Funding & Acknowledgements: This study has been funded by 
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and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research 
Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors 
thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly 
supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for 
Medical Research. NIEHS: Supported in part by the Intramural Research Program of the NIH, National Institute of 
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B58C – T1DGC  
Investigators: David P Strachan, Alicja R Rudnicka, Wendy L McArdle 
Contributions: project conception, design and management: D.P.S., phenotype collection and data management: 
A.R.R., D.P.S., genotyping: W.L.M., data analysis: A.R.R., D.P.S. Funding & Acknowledgements: This research utilizes 
resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National 
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University of Cambridge (John Todd, Helen Stevens and Neil Walker), which is funded by Juvenile Diabetes Research 
Foundation International, the Wellcome Trust and the National Institute for Health Research Cambridge Biomedical 
Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award (079895). We acknowledge use of the DNA 
from the British 1958 Birth Cohort collection, funded by the Medical Research Council and Wellcome Trust. We thank the 
Avon Longitudinal Study of Parents and Children laboratory in Bristol and the British 1958 Birth Cohort team, including S. 
Ring, R. Jones, M. Pembrey, W. McArdle, D.P.Strachan and P. Burton for preparing and providing the control DNA samples. 
 
B58C -WTCCC  
Investigators: Wendy L McArdle, Alicja R Rudnicka, David P Strachan.  
Contributions project conception, design and management: D.P.S., phenotype collection and data management: 
A.R.R., D.P.S., genotyping: W.L.M., data analysis: A.R.R., D.P.S. Funding & Acknowledgements: The British 1958 Birth 
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068545/Z/02. Genotyping for the Wellcome Trust Case Control Consortium was funded by the Wellcome Trust grant 
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Margaret River region of Western Australia. The BHS gratefully acknowledges the assistance of the Western 
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study. 
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nhlbi.org/pi.htm. DNA handling and genotyping was supported in part by National Center for Research Resources 
grant M01-RR00425 to theCedars-Sinai General Clinical Research Center Genotyping core and National Institute of 
Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology 
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Finland, Center of Excellence in Complexe Disease Genetics (213506 and 129680).  
Health ABC 
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Stage 2 follow-up studies 
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Contributions: project conception, design and management: J. Beilby., phenotype collection and data management: 
J. Beilby., M.L.H., genotyping: J. Beilby., G.C., J. Hui., data analysis: G.C. Funding & Acknowledgements: The 
Busselton Health Study acknowledges the generous support for the 1994/5 follow-up study from Healthway, 
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